var title_f1_18_1312="Myocardial biopsy 1 with answer";
var content_f1_18_1312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trypanosoma cruzi in the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin-stained section of myocardium (x400) shows Trypanosoma cruzi.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1312=[""].join("\n");
var outline_f1_18_1312=null;
var title_f1_18_1313="Schneider tracheal stent";
var content_f1_18_1313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schneider tracheal wallstent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schneider self-expanding tracheal Wallstent shown fully expanded.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1313=[""].join("\n");
var outline_f1_18_1313=null;
var title_f1_18_1314="Methylfolate, methylcobalamin, and acetylcysteine: Drug information";
var content_f1_18_1314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylfolate, methylcobalamin, and acetylcysteine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4605023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cerefolin&reg; NAC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4605027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Dietary Supplement",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4605031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Medicinal food: Oral: One caplet daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4605030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Medicinal food: Oral: Children &ge;12 years: Refer to Adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4605033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cerefolin&reg; NAC: L-methylfolate 5.6 mg, methylcobalamin 2 mg, and N-acetylcysteine 600 mg [gluten free, sugar free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4605025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4605028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Medicinal food for use in patients with neurovascular oxidative stress and/or hyperhomocysteinemia",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7710447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Methylfolate may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colestipol: May decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Methylfolate may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Methylfolate may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Methylfolate may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Methylfolate may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Methylfolate may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyrimethamine: Methylfolate may diminish the therapeutic effect of Pyrimethamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Methylfolate may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SulfaSALAzine: May decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Methylfolate may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cerefolin NAC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-2-600 mg (90): $379.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cerefolin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-1-50-5 mg (90): $411.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methylfol-Methylcob-Acetylcyst Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-2-600 mg (90): $216.00",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9505 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1314=[""].join("\n");
var outline_f1_18_1314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4605023\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4605027\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4605031\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4605030\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4605033\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4605025\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4605028\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299702\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710447\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324136\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9505\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9505|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_18_1315="Tricuspid valve rupture 2-D echocardiogram";
var content_f1_18_1315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/53665/trivarup_conv.mp4?title=Tricuspid+valve+rupture+2-D+echocardiogram\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical view from a 2-D echocardiogram shows a flail tricuspid valve leaflet with exaggerated movement. There is a bright echo seen at the tip of the valve, which probably represents a ruptured papillary muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1315=[""].join("\n");
var outline_f1_18_1315=null;
var title_f1_18_1316="X-linked severe combined immunodeficiency (SCID)";
var content_f1_18_1316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   X-linked severe combined immunodeficiency (SCID)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/18/1316/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1316/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/18/1316/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1316/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/18/1316/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1316/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/18/1316/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked severe combined immunodeficiency (SCID) is due to defects in the common gamma chain (gamma-c, interleukin-2 receptor gamma).",
"   </p>",
"   <p>",
"    X-linked SCID is discussed here. Other forms of SCID and a general overview of SCID are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): Specific defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17674562\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slightly less than 50 percent of all infants who present with SCID have X-linked SCID (SCIDX1 or X-SCID, MIM 300400) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked SCID is caused by defects in a gene on the X chromosome encoding the cytokine receptor subunit gamma-c (the interleukin receptor common gamma chain, IL2RG) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/3\">",
"     3",
"    </a>",
"    ]. This receptor subunit is shared by at least six different cytokine receptor complexes: the receptors for interleukins-2, -4, -7, -9, -15, and -21 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/4\">",
"     4",
"    </a>",
"    ]. Mutations in this gene lead to profound derangement of the immune system via the blockade of multiple cytokine pathways important for lymphocyte development and function.",
"   </p>",
"   <p>",
"    The gamma-c subunit is also involved in growth hormone receptor signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, growth failure seen in children with X-linked SCID may be due to both the underlying genetic defect and to recurrent infections and nutritional deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/6\">",
"     6",
"    </a>",
"    ]. This could explain why many patients continue to have growth failure with severe short stature after partial correction of the defect with hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17674605\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;These male patients usually have the classic clinical SCID phenotype, presenting in the newborn period with recurrent severe infections, chronic diarrhea, and failure to thrive. However, some patients have an atypical presentation, such as an Omenn syndrome phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] or a polymorphous lymphoproliferative disorder with Hodgkin-like features [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H7#H7\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link&amp;anchor=H13#H13\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\", section on 'Omenn syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LABORATORY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the large majority of patients with X-linked SCID, peripheral T cells are absent or very low (100",
"    <span class=\"nowrap\">",
"     cells/microL),",
"    </span>",
"    and the absent or small thymus is devoid of lymphocytes and is not visualized on a posterior-anterior chest radiograph. However, there are reported cases of X-linked SCID in which subpopulations of T cells have somatic reversion of the IL2RG mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. This somatic mosaicism results in variant phenotypic expression, including attenuated disease in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/11\">",
"     11",
"    </a>",
"    ]. NK cells are usually also severely reduced in numbers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunoglobulin is virtually nonexistent, except for transplacental IgG in the first months of life, despite the presence of normal numbers of B cells. This is largely due to the absence of T cell help for antibody production. However, autologous B cells are not normal, since they have at least six abnormal cytokine receptors. Thus, functional B cells are of donor origin when B cell function is restored, since donor T cells will not activate the patient's B cells to make antibody.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of X-linked SCID is likely in males with SCID and normal or elevated numbers of B cells (",
"    <a class=\"graphic graphic_table graphicRef69679 \" href=\"UTD.htm?13/48/14092\">",
"     table 1",
"    </a>",
"    ). However, X-linked SCID must be differentiated from autosomal recessive JAK-3 deficiency, which is clinically and immunologically indistinguishable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15176?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID) with JAK3 deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A functional STAT5 tyrosine phosphorylation assay can be used to rapidly distinguish X-linked SCID and JAK-3 SCID from other forms of SCID. The presence of tyrosine-phosphorylated STAT5, detected by flow cytometry after IL-2 stimulation, indicates a functional",
"    <span class=\"nowrap\">",
"     IL-2/JAK-3",
"    </span>",
"    signal transduction pathway; its absence indicates a defect in this pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/12\">",
"     12",
"    </a>",
"    ]. The assay accurately predicted IL2RG and JAK-3 mutations in 94 percent",
"    <span class=\"nowrap\">",
"     (16/17)",
"    </span>",
"    of patients. Mutations in these genes were not found in one patient with negative pSTAT5.",
"   </p>",
"   <p>",
"    The diagnosis of X-linked SCID may be definitively established by demonstrating the absence of the common gamma chain on lymphocyte surfaces by flow cytometry. However, in many cases, a non-functional gamma-c may be surface expressed. The diagnosis of X-linked SCID may also be established by a skewed pattern of X chromosome inactivation in maternal T cells, but this pattern cannot detect the 30 percent of cases resulting from new mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In rare cases, the only way to make the diagnosis is by mutation analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .) As an example, many features of the SCID phenotype were absent in three patients with an X-linked mutation in the common gamma chain that resulted in normal numbers of T, B, and NK cells and antibody levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1316/abstract/13\">",
"     13",
"    </a>",
"    ]. These children had normal appearing thymus glands and peripheral lymphoid tissue, but suffered severe infections during the first year of life. Specific antibody response was severely impaired, and their lymphocytes failed to respond to IL-2 in vitro, suggesting a defect in IL-2 receptor expression or signaling. A single amino acid substitution was identified in the extracellular portion of the gamma-c. The pathophysiologic basis for the remarkably normal laboratory phenotype of such patients has not been elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary therapy currently available for X-linked SCID is hematopoietic cell transplantation. The possible role of gene therapy continues to evolve, with evidence of effectiveness demonstrated, but concerns about insertional oncogenesis remaining. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=see_link\">",
"     \"Gene therapy for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-linked severe combined immunodeficiency (MIM 300400) is the most common form of SCID. Patients usually present in the newborn period with recurrent severe infections, chronic diarrhea, and failure to thrive. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17674562\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17674605\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      X-linked SCID is due to defects in the common gamma chain (gamma-c, IL2RG). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral T and NK cells are very low to absent and immunoglobulins are also very low to absent despite normal B cell numbers. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Laboratory abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation is curative. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"       \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=see_link\">",
"       \"Gene therapy for primary immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/1\">",
"      Conley ME, Buckley RH, Hong R, et al. X-linked severe combined immunodeficiency. Diagnosis in males with sporadic severe combined immunodeficiency and clarification of clinical findings. J Clin Invest 1990; 85:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/2\">",
"      Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004; 22:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/3\">",
"      Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/4\">",
"      Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/5\">",
"      Adriani M, Garbi C, Amodio G, et al. Functional interaction of common gamma-chain and growth hormone receptor signaling apparatus. J Immunol 2006; 177:6889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/6\">",
"      De Ravin SS, Shum E, Zarember KA, et al. Short stature in partially corrected X-linked severe combined immunodeficiency--suboptimal response to growth hormone. J Pediatr Endocrinol Metab 2008; 21:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/7\">",
"      Wada T, Yasui M, Toma T, et al. Detection of T lymphocytes with a second-site mutation in skin lesions of atypical X-linked severe combined immunodeficiency mimicking Omenn syndrome. Blood 2008; 112:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/8\">",
"      Shibata F, Toma T, Wada T, et al. Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations. Eur J Haematol 2007; 79:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/9\">",
"      Slatter MA, Angus B, Windebank K, et al. Polymorphous lymphoproliferative disorder with Hodgkin-like features in common &gamma;-chain-deficient severe combined immunodeficiency. J Allergy Clin Immunol 2011; 127:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/10\">",
"      Speckmann C, Pannicke U, Wiech E, et al. Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency. Blood 2008; 112:4090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/11\">",
"      Wada T, Candotti F. Somatic mosaicism in primary immune deficiencies. Curr Opin Allergy Clin Immunol 2008; 8:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/12\">",
"      Walshe D, Gaspar HB, Thrasher AJ, et al. Signal transducer and activator of transcription 5 tyrosine phosphorylation for the diagnosis and monitoring of patients with severe combined immunodeficiency. J Allergy Clin Immunol 2009; 123:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1316/abstract/13\">",
"      Somech R, Roifman CM. Mutation analysis should be performed to rule out gammac deficiency in children with functional severe combined immune deficiency despite apparently normal immunologic tests. J Pediatr 2005; 147:555.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3927 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1316=[""].join("\n");
var outline_f1_18_1316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17674562\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17674605\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LABORATORY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3927\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3927|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/48/14092\" title=\"table 1\">",
"      Diagnosis of X linked SCID",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=related_link\">",
"      Gene therapy for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15176?source=related_link\">",
"      Severe combined immunodeficiency (SCID) with JAK3 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=related_link\">",
"      Severe combined immunodeficiency (SCID): Specific defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_18_1317="Urinary concentrating mechanism";
var content_f1_18_1317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Effect of arginine vasopressin on water permeability in the collecting duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 440px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Binding of arginine vasopressin (AVP) to the vasopressin V2 receptor in principal cells of the collecting ducts begins a succession of intracellular processes culminating in increased water permeability. These steps include the activation of adenylyl cyclase via the stimulation of G-alpha-s heterometric proteins, increased levels of cAMP, activation of protein kinase A, and the fusion of vesicles consisting of water channel proteins (AQP2) with the luminal membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bichet DG. Nephrogenic and central diabetes insipidus. In: Schrier's Diseases of the Kidney, 9th ed, Coffman TM, Falk RJ, Molitoris BA, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1317=[""].join("\n");
var outline_f1_18_1317=null;
var title_f1_18_1318="Relationship between ascending colon and posterior structures";
var content_f1_18_1318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Relationship between ascending colon and posterior structures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 559px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the relationship of the right, ascending colon and the posterior structures, including the second portion of&nbsp;the duodenum, kidney, ureter, and gonadal vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1318=[""].join("\n");
var outline_f1_18_1318=null;
var title_f1_18_1319="Female pelvic floor childbirth";
var content_f1_18_1319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic floor anatomy during childbirth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Injury to the pelvic floor.",
"    <br>",
"     (A) The perineum, levator ani, and pelvic fascia may be injured during childbirth.",
"     <br>",
"      (B) It is the pubococcygeus, the main part of the levator ani, that is usually torn.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Moore, KL, Dalley, AF. Clinical Oriented Anatomy, Fourth Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1319=[""].join("\n");
var outline_f1_18_1319=null;
var title_f1_18_1320="Hydropic placenta";
var content_f1_18_1320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hydropic placenta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5wHBB71ctJIfOh+1q7W+9fNWIgMVzztJyAceorPMmecV2nw+8J2vie31FrnVDY3MTwwWieVvWWaUsEDnPyJuUKW5wXXtW0VdmLR7L4X0zw3c/DvSk0O1ubmynv7qYR6tYW91MGAjQ7Qs8TBeBymcnrjjPGfGWyfTPDNvAqvFbvdJti8jULdQQrniOd3i/FGz+Ga7i98NxaF4f0XQJkttRls2uwfNtbGctmdhkRTyLIOV6o2DivL/ixYQadptiI9H/ALMlmuXJ/wBAktBIFQcgGeVGGWHKYx36ihy5k03cya966PLjyfxpvqacT0ph4rI1HKOfpUq8YqBSR2zUm7I60AOfrjNSQQtK6qoJJ4AA5NWtK0ufUJD5QxGv3pG6CvRfCfh1EiMlsCZmJj89hkqO+0epyB7c1Sg92S5q/KtzB0rw8kAja/V5bh8FLSPk+27H8q9I8P8AhC5maJ7i3WCMdEBAxz0Hb6n8q6vwh4TtbRRM8Za5blnkOWrumtIQqFwCV4HHH/6qmVzeE4Q13f8AWxiWWlQWNthIwFA52jJPsKjnFvC5fAEvZeDt/D1raYeejEP5cI4LdPyquI0A2RRKndRj5j7n0rCVRJmsYveRmxQPIfNufkiHO0/zJrP1Gc3bNFpzGM4IMoHI+np9atavOR8pKu4bhAflWsq7mEERVPmeT723+76D6n+tZ35nqXCDuuUow2DtMwU7w5ySST+Ofwrfs9HhiCyJGzuB97tk0W1nNaxpPOrLbM4jaMrkg/h26VY0uVLe3mjleITyzNIshmAUJgACs5dke1SpKKuCLd7ZYhIixvzkqGKj0BPrTNY0G/vtOmhivlgaZVBVo96vjpnuOvb8ama5axUyXKt5KKclV4XjOTWdc+LhFZmWBWZz91x1AIORj0wf0qYuxrOEnrEoaDDLbm5t9QhtpDZ7VjWTgs2OSo75657VmeJNTs7dHsNMXzJo3Mk9wU2qoPYenpWRYT3+seJ5rxnYW9vC5b96PmUA7VG488n64zUuu6TPp1oWkkh3TxoCscm93bcTjHb1yeOmKpu60Lo0k6iUn20KviNtRu/BEd2bJYbEzCFJB8oZhknA7j39682eKUXEcc6qrO5AOedwxwfSvRtQvri5gaJrIpYzShbeJpifJjXAKZ98rlsdq4bxjDHpt2YY1b7TGzNKGYMVBxtBI4J+lax5baGddSi7yVlf+up6W+siabS41nW1upEiWFEkXZE4kAZmBBxlQDkYzjHIJr0Kytp9FsLF7G78593l/vcbgQOo/PGO1fOPg1mutSinutxCMMttzj04r6NguIf7EaS3hXzIlErAHeI1GPmGf8gZrKU3J8nYSoxjBTS0kUr6Hz/F9tcXEKqs+BvPQKo9c9SePWpdaZftF1bm8iCxqj+VtK7t2WB3Enc2D36Ukt7Z3ejya3qxea0ikEbKjFfLbpuGeOuOnU1mDSLm9voJ5DDDg79gbcR2yw6Z469qG769yoqzV3sUWhfX9QewnMdnFGok+RgfNI4ADDgn2rodA0+HRpbSa7lVLQwtLGAw3MSTxj+8eeD0pE8P6Ro0BA1NI5pW3tHuwue3PetLS7ezQStqBgU43FzjJB4HzetQ5qOhtbnu46L0/r9Stqd7K12RDZT3W5B5IQBsv7n0z7Vz0tnq87S2eq3H2czMd1rAq7zuxwXIyBgDvmtufV71p2hsGe2toxky5wzsO6enHBPPt61e0rSDcKs7uUeNgwSTksT3J71XM0rLcwlBJ3ktDIS2t9Ka0hjgWJR8qyA8KADwB3ye5ya4z4nXjqlpY7GWJ2BkkJPzHJznt0IruvFlyJl+02ZYLE4dUdMiUBuu3oR0OPeufv7eHU/tjSwBnjQSA9kAHT86dugRajaTRsaY9i6raRFpJYlVIgFDcFQMAKcZFX7izgsdOIuJY2Mcw/dIgDng859jjP1rjrN7XR9LkkmZoJJP3aoignJ57jiuq1WwsbjSRda1thWRiou4GIMDZwGKg4K56jHTuOtJJOXKU5ckeZ3aH6dfJ9ozceRIsjAFO44/h/Gta3gtWZ2VZLa4X5SioPnyccDj16V4jbeI4k1iUXU7SNExVZIuhK8Ag9AO9ek6H4ghe8NwZxeSspMflHe0YwCAxwBnnnFHK4uzBq6ujppvD/2OS9vp7kPdwtl4ZJAoYBclhnr9Pyrlr/SXvGmuGTZDKGjkRWDBkYe3IBz0qTWVl1K3dnuBApUebBG338EkFmPXBPSjwelzb6vd2WqajbTEqHVfJO8qRxuYHqAOgB6jkVo52s0jllBuMud6ryPDPHPhKXw/cNNBh9Pkfahz8yHGcHvj0NcoRX05rmmRavbzwReXcQAOqzMuRuHY+o9xXh3iPwzLYxPcQphUP72IHPljsw7kH9K6l7yujxqlNRlY5QCmstSstMxSMGiFlGKrSJg8VdIqN1zVIgpMKjJP1qzJHjvVdxTGIHA68UIATwaYW6jg0i43ccGgCzgjNIM55poLA+tPDqByMGgQFSxAFRsKnUqfunBpskTKeR71RNyOURpcOkT+ZGrEK+Mbh612/wAO/Hl74Ge9NhYwXbXewkyzzR7Que0brnOe+cY471xy2mWwDwOM1q6Hp1pc6gsGoalHpcDK2bmWJ5VUgZAKoC3J4yAapIttWPoTVvEU+o6R4dk1+eyuLqXTknbzptNkZd7MwBiukD/dKjO/kAHrknyb4vy2bNo62Vra2+Y5ZH8izhtg5JUZIhlkRvunkY+leseIXgsZrCwt/EEax2en2kIjOtvaxyYgT5hFPbtEA2c8NznnByK8Z+LLg6zYqrW7AWu7dBLayKcyP/FbqqE8dxu9e1XUuopXMVZzdjhT1FI/WlJ+amnk5rA1FUV0nhPw1PrdypJ8q2B+eUj9AO5rO8P6Y+p3qR8iMMAzAevYe9ev6d9nsIfs1vGfLRdvHBb2Ht6k10UaSfvS2ObEV3D3Yb/kEOnaXp8SW8KkhByB8zH+gJruNBsWjghleJYVThIhwFzWToFr5u6V4Y44VJIwgyfoTzn1NbOrXktmhZMsQvAxwo9R79qcnzO46NOyt1Z1GnyhDyc9fxNOup7u4uUhs0hKKczNISAi4P5nP6VS0pZzYxll8u48vJBGfKGM8+9T2UU1n4ft0hDPeuuczcFmJyWcc+vT+VefWm5PlietQpKH7ye5aQPErTXrlVDERvnkjttX357VnX7MEaRfMjQc7Gb5m9zTbqZrUDz5Q9yQFaZ+o98fyFY2r6pBBbMY3L4By5bJJrBU2aSqJvQy9Wv5oVZlQyEDCKi8n8K0NItNQHmzXUMA2shcNICVUgEDjvjn2zXP6RexXsU1/I7NCu5Y0QEkjoW+mRgfjXZeE9Ntp7YT5cwTkHdEuAMZxn15obS2PQoUrK8kak91NHPDDuYp954SuVB6DH4Yo1GwNxd2Pluka7gPKKZBPOOe3J/On3moR6XAZMMzITt3oPlyePp9adc3W1N0k0Ul5neHt23IowMYI/PNZNXOuHuvQ1mkRoSWg+VBtGRwpz39u3NYuv2ceoR3FubeFs8qwT5f+A+lV7S/AvWtLqXYHRwHAJ3kjjP8vyrQ0uyM9jf21xfOJNo8pl6Fu6k+vbiiL1sVKkknLsecReHV0vVI5bicXBRt5gUbVZR05rpfEWn2uoaOlzCEkZEwmO/GMZPb61meLISkqW9u7os5WJiTyvPUjsO/FasUEB0C13yNNDBnLJna2D+eOhpPRM0pyfNGaepy19dS22lTve2yW8kIwoUZIHbA+p/OvGL931LUJpBITGCE3MOpr1rx/wCJLLSdOuHg/ealcqohUjcFwQd3sB/OvN/DRsbjUFF+ZUjxncibsOfb862pXUbmWJkpVOTZdfU7T4UaPJo9xLf6sywxYBjDLu3DIOSD298euK7WTxLHYa3cwWkNlaW90jFGugfKbKnJII69gMYyK5fxf5k93DBZXLPdaRAgnlYCIKpACEc8sMj8f05nSUvtX1+IS2q3dtv3Eykqkmwcru/ujjPf8a1jBt6HI5rkcpvTb/I7bwhZavq17Kt60U/h47o5VbIjbaQSwB5B+ZTnHce9eqS2UVnGkFtalogAZFLFHwqgIM4x68V43pbweH7q5kaRp9oJktFmIEZPTJ7jgZHXA5Ir2HQNckmgFx9jDpNtlCsQxXjgq2eD94D3GDWbfvanROLcbx/yucdJa/21exxXLRvczS4ZNuFtwvdQOh9zySa2J9Lj3m+v7Z/s1nL5ky7QMqR8gB6nIxWZoGpJYaoRLgahP5jgyjgKGwNwH8XB/Kq/iHUrlrq1tPMa3s5W/fNK2c/PnI2rkHgetRZNu5s5SilGP9dzpbUx6xLPOIjHCxAQb/8AlmvRcduc59c1c8TGa3022jhuY4pnOHKkZ5GMYqDT4Ejje/gWKK3toDIQx+V8DPA7kelU49SsruwS6vI5lffkyuuA4OcEdwPY0td2Zbuy6GXbxpe3qfZbiZhabgASWiL8ZxkdD/hWB4lvI9Os7tbyOO3E2EDg/L1yc49ODgVv+IvFNnYWcUumWhubyB13MrYQLuA+cg9OcDA6nn34LxZDfTpE1xaxeZNKrCFOUKbju3EfxHHYjA469NoQurtmNSTTSt8uv/DeZ2niDRl1FLK88lYwkaFoiOXHHvwf8a0oLx72SSIwNBb+WqsoYEFQe57c+lU9J1O5vriLTdQs/KmmTfHPuY4KgnBXtxgc1sa1cpBbm2g2C32h3jTht45IJ9BjP41LSY6UpwShI5HxF4ViuLyFrTdGvR/3WEkOeMHOce+BXTWOhfYNPQ20Sxsd3mEdAuOgzyaTTp/NZkE6NFHE0mJDtyQMkAnj/wDVTNR1KWc6Y+mKJNzKhtXJRnXB+ZePlUYOSep/Klu7suTqaQRneLYo/DcQiW4+0y3MaPNDCR8hznYG5zkAU23u4U1FLmNdymMFwWLGPttz26ZP1rJ8ZWV3axxMscgdZCXlHyhDnkgnrjIyBnisTR9TtLTUZbSS5knhJXc54JZscsOpxyCByPcU37zvsi2koJXu3/X/AAx6zbN/oaPtit8jOw5Iz+NZepQ6E0kZ1BrcT3K7d0g+VuPu56ZrA1DV7Y6RYtHcS+ReO7hmIJjUBQAe55DfQEetW2srPxSiGTZIbdVUPtA83opB9CQTz19MHFKFRwmlfQ4KmDdSEpNanlvxJ8L22mXAu9Ij22bsQYRkmMdj64681wZWvf8AxDZG3S3jsbhpCnBgdC22Mdi/TPUbc9ufSvMNa8KyGWWbT1IBkObdxtKAnjH/ANeuybSZw+wnUV0jjCKaVq1cQSQTPDMjJIh2srDBBqAjFJM45RsQOvFVJlx9KvsDUMqjuKpGWxmMoJpVU54qV1GTg0wDHWmUA4oJzSE0YzQA5MD2qTzHB65FQHinpn6CmJmnCOeFGO2K6Wx8Ga/qPh59bs9NabSkD751kTjYPmyu7dx9K5WIspVsnHQYr1XwF40tzY6N4eXRVmv/ALQsMd1PNHKis8owRE8TcAHkBhnrxW0Gk9SJJ9D1TxXFfW+tX0ds+vQ2UZSOPyLjUYkAVFXGBDLFjjsAPavnj4qyPJ4udHlll8uCJQZXDNyN3J8uPP3u6A/XrXtXiNTc65qksWkxXfmXUreaugLJj5z1ltLjc31Iye/NeEfEOYz+MdQJUIUMcW0CUAbY1XpKS46dGJNKrZKyM6bbdzmWPzGgcmkrV8N2a3WoK8qhoIiGdT0b0H41lCLnJRRrOShFyZ3PhHTDDawKy4yN7dtzEdM+w/KvQNB0j7bcbdpZQMHAwOP6CsbQbOa7nM0oIMp2xp0Cr14HbtXqmi2K2NiowBJKOPYf55ruqzUFyo8ujF1Z3ZRt444XSFECovRf5VOqxz3bTyqH25SP0BXq34ZpZIkmvjHvKgcE9yx7D1P9TXC/ErUptWhOkaRdQ2djB+7nxIN9wf7iDqVU53N0Jz1xXn1qqWh7+GoSk7xR09rrEGpavHb2F2kmnrlS6c+fIDyQem1SOv8AEfbr1Vlf+ZcT2rSIXQBiwHLg9x6c8V5T4CW40Zza6jGILZF8uzumGBKMk7fZjyfcVp+I9XXTIf7Va+SzhthsAyN86scFVz36HIHHU1goSkm0jom6cKipt79X3/rQ7jUbCG4tZ7icMIIk3SvjHkgnHJPf/PSvCPHeuGWV9J0CJrfTnOBLMczTj+8zdh/sjj69a7STxifEun30Vnp0sdpYkM9tNMJN0gGAzk4DD2HBrzGZBP4lE+pbkhfCtGjcAYA2j0HtU3srHdSoqLu9T2PRILew8NWENtdWv763VgCQAFAw30Oc4713fhmRY9LNuF+RHARVXGRgdPp0rmPDPhS3fSLppy0FtHj5W4KsAOMfw46mszVtR1GRbcQXUduYW+V4ySnA69PasZvoj0KVOMt2dp4vkEpDfYYlEgZUwCPMXHO76Y69efy8v0TUW02+k0u4M0ciqQp68Hp+GK7jRb/VL22lg1O5huVTIjl8sDap7+5rmtT0mPU9UjvbcKYrdvLmdTneMZIyKHeS8yYyjRlyX0/qxnNLcDXraMy5jx+7DNnBHOPxxXVSeL4YmW0jASaTluclB3P1pnhsaVf6TeRfZ2DWsnk+cedjnkEMOnXvXIaRoV/qPirU0tmilsrYmIXefl3EjgcfNxkduxz65+zvqdHtG001sdVe+M9LvNdsdOmSKaz3MZZwuJAShAAPpW5Clrbx/ZbIlbe5BYnHC8dBnoTXEXPgOeyuIbqxkNy0ThiZI8JIc8qQD93r0NdpbXjPcWWiy2SWdzejAd5A0S/NglWAzgZHXkfrVKLluzOfLTj7u39dDzj4q6ft1W0lGwacyxkpgZV8EA56hSM5B7gmsfwh9ksbjUbrbDBZbkH2mQbmjcE7VEZOfmLL82eAGPUVpeMPEl3osviLw9eyCYJMJAj/ADiMgdUY9COn6dM1Rj8M6/rXh22eaCGOykSO4LLKu7yH5WTaOSBlgfTGO1d1Ja2fQ8rE/Da6s9d+mj+811smefUYbR7jVLRvKF9cmIMI9xO0hicB8E4zx8xPasrw1PEbm6tBfmJLaHyTIZCzsSflSMY+4p5OOTnt1Hqk1rpOmaSnhiC4jt7aaLbM0HCMyqWXcy8sTtPJ9RjgVx3g7w1psV/DmJFdMSFpie/QD39O2aus1RVluZYKX1t87uorb/M5zRbKaXWEvxG1tawPuRnJEhO0cAjHU55HPvXfaVqa6cL4bCFkkCxSBHWK1GM7QT2JwOT25x36WeK3vb+KwLQTlRvQPwe44z1wAfTqKXxX4dXU/Csun25aAbTIZ/4V25JGByeK4udy3PWtCLXn+RladprXFy+oTwI145KfaOCrEdOP4cDGfem/EHw7Le2FncQhUKndPIp4UZxnB6DP86veD8waBHaieWe+uMSXEzKrHeeu30GMde+c1NqGtaXcWS29/NudkUO5jKbH7j0Kg461mrN3NXKadktURwWP2nQoJ7i/jgtUtyfLOQvl/wAR3Z5JAx+NZ3jGZzaQ6hpkQj02K3IdnwDKQASwUnjGDgDk81leL7me/ttP0eyBmik2Rs8O47VIBfK4xtX6HvzUXxFisrLw9ZWtvcGWeFwnkk7lAYDBx2PTk1rBaqLOaSkkpre+36nJeHbi4n1WB5HfyomZ4ojyAx/iI+mK9Dllt3tIY7VnjnlYEskYb5QfmGei47Y6mvO/DJTR4buTVrCRrRyEdxn5X5IGcjBPPfP16U7S9W1eHXLYWK+baRzNJHGJCwYdQcjGRg9frTs7aFTtKd+vfudxe6lqFvfpBDN59wjtbKwXYxUM2193vuPWm3ltd6laRyPOscQJQkyEtKwOD9P5859KU3d74k0u9Wd40WVEiW34DZU5wO/UZ/Cug0HToNOsbZIbcS3a5IHH3h1BPQnPHNRJ9UWlypaK6I7n7FcvZx3s7revJjb5ZBkPHOfcn6/nU9/YPp19BPFblbN32SzxtudwvdvQD244NW75kd5JNRiXznl2xgY8uJh64/unqe56VEn9r/2q+nwbBcKq7iBkOD06/wAJBzg4pWWrFztJL/hv6RQns5dX1Z4r25PlIwQAJnardwPXGKw9W0Cxu5ikZE19C7I8irxsA7nHt355rob62SKaREnkjTAUnjduH0xx71n38c/2pAbp3LRot1Gi7WkjU4wD03YAHTnv61WnwslcyftIux57f6TaymSSYvbQtzbl2LsxzjqOADyfyrQ8Da3DpfiB9MeYFW4R+xccheO9dH410Rr3Tc6ZF80lsrQx4KFVzgqQMDPTqMnNeLRX0+jXEsFzbICx+TeOVcdCCORU1KWiaNqGI9opJs+rrW0SHTVljkW5t3J5KgbWxnaR681kX+nxT2rzrAoVmxIipkvntkdxjNcRoGp6nqGjGDTXW+ltU23LyPtK9Sh44IOMevFdVYeJ9MhW10yW4VruQ4laIsghb3yeD261Cq2dmE8M2rxd2+x5x4/8JWtxHbT2btJcyMQFVVMhB5BODyMflXluq6Tc6dIVnjYLnGcfzr6U1nRZkAm051jO4qpGflBHUe3UfjXl2tNYi9t4nk8i4c+XdJGvmIsmSD97sc/d+vPHPUm1r0OCdCnWXK/i7/5nlTrgVVlYA4Nd74/8EXnhhre54m066XdHNGp2o3OUOe/HFcUysV2E/Lu3Y963W12eDVpuEmjOkQkEkYqpIxBIrYkj4qjcQgc4qjNMrxsMdMUpNJjFGM0DAGlOTSgUuKBHRNpslr+7uWjA27jj06mu7+EFnpV3400d5dUsbSaG+jdLedJA0wU7sqwUqPu/xEVwlzqPmoyRxRjzIvKdpQCR8ynKnsfl6+hNeweAvh9DoXj7S7y31SXUZLGeWK9h+yTQGOYW0si+S2GMq/IfmQbuhCkEVpCDkrs0lKMX7mxH4q13TdQkae1bQZSFdnO/TbktyTwHjif+vNeI+IZPN12/fCAGd8BFCqBnGABwBx0FeweJpbx4zDcXU0m5huW+lMz43Dp59pG4P/As14neSebdTSf33ZvzJNKpfmszCFrX6kChndVUZZjgD1Nel+DNGEMaosRkmduXPTd6AVxfha1+1amG4PljIHueB/Wvb/B+mnzYUjQmTbjd6dq68LTXK6jPPx1Z3VNHS6BYIJ1YD5V+RfbHU1uX07s8XlMAv8TE/dX/ADxT9Ptt0flQDAI2KewHdqmuLONXVU3swG1P9pvX8Kxr1UtWdGBoSlsZmryTrp5s9PJjv7wbBcEcQKT1z/fPJH0J7Vyvi/R9LFpo2haRGsQjnJZlPzFdjFst1JPrXQazatqniKCGFzs02Iu+wn/XvwAfcJn/AL7rP1NdM0KzudR1OEszENCm0tvIABP0x19j71xct1zy6nuU5OM406a21+fT/Mx/FGtabpOiGO/BnXy/3cI5DY6AE9/cdK8E1nUr3XNSE147yHHlxIWyqDsuf85q942v9TvNeujq7SpdK214ZF2GHHRNv8IHpUHhTMmqpAsCzNKCqg5yrdQykdGGKpz01D6vHnUVv9/3f5nWeDL2HSdFA0+O5udUZmkvgEykUGUWIDrzuZsk/wB5Rirn9nTPqKam9nctaWkyvdQvzxu6Z4/LivT9B8CaJe21nf3dnZW1vLbKW8yV1ZTv3mYuSclgWAGNu7Bx6c/Z3El5eXOn3W+OytJiJCVwRtPC/rXPU3Uk9D2MJyKDg46r12+/X9CXWhrGs6tdX+ki7tNMuYVEIlnZAr5BztJJPAbqfcVX0W9CQ3SXuoXcsyTESQvBkiLswbuT9B0967bWfDkOq2OnCGSYR2gOcTlHbJyCMdDn+dedWXg7xKmuSy3SBrOxbDlJgnmqOTjqSx7kjg1nzJtm/wBlKOn/AAP68jptUvdTOpR6VpFvJC94oZfOAVVTGN+M9qZp3g/Un+12emajFBCkg89S52yMQenvwan0W8k1nXLWeIxotogEjrMHYoDgqCP8mp/GlraahdTtoV5cw6i0nlEAksFwGYuMYA+bA/nwam99jRRt7r0f9bjvCU2paHPfaWyrMitliEUE9QQT35PWr3h2e7s7OWyOn2qyzTmV4vP2MMZBPTjOVI+nvWl4dMWj6AYriGWaEHy5LmRcNu/vY9ParT6TYWtxcXOtvHa2i4bz/MHzlsEbW7KM/qKHzMzvCN7/APDiJq01va+Xf+XAyyf6tDu4zngfr+NcN8YdSnsmtZ9OkgWbcJQFILcgjIHuD1x/CKNW1d7PXrmC2mS8U7WtJ0beHj28sT254wfSm6n4Xl1S1MlzqNvYXUcRmhNwP3e4DIUsTxnHoeTTV07dyuSLtNkOpeANT8YWdvd61fmwkaJJEjit97zuFwzsSQRxge+Krajp2u6Lplr5V62rQwQrbpPGgSW3hXcNmATxlj1J/Sr3hLWdR1DU7WS8kGCRGecsh6E/j6V6NpS2B1GeWG6jNzd24U7JlBSYjBXHHGAMH1HGc1UKspO1zKvg6VKPNKN3ueRTtp97c6XFDcMzxTM88krEl1z6cn1rsbfVE/sK9uLOGEyKyK65Ad8DA2+ufT/Gsx/Bv2KzuLuyuHeH97mVztkGUbOOmeMjbXLeENO1CVf7UQNB5U/+tJZQrryCMZyPw645q7ORipQhtsrHfraStYCe0hkacbpGYrtQIAGK5J4IwxPp0FYPgvxteX3jO30/zTNY3D7XjkbgnBI5PfIGK5rVvHF7LbSRzXjG2jQwxIpyEHt7da5WAvbPBcW7bYy2VkTOc9QePesJR5nsd3PGMGm02fVEAWWaSNTCkciklkAXzF5GQT1746V5HqunN4k8T6j/AGSZYtPt5f39zsGyJCfvMwJHJBIA/CtG48R3qeH7K4vreO1a5t9qyRMX87ABVuDwTyD0x0NUNGtJ4Lk3VwyC4vyp+yxnbGFVT8xGcFgDx+PrVJ2XLIdKHN++pvfRfqeh2cpmhKrI4AyBIwz5w7n2968y+KOtKutSWNmivLKIp5FXkoyjGc44r1O4gs7DRrYuHbMZKtuwFAzwB3JyOtebXtkmtaomoBJ008hIxOw2kMwxk/Uj8hTp3Sd2Z1GnJcsfX+vUxtb8zVtHtcJPEhlzPAHxC+OFcgn5pMMwJPauy8G+F7WOGO9t7uJ2DBSGyAgzz7f5NZs1itjqVxiaSOwRVt1lnQERsVG4HB5GQcH09639JthbG6a9vJptKliZElhC4CAbcAH34zyacrtrmexjCfLBxhpf+rGxZgQurPZrcXbKXN4gCxgdBt/vE9sDHqa17G3EccEiurBD8uMYQHOTnqx571z1nrrLokNhaWrQlgEkZo+WUnKgZ65wDj6mr+i6hGJk3EBI4yMbgvGcbhn3GAetS3zA4uF/6/4Y0Lnyr+9Nl8jwIyHPleWGI+YBcdQfXp+VXbm1kXVbuW6d7RZgJAyssrqg4Vc/hWP4etpLCaFGlivQ6koQp3q3qc9gCQKteJdQtYFmjhEcMn3wufvtgBuf7o61cZc10zOquTVbf1/Wxw/xAll01FntbuPfcSeSRuBZMg7c574XOMccetP0q+aWaOBYw9wEVA+5uoHJOSeckn0riEefXdc1G+ulZrWzYRjJ2h29B+Vdfp1ncQ3mnTW9wHiunlLCJcfLG20sOSdp4578+mamom/hR1YfkUbVHr/T/I2/EFsxmjgtywSRVUupwXxk9+je4xXM+L/A+k3VobmzHlOEwYyxflefl5zXa6mPJ3QmBxnEm6P5iWyMZPYVs6Mtjqkhgdts6sUBgUvubjjBxjqanXZsSkoLnSPNdK8NXp0ZtPS8S3s5ik8hdxHvKD5QT+PAPeuIuYrnSNQdJYiI2Yld33iPX617/cqkM86EiOSJFKBlGS27B49uvtXk/wAY9Vt9QlhFq0DXkspUsFKuygAEkf3QwIB78+lN0lKLT6BRxDhVsldSOt0HXG1TwMypO0dxbDar5+/ggAZxxwcfhWdrmi2d1nVdSsBJMU2XCLOUBwMLKMdSPTnPFZ2nWN2un21rZGXzpYwAikgSJjPToeAT+Fb2nq0WmW808oWN12pG5zkj39/Q0UlKLVwrShOLcN7/ADHadFD4g8D6hoWqSybZImitHBztcMGRiPTIGfYmvm+SMo7A4yCQce1fQcsK2W7aGt55HDRLjcpK84HfHYr+VeY634LunnMmjrHcbzj7PCWZt+fuqDzn2PNdNN2jyP5Hk4uiqrdWmtGcMVyOOtQyR8cirjwvE7I6sjqSrKwwQR1BHY1HIvFa3s7M8aUbGNcx4ORUIxWhcKOc1VWPJwBxVE3IxSinshHOKQimBaQ4ZJDkhDuxnrX0l4X+Kkvj6+u9Pt/DdtBBpmj3ToskYv3CERoFRQIyOCQQG5Bx2r5rGWiJPJIr1X4a6FBp2i+JtRu9R0O8trnT4bYRJe24ZXkmRwrLONoI8s5z6cHuNY7oTtyu5Y1e4ubB3uYtEjgiXJIjtNStAMZOSDI0fGOhOK8TP3R9K9W1vTbS30W/ubeCJXjt3bzLdbdlBIxy0NyQBz/zzP0rypulRUtfQmB6R8M9Ekk0WW+nsCsc92qQ3xkIBCBt8QXvkkHd/s49a9j8LXP2fSpxCo3zStG5xklSvA/n+dP+DUFhf/s/RyssSz2cs8EkrDmMGbcWHvtcfXNaPhLSHQ+fCAY45OC3qeeB64x+ddjqqlR06HmuhKvieV9Tft4kt1htRlrqYfcTkgDr+VSTyokHmQQhpCm2BMYLZ+6PbPf2rVnX7JZO7qC9wpXzG5O3jdj+VY32n7A/nTkGSWNpo8jPkxhiufqxwB9D2rx5Scn7x9DRpxslFbfiQT6RH4S0iY3cou9RkieVl+6Z7lskZ7hAcD6d8Dnx3xUL7WNMt9QmvZhZXSyNESpG51OHVewxgZA9B14rpviFrQmg1GO4vZWupIAsABO5d2BuOOScn8f5eR2ZvLDSlsx9tecy7WgVXXORgOAwx0x706t2rdD18DFRlzvWXpp6HLahbX+qX883mTX0yoZJZXYswRB1ZiewA6+1dN8KrNLfxPYT3axSws0crMqMXhCuSV5wMkD/AGhgj3x0I0CU+H5nvVlCRyGS0s5ohiQuwWTkAANlfTtgdK9J+E2jaVY6uNS1Extb6fbPcu2zI3qMnIx25P1FEaj5lDqFXBQUZ13olsl39f67BZWmsv4H1KTzfItIJDBG74/dyq2duOoGecEd896808P3l5Y3n9nXIaPzJN0izcBmJ/XPrXoVnqGoXtlqthcbTb6zdC9IJJdXLDIQ55zhQc56Vg/EHTBHeGwkkb+1LXenm4GCA3THXnjHpzVezS+HYI19HGej8v67noCeIrO58HXYs9PW31a2lNsyYydzEhRk88McYxxxntVa6W7t9CsZbOOSJGidN0jKQ5U8uGPHPOAOo55rldR1YQ+C9P1C4me5nuI3kd5iCVZWy2Np3bw+85Ycqy56GvWLXU9N1vwjp0As2ithpredAzFZIGUrypPGAeRjghvpV1KUWjlo15wqK+qf/BTPINPm06xlv1iESeZtEwxyHP3do7jPp3qXVBe6fez3kkzWm4xnYIgu5Rx19/pgntRrOp6fpDO9npxnaK3MHmNtk2Sufv5x2IyPf8ani1J9Y0Syi1FWluEuIo0llYAqhb5sr94gdfbmsOVNWieg5NXnU2v1erR31tJFFALcWnnWl0DJK0krEyHgbvmHOePpXM+JbVdJvo7fWJfMsbhNyxhiyxL/AHGz2wRj6YrRutT/ALL0+2sQ7z308ghigjG5m3c/KO9aGtBb20bTdQZpT5XmySOhLiP0z/vEn1qHGy94mM+aVoP/AD9Tnba/sNNiaMZhtp4ikc0a7gwODtzjHYHFcX4z1Tfr80CXrywINslxs2CViR1UccVs6xot/pWopp9nIkFg6+dHIpLLMwP3hn7pz6f0rQ0jSbLa19qX+k3E6KrwPGqJHHk5AODluh3cY5FQ22rM6qMYUZKone/9f1qZHhVJ7W8S5mjYWyuyq8RUS7ivy577cgdfQ4Oa7TTm0+60W9EMNus87bhNErfvNsmQpJJK4A4PfPOetQ+NbS3Phy8n0u5jsY51VQirkNyDswvrgdOnWtf4f2dz/wAI7c204C3F1BymFyrKCRgfTPTHWlTvdI1xNVSh7RaWa8jM1O505PD8lndArH5LZDn7pKkfKPbIP4Vx16FbwzJbWDkSSI2HTjbyNzAdOVyOMV0/xC02yPgySexguYZ04WSVmMcq7eVXrjrz/MCse6utMTRLh4nWS48nBkjXerMUIJ68N6DtitOXlsrnnuSndpPc8i+yXdxFqN1pkTT6fZH52JHT/H2rp57LyRoiKUjTUREke91YIpHzHK9CBxz796wNLlEGneZLJ5Xl3AMkqkZ2nocZ+bG0kHHfknjHRJc/2tBYFGichy6eUoJHclmwPmHGePStZ2jC6MMPGVevyN7XO3n0MwWWntaOtzZWgZbWHcCz5GQW+uAfpxgVqxjde20scb+bliq7w4UgevoMU20IMMUTSLa2yomIUJIyAQGz3HXIHrSxA6XPHKRscy4WNTu8sEc5BHcVxTldXPoKUOWy7bHY6np19rWnPaRTI1wlptQvgKvGSCD3zx9a86027gn06K0McNvdWjMriUYLqeO/dcZH1PfFd9qt+g06L7OpN425g5GFyRXAXZv7G/We8t4jPHIQ8wUOpIY/dIyvU569TWqd1dHDL3XaWl/l/SOn22WtwLa3TRsiZjjlTJG0N1UY6d/xrK8RaRqtvDaaNp6G9iDqfNjJRQoxjqT8uPbNcvpmv3MXi5poVVoLf97tH3QT3A/XivTBr9rq2kT28M0MUpUqXbK455B5B6impK7jIzcJRSlHVGZEgSWK4uFdokUWcUMvARySWYt2O0Ad8A15rc31zd+NL+K+eGKKPKt5AYqm3Hyg9cg8Djmuv8ZXKp4ftbGW9Sylt5Q5l8oO1wNu0sMdDjuetcK0jMjT6YwuAb05aZ9hkC4KllBJVSCRnPJzg8GtNHHQVKMoSvLrsepeH7y2abS7sbkWMSxyuMsSnG3P68cc5rn9ei1LXnubq1jg8u33gGIlZJAcDDE8HgdPc+tR22t2/lmKKFVmd/nCEhTnqAPQZ6ms3xP4iuNH0yVLC3EMTSGN5JGByw6ge2CKiDvflNJ0nop7+Y3xLqVjonhS30WzMZnlQSOyDH7xjy3PsMVY8AXhi1CdJLsW900Wx4oyF8xeSe3QdwT6V574tnsLkWsltKZLtDmSQg7WDfdAGBzw3X/61Un1C+mhjmvHkeNdwDtx+CnHbqRVOMlYin7Ozjffr/wD3LS7k6jqNzp1tqKw3Mkyyqh2EEjgAE9M557Guk8PT/aP9EeFkvYhtzEhDBgM7j3ye5968+8MQaH9htJrOye41Bl5kIJRcgjlv1/KuxtY72012aeO7mknvmRl+0MJBIACuXI6N7eh5rJXerN58jfLHt17r/gGnrM0Jtop0RYiYwpIfeCcHJPp06da8es9NGr63qtxbxB8SsY0UEhhn356V7Dq0kSxi8W1820OW8uHCh9pwxU9PWuKi1Wx0m8vr/Tg8xODbh8LgsOrY4wMn6mtrX0OSTcU5Q3t+p5/q+o38d2+nmRoDDEG2ythkXGQo9PTHvXoHhrW5YdEiivvKd4I1KPKwDypkfIMDBAPrzg151qOi3d14yiXX5ZY5JpM3Fw4LN5YPVQeuADge1df4d03+2UkFvHLMiBvLJkAZUXABI5555AqpJR1RMJKdoTt3MTXPEqXN41jBIDJAS2yRhnB5x+HStTwXqtzLfTQtA0xijNwWxjdGo5IJ5O0ntyK0k8Cz6fpmuQWlpHMdSj34ZATAwO7evfPGB6ZPrVL4TaZeP4okudSjeRrKBiSiCQZ24+Vhx0qVOEkh1adRRk1b5a3Xns16mZ4q8Lrqb3OpwZSaaQyPIz795PJ3epJ5z1rz2/066s+Lq3ljBOAzKQD9DX0jqVpHp4lu7cnezsJ1VcITnIIX+H0Ix1BrB1FrTWbRbRlicTD5Y8fI/PIz2Ydu9audnaR508I6keaCPnaSPBb5EfcpXDjOM9x7jsajS32qBivQ9d8BXltE8+mk3MYPMO394B7etcU6FWKsCrA4IIwRVqWh5lWjKm9UUGiwORxUEkfXFaTrkVVlG0GrTMCGLGwDcOlelfC6f7N4J8VTLdm1M11ZweZuKggLM204hkBGQOCB069jynwwt9Nu/FUQ1kwNapEz+TM8UYmOQCu+X5FwCzZPPy4HJFehvqNjbeGLxfDFpEti+p74ri3juI5XUQKQJDBKAGXzMdCOvAOa1i0VPRP+upy3ikiTQLuWa40aZiFC+QtkZslx3RElHGcnH1rzicAA4rsvFmsXl1pBhub27nDSISktzcSAEZPSVev0Y1xTndjNRNtvUmCPb/g3d3M3g+10oFlszqlzduAeJCsMChT68tn8K+hdN0/7NYRIRjA+cgfxZBJ/DIFeNfAXSvM0LwiwRm+1XeoM/8AwEwAf+g19DWxiSKQSKzqAUAHViW3E/mAMU8U7whD5iwsbVJ1LdbGNqbJdarHZRA/ZUCxJPxtY9Tj15OfxxXlfxH8UrpV09o0yxLdMrLLKpJSMAhSQvOO+B1zXo/iS+GlWF1euqEQxvMik4B2j9OlfL3iiWbUvFks+oyPdWs7AiZSW2A98DsvZeBwK5JO2+57mApKtJvol+J6nodhqU7xW948NhcxgJeQW0CmZgIx5ksrffzhiGAOBgjBwa6XVdGtb2yOszhIWlj+yvFBHtEbIQqY54G0Icknmq3w9uNLisIlsmu4L64tpPs1ukKuHK8tu+8dpIHBxx65qXxNdNdWmmX2i3H9nDe0GpWiv5ZZgA23YcrtZc4449ua35Lr3i3VfMow0tp2/r8TC8Vm4s4LDRxdRjzWZELrjcxIJDYHTPP41Q8L2jDR9R3zgi6VwwVuA/dRgDjGD+OK2/E2nWc8y6hpiIUQRy23mOXEOQCU5PXJIOfSuS07xFPoj69Dp0dtPdiD7Q8M0ipkdW25+/gAHA56+hrDRPXc6Oac4ctP5306l9jqZvYEsrf7Re6eyLGPKDq7AgqSncEcY74zUvhm+a/fVIL3ToPtUN6VlZ5tk6FsAAo3VVKsCeo3c0vhXSLiE2/iGK5lkvJJFmkRQBnHYKOmOcUatax3XxCl1G2jmZL+5kM0AKpliWZU3ZxllAOfUkDJHMRrNQfKb1MNCU7N9N/Nbr07EHjbw7NbTtDo8ETRKVVyxGW5OcHHHX9Kx7K+8SaRfR6ddQyzWT2yw2G995TByArDGOPlx3Awc9a6jxDqCSJHcRWTKkLHciPsKY6L7Y4+tc1Fq81noxjvGnitxKJissZUsWBwVB9M5BHqahVHJ2NaWFSgptJtf10ZiTWZuryey1K5W0uHkDxSFTtZs8rjsee9b+nWtxDBaCSRo5oXMshmTcZep5OMCnxXS6hfNqphawUMZk+UMwBGGUEjBJB/DNYPiLWpb65HlGWKzQAeUHyC3ce/r+PtWqko6I5KlKc53mei6NFNPJZa/LM0LyXMkdjDtLl9oC7yewySB6jNdHp0c8epTMrMWnCvMzttCYTDEZ/l3z0rB8J32sa7DZvcBFh09RGoypEjCPCZwegUD5+cbR3ror25gZyqSq0AAV3B4I44P1wPyp1NUkY0Y+zbd730CTSDaaXcI0u+J7UlWC8AAjJx9PT1FZekzrY65cWNpFJd2E0SO7gFhGQzcE5A6ZYDnr+Uk2pQwxvFIztbzQyxo6vtC8Zzn0/+tXGaNe3dvdNPa3Fw5kTZAsa4D4zu3cHOAcYGPvVldJWR1wi5tuT/AK/4B3+oWEF/FPY+XLbMoYPGRt+XBJ6c4xk46U+CxjsNOKWt2/zBYwzneR3z7Diq+i6rqFx9kuFi8i3jYJuLE7nUZ/HqPatiOW3/ALZW5itoIygEUsavsYMcZZRzjAOfpmskuZ6nTJuF0lp+p554+1CT7DJFGhAdcx75OQg4PsSf5V5fq/iRre1isrS1VGQbRLGQpKliRn/aBY19AX3h2zmsjaXKSOUdhG2fmjXDHAPoc8djn3r5q8aaS9hrZt3PC8IQCCR6n3rVeZzSs9ILUvWWi2UuktJLemK+DeV9maMkkYOWPoQcDHfJ9K35LyHw74ZgWBLZb2OIRBvJ2mM/MTweuSxJJ5yB2FZmiGFjHBaxSMyjJYnIDYzge5rQ8P6Mut+KFt9VEi2hIaQbTnrx+vvSnVb91G9DAwg/ayd3ueoeFY7m+8JWNxeMj3j225iRtD5XIG3pxla1PDmi291YCSZhHOWMjODuI6cEewxVDxTqccF0lvLGLYB8oUGSg4GBxyOAfxqt4V1K4tNQmWGM3cRZmV0QnLen/wCusJLlfc6ablOno7PcsQaFPqepXVtqUtwlnDu8tIzxOP4cEc4OMkVH4j8Gz6o8tlpqw208S5eOOQBJhtGwrxxwMn1IPNaWiyq2qXM21wHBDozY2kHO7j8v8ak8b6PcPFePp10kEq24aO7V9jSKuMqeNvBzg9Tx06100LbI8/HKSd77r8TzLTdH/sLwzDqeoXmVyy+UpA53EAHPJzyeOQMcc1o3BtdRhkurO3BjWNd86AgNITkdf6+lSWllbTfD7UbPVIgqh/PWRoy7gNnHBPBz3HrWVc39ppPhIWl5FCkuAxVQy8gYD4JxuPcjtirtFo53OpGdjYFy/iXTtML2URuIWfcxA+fbwNg6nnPt+VcV5BTUILOzTyfNlVYhO3+sy+OWOAFz37CvQfhJai8skuLiy8tAjSi53MGOXJGM524GMEdf1qPx74Utbe3Op2k0huI3XKyHPmFiPy5Nc879D0sNOmnyvR9L+pyVnrAtNbnSOwtzIt0Wdtxy8QOAi84AyCSR1z14qj8QPEH9qzTM0cb/ADeaWaMExtzgBjycZrp7nwldWtnLqN4YohFtAGc49Qfpzn6V5zfrLOlzk7o1bHy9wTxgVUJu91oXiIU5LlWrRmQSLLbxHG7zGGWRcurdOnf2rfbOizwvcPbalt/ewwk744nDYIdSAOdvI6Yql4bs47OWG+1GzE9is2c+dt8wqR8pA5x713Wkw2Wt313cWf2aNUlMxSbnaXLYXfxk9+gFbXRwRjZ3eyG+G9QvrLw1HC1tF9ncErzyrFuVx1A5Bzz1+uOx0WO5eV5WnjTCbgJpwh6evPTr61hHR4xGkktyFG/fJ8m4r6ADPNdtrdrNN4fWy0QvObkAuXIJZU+Y5PHA5OB2NY/HKzOy8KUbp7sjRJ76xvYrtIbvy3yqlSgbeudwGOnQ9PQ15xrL30sktrtFubeQCVYxj5kJGfqMmu80W5kh0y4N1KPs9hMimS2YOsvOXCE4BG1Tz3rjTA+oi61FZGeKRncjYWkbcSdxHTBYgE+pHFUr8vn/AFcI2dRt7K339BuraTd63p+lW4cz3CyBYp2kwxEhLPvz6EHnI4PTvVbwdfz6OzW4ieSf7RshlXAjGTjJJNd1os+qXdhdW6PGJdLha2UswwshG0/N3IXA9P1rI07So2e1FyRBYXskZkbH3cM2cAfe4XdzjHpyDVyanFLsc1ODhKV9r/n/AMDU6JtHu9Q0W+XV9WvVO7EaCRUWR2PCkjBI68c9K2PDtgmmK1oziMvGPNEbhwMgcr059qb4b8u3Gt2FxC3kQsUST7zBQ42nrgcYqzZ3dtPezy3cgL26bdxGCwPIz6ispxil5pkKU3eL2/4CIviOHFnFHavGIrkos86Dbuz/ABAHuMd+tcbB4T+y2xhivmmQrv3BAu9cnOD+H513/iGWO5iLxzW0QW1YMJQG+Ugj5RjrjIzjufauJ0159I0yONXjltiSY4pDyBn165qqj5orsVhbw2dpIgstRihjjiu181I1wJww3Af3W9R+tVPE3hGw8TQ/aYVEWoFMJKrbf93f13D36+9dLfeDhqVu96W+zs8fmRxu33frjtmuCs/E13oV7CmoI0Vkk22SNhlowDg59selKM3CKklobVMNDEuSjv2/rqeY6vpV5pN9LZ6hA0M8bYYHofcHuPesm4g3A+9fSvxF0iXxN4TRLOATqLYalpsxG1jhtssIx9/IO4fQetfPDJyQQQw4IPUV2L4VJHy9ehySaRzMMSzSLGZUjywG5z8q+59q9DfTYrXwPpNvPd6XcvNc3VwHiurX7v7tOkyhgcoehH0rzdVOeBmvU4Xt4vAfhiC4muo91vNOUW5MSZaeQbtrQOhOFAyG7cgYrVXMJuyOD11fKtY4wiqpkyCoTnj/AGHYd/QVimt3xQkEckC20qygliWUwtzxxujAz+IrBc4BPpUvcS2Pqf8AZd1GO58LW1rFiS/0ye7fyh1CSmDB/Ehh+Fep31ywv7qCLC7JCi9cZ3H19PWuV+E+neGdNvdek8J29zbQyWtoZx5m77PJIN/lqTz8gxnOeWI7Vj2WuRf2xcSSXbTedIXDEnBwwBIz0yeeaxxTtOMWdmCp+0pSml5j/jdq5n0EaRYx/aLW1eKW+Ox/nUYAiLDBwevFcFNpJk0y3FrKltHcHy3dyZHRz93erYUBvlXrxjoK6rUZ0ubvUmIEluty3zK5R4ZDjDEj+HJ9+mK4nxb4l07SNUayvJFkikQLNEfmP1IH0z1zUSnbfW56OEptap2t1OssbG4uLKK707TGh1V4yHuEkeFrRsYIeMg5XPSVCNqgEhcE10981slrpWk7reF7hWuJVdvOufN+UN57FcqVycHgMOa5Dw7rd7d6ULzTr55rb92slwDuuIhHnAGep5PBGSOBWfovi+9kj8QWFlbJ9sv3dmupVaKRl3ZMabQNhON2On8J7Vs8RFws9wWBqSmuV+6tdP8APbQ2tblXTzDZxb5LOdyuSOJCOuDXNr4a0+PWDc3MEl2knMTBzmH8O9VLich1VvMAXKl3bOxu+D/StSC8cQoolIwuFGOeK85wuua560VKknTgdY9pPDZKbANPHEfMUo2CvHIYVzeo3TSS2ryQCJWRmUBcgkHg/XOKl1Bp7dbGfLxBgScHBxXfeEUh1Hw6ttJapPIN6RnAypbpgnoelKMXOViJT+rU1KWv6HmHhK++1a3tulhmiGX/AH5wu8jgnHX6dK1tbnnuNPt2WQQ3VoxWJdqvGVIwwJOeMdsd6Y1nbWvieztoI90t1MLVYn+XLE4Cn0571fl0Q2s8kQhDQ/aAZFhfJI3YbaenrWtKLS5QrTjKSqx/E8+vVv7hYltCQFz50hb5gvrz2ArV0CLS9V8WWs+ipdXItnYpbGLJkiCnLuRwSM8jocdccV1d9b2+j+H1hmimnur1HjYIoZXGRlRjkHIrl/Deh2ukaprT3kxisYeUcTSROkcoIJjGADzkEFccEDBwa6adlucGK5pax/roeg+GtQ8M6XpGoX09xHnehK+XgomP4PTJAyOM4HpXI6744067S2XTlIsllLv8mMgDjcO4/pVvXJbK28B3M+l3UcdtJagtIkWZJB90xLk5wAdzHjOFwOteaeD7GWOzutQnjkNpjyo2IzuLcDA9cGoqqPs+a+w8G6jxPLNaP8z1/wATzRQeF4Z76zbzJYQ0U4AKoGOdoPTjg/jisL4cXf2eKaOaTKiUMiIxWWOTGN6n3HH49K7Gy8PRXfhe20y62RCGLyi7HIBz1Knp1/A5rzTxLo91p8oguXaG5iTI8vrg/dIZTjHbPrWCbdmdyjFXgu56JNcxyXixQJIkGSGV2bao7tx0J9Melb1rc2st0WSTapXImQkAkdFPsRXD/D+KLTbZ5vEfmzOyhSlywwWycYONwXBGfX6V11zqN35Bk02EahOp+9IQkUQA4XKjknHA9u1Q12epqn0toauozQ2wtPPMYlCNKq7ANoJP3s9RjGPQV4D8XNb0rVdYS+slfzYkEbMzAh9owMAD6c9a9M12xvtWku7jxBcSB4gg8m2ZUQKxBKjrnKnqTx0wa8A8fW8FtqLR2qlYlJA+bPHat4SZyVKagufqvuPTfhCLq7s7eXyIEFgXvc4AMoGMKx6tzgL6bj1ruLvSE0+XVNT8m6jnRsQC1iJhA6sH6YAzjGPcVw3wquWn8LR4ZYSB5THyt24L/n+VegyStDpsmmXX22ZAxuQUIMkak5UsemQDzipcm1axrTjqnfRnO6rJJrv2O5cSRWuzEBjBchl3As47DIA9sj0xWx4a1X7PY28dxG8ESyKodgRg87icngnGK05Z9KsdHule4ewurq3do55chVkZRwcDj1+teTaNe63qF3c+VHNexqv74cuxHcgd+5qXLRWNfZxmnfRLa57JqVvZz6hYTW7pYs+Y3LHIdFHykD+9ngk+tVPEusjTPIguw13FcxPEqRx5IPTbg9jn69xXmVxqCRahHaaO1wkQIeRX/iI9M9PpVDxV4gur6aH+05ZQUA8ps4IXPOKmba1S1ClTg7Rm7r8T23wnaSf2WlvqcUAkkQwCOYjIULgA/Tp+FcH4q8CWVz4Y1GbVftMep25b7OqscHBOML0wR6813XifSvs9nDeaS4mt3AMcsZ3ZUj73uBgVb8SQy6voEzwyM9ypEnlE4RyFHPrk46dKum2tDOfLNKcev4WOB+DXjCW9sH0i4QJLZoqgOPkZF7n3HA5612d8+napcPbPP5MKxjf5g5kwQx+Xv8wAAP8AKvF7a1v9K8XzXc5ZLm5cxXJUFVXdxgAenFdvA5ae6gF/HJd+UGS3ul5kwuWw5GFPXAHXHWphJ3sbSw8GuaO/l+Z13hjyNY0+7027hWa3IMLD+PaCVCEqeDjPvzXlOveD9R8P6pe3ej+dJaWq+dvVh5kA9GHqB3H1rZ0T+04LmXULEBFn3DZ9oVmcA4I2feJBPXHQ+9dhZajBPbT6ffTxwNKn7+RQVdQeqkdwABikpPaWwVKTg3KGvl+dz5ykuzagwHJt92Queh71a0iWJUlhtpyHkI82MclgDxg4yOtdN40+H1/Z/aJrVUutPUFo5Y2zhTzkjsQK89ure40W+hnRw2443DgH2Nb2urHE6vs5c1j3SK40j+z2ubv7Ulw8OZE85lycE8E9ecdfToa47Q/Gl4t3aW86COK3jlikRpGQS7yf9YRzjkcDsMHjNcrP4lm1OxjicSCSN12nI4x059c88+lZ9xPcxf6+WL/SAsmXO92VscnHruJx14oUHbTctVox1lqn0/r1PYPDfieyjSfT1hjvEjeMlJWPluBu3AgdRzwe2Oh5qkmpR6fpaaeszF5ZZDLDs5iAkBUBwcMGCKSOgwMck1W8P+H9LkeG3tdSuprWbAkNvAzy7z0U9M4zj/8AXV3TdOhstZiZbm2aMBVWaTOwOQ5G7IwANhBPbOc0oOVmo9Dpl7P45XV9eutvX9Durazjg+HTskgklmVWc42+UxKjJ/MjnjAPrWPr91d218umW88zyr5NyxhcL5eyPypmbPQsNuDyCOnWtmzlhXS4bX7XZQNtWSWYSggSvlVCsM7kAK7jg9PrVbwPb3dzqWrrPEGvUkeGO5Vseci5VRz/AA8fliqfuRX3HPSd3KUtbO/5HUeGbzTl0+Kztm/18ayyyMPmQjPy5OcqD371D4ibTJLeeeURXFw5YALHslZtvABHP3u3YVOkJg06drqCG2mdCiLGiArtPGQoxnOfSuV0yG50rxLd/bopLm5Em5ZHUKqoygg4BPBB9ec4qVKUUZ8kZTck7P13+ZdsEEthAs928smSq7gDg4Ax+lVYLmO8uFFxGA0MjI6lcFD6AY61YieOSSe58nje8m5UIAOc4we1SeFUtb60ug8WZ4pJbiUyhi7LuGzLDjnPX1zWVm9EdF4rWSNTTZRLHLFcSSpFIrwnYSMDPTjr2rnPiNomlS+HGklj2XjSACUdcgfdb1yP5CtjxJNb6boaal9vVS3mNLuckLsUFeMbsngHjr09+UvPGFvr9vYR3QZFkiBKEHqeBk45Pp/9etowcFd7GMJ81ROPR6nS/DXVZv8AhDdJtEliuZrC/wDs0TSH5EikBxv9gQQPwHpXkHxN8MnSPFF8FUC0uJnmtplHylWY/L+HSuz8DTR6fq2qWnnFIZ4niKcLtlXDxNk9iVK+xatbWLQ6n4esmuIGHnLvQTMGWRGGRyCcHI/Wt8K3ZU3/AF/V7HFmUKalKou9/v3+5nm3wZ8MaLrHh/VZdUW2uLgTBRBIlvuiUBfnzI6vtwzOdvGImzyRUniiSWK20GSDTHs7ddKgZRZx30UI3gtlXR2B+9nOOpIOcV5fYaZLrF01tHLZW7hSyyXlwkCnA4Xc5AyfrXp/xE08prbWyJZzPZwW9qxgFtI+6OJEI3RzCQ8qfvDNb82mp4M0eYeLpxPfwFXlbEXPmTySnJY93RWH0wfrVPw5YLqmv2VpKSIXk3TMP4YlG52/BVY/hUniRWTVCkm7csacMGBGRnozMR16ZrpfhppbT22uah0Cxx6dE3fzLh8Nj/tkk350QjzSsROXLC59L/BpGsfAr6pfDZcaxdm6mZv4RvQAH8AfzryT4kLeWniC9+zqkaebM/mZ25BfKqB7cnPvX0PDp0tl4WtVtgn+jwuhDLkbjjt+JP4V83eM9Qne2g+1OGLQhWJHAK8cE/SuLGv3kj6LJoXi5L+v6sef6j4q1eNLhIr1kWeTe5UAnd3w3UVgabay6vq8EBnijmuZQpnuZNqKSeWdj0A6k1ev7SWUM0MavGOcqa6D4aeCrnxPqitt2afbuDM7cbiOdo9/X0og1Hc0xFLnfu6I6vS9MhstWI+HV9fX1rBb7L6/vkCQ3MuekSYzt6feyf5nsoVi1jSIr9bcRuuUk8vJkikUkde/Iro20NrSzFvZugVeBGg2gD8Oa5zUNC1Hw1ZX17pKRkXDhpEYknIz90jpnPP0FTUfM72NMLaCUG/Q5Wx/tFHuftenrPgkmUAEg+h9akF1JK2LqP7L5GGRnAHPp7j2rl9V8Z6hDGyRSyWV3u/ecg5PrjFdD4Hu7rxZeTDUrhJJI412MgVSPcgD8M1FOOlmdWIlabkzs9XMd5p9rPChEYYHahzt9AK0PC+rSaakwTJBDYUqeGH9a5KaeXRbiG2luY0hll2xjP8ArFJP/fPPP41vaTLEL66iYETxjMal+Pp+NZuHvXQO/s+Seq/Q5mx1Ddqvn6lDJ9nhuTMokGCw9MfnXoGjCRmj8oOIGPy7hwpPrXCIl1d6xeNdMZUB8wq4ztP+71xXoukwwXCRwrIfKRB5kZBVc9cr6jpUxujbETjKyS0LHiaxCeJtLa0ia404MUZweQ5iJBwPQg9u1cN4ttJNT8QItmsE6/Z5GuGRgHjWPs2RjBLDAHJrr/HerWukaHHIsjmF59pcHDK4BHB7Hn8q5zRdNGl6I98t2ZJWKOZXC8gjJUEE5Xn1/UVuqivoccaH7vnb8kW9LFlpkSW0+jwSRBQu5nPyt8x3qvqM4J57VNqdxaxXWm21pbQRWyv522NAynGcDGOv8utV7KDUb23l1K9eKCHBaCV1xtQgc7T0/wB4+1czeeKpF1bzLDSrvUoYsxeaibY2OME89evbFJSUttBSpSg9dWt93qekzalaXV1BNJO+wHJtypIkPoT3/Pmuf8RarFPdtcDTkghtAdz43NESRjA54zzz70zw/Yf2ssk81zf28oYhAoAiRuh28fMPf8q09G0+70/xDLJNcwXMd2NjvIuQw4BDAduKhpq9zphOF15Iz7rxbZXGnj+zoVYSJtmMikgPjPuTVCz1w2tlEtrbtBEcs8rEKuRySwPf2rsb/QtJ0+b+01tf9F3yGe0LfI64K7gcHaec+3HSuZ1Kxa7sY5BD5oeRLeAqoAmcY2jPQnBANTy83XU2U4RWkdP6/Ixp9QvpIh5G4CQmZw5xuGeuB055rybxUJpddaO6iEconAKE5wNw6118E+tHTZ9TMW+1ad0YB+U2jJO30A79K43WrjbqKXCJF8rK+0nIYjHXPXp0rSnHlMMRLmi02j274eaKtl4RivX3fYZ53Xciglow+MrnpnA5rr9EubO81S7MltDO0ZHlCZcjbgY+YdCMZz/KvP8Awxrso8IWkFrI0cLpzEBnb13bOfXsfWuq+Gc0M9veTqHXe5iQEk7ccHP14olJqV0RTh+797oUfGWnTeI7fTVedBMsxVljZipAJAYDHf1pfsx8KwQmN7OO4EUkzeeCVcKVCqmB8zk888Y64rtYraRra2jdZRJGoVyuOoOT/h+FUL+ytdd8PHTppme9aQEOFIKsM/dPbvninG102aOd4uPT9DyDxjcRXt0+pWAlW/Dhm3PuUZHzZ47n19e9cdeauHV7TUQFkIwryRkkHPrXXanpmq6XcX4kif7KHVIZ2cDIzjkdm5HTpiqOjaXaa21wbt7WGSMAsZJR83H8JJ69Bj1NaNyk9jBxp01oz1/4f6/KPD+mWCMHW2UQkjA9en5GtrUp4tKie5tUIjijaQGTpjGSAOmfc1y1wlta3Om/2akQs7eIAvHJkJ8ozjHHTPXit+9trbWdPnktLoRgwfIgGRMfp2PfPtWaV3ZA2lFSfXczPDlhDqNtBf8AkSJLK7OWbAXOd27npkc4Fc/4z0TVJbgvZDzGO3KqwyBzziuB0TxrqmgauljPcBbPzfKwwzsJONwPfBr1nQoEvbu7uX1BzdRRfIFJPmZP8h6d6iSc9Huar9xNyTuUtEktYtUVpWkikRlNv5ZAfdjDKccHO0ZOB2q944tPKvbC7to44Un3JIh6nGCCfUckVn3mkIkkU8qyQt52EQHDPk4GPx71evtG1nVHs4JbktCkQUlmVSoBJI56npUXbulsdfuQcJSep0NqCsEsEcsJVUTeg4MjEkccYJx29PWvNfiF4IubfQrzEKKkhDpJLF8yAfMAG6dCM969S0G7toJmtYgbm4CiUGMBNo3YbI7kBePr0rnvHeo282kzvDayJaQyMZZp5SGmBYrkqeN2Mfr+HXStGOrPJrxlKpa2h4jpPhCSLSoLrUZHjMpGByVVd2cgfWsTSbJ7fxEoisxdKkpcKRncoOcEDpx1xXumnWD6joUQgiYouPIMmQBz+uegrg9fs5dL8eKlgsbSX+0hYePIk7qDycYJyOufpinzNxZnGklPlO10/UNE03wibS1ie7mdQ1xLFuUodwOD7DGM57ZrC8U6ho+pajbS+E7EWolt9ssEmSIWVwSUy3LN0IAPHPc46vWNKl03wEunWrplkDSyIu4ld25gw9P8BXGwaLqGp6fpsKH7Xp0UVxeKLdlLRSEYOTjKj5VODwdpxSpNpWXU7JSpzfO7pJ9/L7vRGzcXiahAxu45UurqfNxcgjLp/ENoGF5OOBiuu0OzbQZJ4rVUlsXVXiwQzIp+ZVY+ozjtWX4Wgs5VA86MQiPyJSp+adQxwQemMgNjHOB6VtaiZAkz2waC0XJklJwFVcnJ/DvWM/e0K51D3UtBklxJqeuraTzNDbOyiVolwYwTkk5/zwayPB7N9q1N9RnJIkaMjzNyghiP5D8sVz3hDUo9XudTvdRuZZbV2ESRA4IQ8Ag564yfxrW0947O3Ih05GWKRiJpDwyDIGQO+MdzyOKF7yt5/kZyvFtPyOo1C5sYjC8JOzYAwPILZOeB2xisKfUIrTU7m6UBN+dqKNylSeF9Ki0/WLa/kSCWwuJAoDFgwWNeuSccnoOPrVW+vdNmDXLObSNJVTy9nDNjkE/w9z+FC12N40mrXTMnxHqWuXd1e30Ntd/bfL8uNi6NyylWbpyMM3A5FY2gWM3hjxD4cS/aS6sppFJLKZNqqwLbV9vSvSoI11PRL65jZBbJEZC+8KHVecDuT/SsDTGtfEWueHI7e3uJP7OvBcSR20ZZZIi4VpA38Q3AA44/I1o1KUfvM4zhG+m2/wBxgeIdDkPiO8Ok3jtAJW8vzUwZB689OK6a7vBc+DNNn8RO1reaVNHYPfICysoO6MyKOqtGZFyOQyg9GNXfEjWkepSyW6sTG2G7AnPz4Ppnp9azNbuLS0j0q01QyHS7y7jtr6FOH+TcVdfUZlX37dxW6TjUc/W5yV5qtTjCS1Vmn10/4H4nzrBay3d9bRSK26V0VR6hiAP516d8Q3srrxVrS/6P813KoJaxc4DED7yow6dzn3PWtHwfo2h22peE4YIdA1S/WaxkvYpXnhuozMUcNHtl8uYLuAIC7gRypGTSa1fRnUZH1FdSVXnLyJ/aF9HkFueJoG7e9daWmh8zUeyfn+h4xq8Yi1KeNUCBCFwAABwPQkfka+ifh34UW30f4fWPMbXUVxrt2pHLsWRYifQBOB25PrXzxrUom1XUJBjDTSEcjpk46AfyH0FfWHw81AatOmqQQusFnptno0RYEbWjiVpBg8/fdR+FVQ6syra8qPUtUf7L4amKBmYyBUH9446e+a+SvijH5U6QhsAMy7f7vQ4/Wvq7X7j7P4aiBUPOxLxhs/Lx1+uelfJfj1pLnUZHn3CUbpZN3qxrycdK0on12QR0kYnhjw/qOq28hs5NsBuI7QBujO4Zj+AVGJ/D1r3bQFh0rSrKx0+FVt13QoQOWZc75GPu3HvXA/D6O8sLtbG8jNvb2EUt1905knnWNQP+AoF47fN6138CPBbpEk7hAS23Hf1x61aWmhrUk3Jp7X0/r8fmb+mtKxO5x5ueoHQVdMUM8w4SRY+Shbk574Fcxpt75RminuFVF5DHgkfWrSypsEuNsO0GOOLoVB4PBznApJhKl1MT4jeELDXtMnENokeoDDQTKvQ56E9xXh8dhqngnXYXuoht5wyk4cdCAfUccV9PCQfZfMUkyHDEK2SPQHtXD/EDw/LrGip5hiicy/aChG4o2Mfw9Rjrj1pvQmnFNpM4HUbuPWbQXMMwmiUBFV/vqf8APatrw54niv7dbHVLRjcqNqXMYG5e3zCuB1jTbrS7wKiNGJBghMkZ+nrUFxeaxpEdtfx200CSn91PNCds2Oqg4wcY55zU8vNrE2qT9mrVPke1XC22l38KTJ/pEqDcygkls5A9/wAa6Cwubbyo7acCG4Jwiq3B4+7ntXh8nxHurlLeTULQO+cS7ARjHQjmu50/x5pN1Afs8lv9pjTKPLGQOO2PWspxk1sZRabVm2zrte0oal59pq7O0UG17beQSVP3gDwMjH1xXFeJtV0zTdLuYdDW4W8mLIgRyREmSMknr8vHH8qfH4mSO3ffqLahIw3Dc58tW7Bs/wAhXMy2VzdRSz3jctn5UXA55wB7elZRd9bHoxThGzf+X3Fvw/8AFPVtKnkXVof7asyuVimYKyMMYOcHI+o96vQ/EvWb5o3W1s7NRlmWFfvck859q5HVNNhso1W8fy2IBXepVtpGRxV3wboLa6biK2KQwxq2JpHAIwpY8d+Bxit4xv6nNU933unoeoy+LUvLaCUXCxyrgboZMI2epb/6/IrN127mgugbi8SeZl3oLZiUj+p71B4e0jS7Pw/EjauUupbogxhkdJYgMFgv3kYEYznBFQ6ha+ZMtrpkAuGlb5YY+MAdWJ6AY53ZwBUVIyiu9y8NUp81rWsem+B7hNWtMXr2txcyJuZGbBHGC2B1z7+3FY3ipD4disbaUxG1Z9sVuF3JK5zwFOduFxz/ACrxa0sdU0LVor+e8k0ySOf5bmJdxRc4LAD7wA7dxXfeJNeuvE1vYXcj287WoVIym5TIWAL/AC9Oo9unFTBSjHQ0nGNSra/uv8P0N28sYbR4b2xt4Hu/s0pNswUQeSVdZGcl+CARg98dCevzz4qtCdXeKyuEvI4xjz4EYRsR/cyASuMckDPNe1a3PZ3Y+zabcXAtniKfaAzIJAy4ZTkAlevB+lY/h/w2kusLbyg8R5RSv3lPcH/PFdLqWVrHA8PZtye/3nI+DYLu9mMEMghBO8Rqx69eDnIxXtfhaT7JpX2fUkcqJCWZGw654KsSPYfTHvVB/A1s2SL02yng+RCWz6kHI/LpWjqekarp2kX8lsj61JPKH8xwTdKo9cnDfhz+VZ35i7xjZJ6f11N/QPEVvFNNFDcGXyYwTJ/q2GVwRgn6iud8ReIdMjtYbPTZJJ72e4Hl2kAMrsedi4UZ5yPrXm96N8jSLcbrpwweNlJ56bQOuc0aHpt9FcyXt9LcWZsk3CKJfKdlYFRz15BI9cUlfrsbWjfmjv8A1+p2+ratc+KNKh0+LS7aJ4Wa3lMhIkgcOdy4zjO7IweRj6VgWHhHUrO2uFayQI5x5s6k7fXBxgCuy0OwfT7C1kQQRqJBO+CMqmAMKg7DJyR7+ldJPr6Sq1vDbIAyBhHL6HoeexNOo38iKT6Qt5/07nMeDPDkdtFIbpjKYRuT5P3AU9sfxfjXUXSXNldx3FrCgG4YRVAXnjPpjk1Ab1pdMlhWOIMwYJgYBbsByO+MfStC21E/2PGZJQzYBkieMgx5ODz37dKzW+jNZ3km2r9D5/8A2g/D50g2eqw/Ml1LLDKEOUSQHcMEeoJ/I1g+CfiTPaXdqmpD5gwUyg4Dem6vbPih4Wk1v4carYWeZZoWW8thI3zlkPY9MlCw98ivl/UPCWr6coa9g2oRkFTuB/KurljUjrueTOdalWvT1R9FS+JY/ENzbRYWNt6tGwY5Qg5yAPvZ6c9K9Btp11bTYLK2US3iE+Ykr+WhUcDrXypoWpG18l45JTNGAB6Yr1bQNWn1CBjKrYdMeX13DPJ+tcsG4StI9evCNSCcNLfmdBpyNa6A8TsLW9vJnZZTnbEmcCM/TB6E/e5qyGtItDNsUnMIZGxKysHI5LHPJ/xqlqcaz6VC6wjAXaQGwSM5596858Ua81pqp+w388cCEKUl+7kdcVo1rotDFVFJNS3udc3xFt1mdbVZ/s6TKrbGC/KDngdCeP0rgvFvjS8udc+2IqCRH2hwu07RwucAduCe/era6xpiXzays8KwRfvpYJtrCRwuASndmJI6d687kvZb6ZnUjDEkdyBnvW1O1nbY5cUlBxtu0fQOj+N0msHWwQyI65fy5NwBK4wwJ4wc9u9ctJdatp0FrpAfzLVZmKQgqSXcc8jqcflk4xmuP8OXOog2n2GB51tidyxwg714yrEDP517NpCWc13D/aVqbe5ZN1tBKSrgMORnoemQfSsmrP3WdNGbpw9+Cf8AwPUt6RaHSPD5a7lV53ZVCu2TEgPCLn0/rUXiXXfs+l3kdvcL5tyv2dU28rkc7vX8akuLyCwv7DTrK+M0ssbMZnC7oyPQjPGBwevNWPFFo15o1sI5Y5ord8+fKx8wZH3AT2J7eopxhZtdUTOTdpvZs878JpBYXFr9peeNVVxujAAU8gZz9Qf5VqXuvXK6iqIwdFTYzIMLyD1xxzVqyKTXElrdbNsjZ4fcQcdPzqW9sLaC4C71WNVyztxx61nZ9AlUTleSJ9H1NLW2YyoPs7/6xlX5hzwfwxUV9rWn3bpb3EdrPIrfumlBB59gefx6VRFhaTPfNHqBViI/Kg2NidT1I7cADHrmuf8AEuixR3lsdPeeZlBDLOQuGyeR2Axjr701CS1udMasZ6Wdztb6S3gsPNl0qydoWaS0jlTcFDH7pzwQOw+nWprXxTc2lnb3izq1wpW1mtyzP/o7EAy4A+UodoHrk1ydtpupxNfWmoTXEF5C4jcyMrRqhXPy55JyQeOMVXtFu7bXLGKdYks7XUIFa8jUN5jMu8AnP8I/h7d63i5HLUVPlvJ/1/wT0e51vQU8Cz6/qGnzz6Vca2XKrw3kr8oEbAjcCwIJBxwa8c0zXrDUdRt9U1vVjl9Ta3fSDFIzW9q5UmdJOhKkAYJz8o616f8AEb4f3lxoum2/hbW7vU9K+1eYNH3b4SpYuCqx4wMk56Y3dRXL23w4uNE8KXj+IoNE8g3ixXUQjYX9oXwVxJ2Bxx94fUZr0VBJKK/rf+vuPnqlSdb4X10V/T+v1OS+DGjtN4t0zVHu9MFtZtNPJFNeRJKPLiZs+W7KSM45yBwckAE1rJD5RT7PHbOg5JtpQf8A0TeH9BXP/CC2Y+J9SuOMWekXkpJZV6x+X1ZWX+PupFS3kkCxP8lg21SSGGnuTx2IVGz9Bmp6HDU3R5+sm68MgG7dLuAPOfmzzX2d8KHk1T4eWutXsKpdXt5LeSBBtQu9054HpjAH0FfGWn2s97dQW1pDLPcSsFSOJcsx9AO5r7o+HZht/hh4Ot40DSNYQSso9kyD/wB9NVUpNJ2JnFSeo74iytb6emxsSJbIducAEtya+bdUtxehrh1aY3d2w+Uc+XHy3+favffi1J5EF3My/fhjAB/iPGMfif0rjNS0MaPDBbpM0NxBbRW5z95dy+dMR6ZaRR9FNeTWg51W+x9Vls1Roru3+X/BsGjrdNazXWpttvbuSS48nIKxB23EKPUcD2xVdlmu7xba1ikzIc5U88DnH4VBFcfbbWK7u8eYUkKsq4wu4gfjx1rs/Cvh19S06Sc3aW81mHeO3RP9If5R97J4XOMcHvW8Y843UVBty/4CORPmExG6KeTIpEK7c7wCQSwByCME80DUbswi2tYDbvMSEdjldvHGQOG71dj06BruyuIgl5MF865gJaNVJ7Z9Rnt9KaktvA9tPdStEf4QoLck4H86i1jtc1Lpf+uxf07NtbeUztcTM+WYEnaMcE+nTpV4+bd2XlRWzsBwZBjauTjg+n+NVbSER3kzpK/CZ44555A710OgXVtpts014Gn029xCLB8MzTK25Wx0CHpk/jV01zM4q0kldanET6PFCfsl9avN583lQhkO6OTsueuc1x0gW51bUtJW3vLd4n8u+QpuinaNsrvj/vKQcEc4zyOc+9PqD/8ACbLYXsNvBqLI81tIeYfNMexHYDG4rhkB+o9K8q8HQjQrvUrS7v5IbpZDK7OMyJlNuO5wXABOOnPGaKlPktysrD1/aRl7RX0TX320PPfFPgyTRvDthrEVxFdwSyNbSwqmx4ZuSOD1UqAd3rkY71wumBbYPPIi7Mnq2M+2PrXsnjLWheeEIrC2sbuW6nv/ALZe3DDIIRSqIuPZic8dhzXlHiLRptPuGmCssOzK7unI5BHbrUtxdkinGcbzlum7eh7T8MH0ddLuDPZ2xlW3dQskQPMjD5y3sBjnseOprP1CzOta5c6japttZGEaoxIVCvy7sDjOVJrnvh3rFjLodzp918txcMix26xszzMeA27oqLk55ySRj1HoeieHd2l/YZ5bhbeQmRIY5ysYwcEke9YTTskdNKUYylPv+XU4K88B6x4h1ONY5pLxR96diAiDsBnrj2roD4M1TT9MMMdtLFEhPyQsHVm7HqOuB0rurUyQ32mWojisrdDnajZZlX0HZfc8mt+91nS7bdC4mlYqSjIM85GBk8DnJJ546daiCu7NjrV5RtaP9fkfP82l6Tf6bMojlttSjlKyZByW/uhfriu1xfaVZWaXllb2jXpQf2daQLErnGAHPJJ7gEkDPauI8QeLE0/x4P7OgXzA43ecQ3zjPTOAPb+deweDdQufETRanqbRFptrQRtjeNoPzD2I7+2K1u4xZk5881fVb77HD+M9FlvggnYQBXx5Q+9I5P8AKuSe+bSdIu4fmIZg0K7sNFIDyc/QEY9SPSvYPFyxR6tAt5byy7iDgSEIOe+fX2x0pw+GPhe7uYr2+S98vLBrIzFYmY85yPmGOvB5rOlK70OivVjTiufZ7WOM+H9jd6xZR6oJUbziQzE7toBILN6dDx1OB6iuq1eaPR7dgJEjtNqoxCLJcSYPrk7Qfw/GsufRNP8AB8Ky+H7qaKGWXBt5J9yyYyMPx0PPfisx7bVIGjvPscGpDUojCLe4UCaEFd7vGgP30CkD+Rrf2amrHmzrtS57/gR6d4uu7aJpbsrCrsVhtVjJbGeCT9MHNQX/AIlutTuPJnup47bYXhSOYxNI4UjDMpBxnnFU59Qs7nQLr+yrC6ujGjfZ5Q5adI8CJJJsqflBC4TI+/2xzm+FLW8s7Oa4v2iFxEVlJuBuEQU9Ao59zxjtW06Ps43RnhcXGtU5bbb/ANd/xOws9Ht9IvIp7qNmeVFWG7diWJ2jqD3xn34NWbe4F/rGqabf2kdxa3G1xNnDKFGNoB+bjAOM461jaddah4r1C1lzaz/Z2c7HDKJPm5dsdB2GOa77TdMN8NkCxRTQSMYWhGctjkHP3vTtWL0fumzd9ZvX8uw/T7KTQYEmtbiSC4RD88rbtsZ42gHtgn8aitL5ppbabYDa3I2JDGB2yvzE+2Dx75rGstUk1bxLdW+otIxsY8RxxxACRuAS2eMdf88Hr7MWeqThxDGIULFGi/d+W2ehUVnOTUbo1pwXPafYuavpt3b2y/Z0Fwyc7FG0Z71z9vrjSWM6apiFlfhWxuIH8Pr2xmpfE/im70bQ7u6sts06jZHFLn536HA746155o98NZs7q610iO7hVnXy/wB2PTH0rHV2Z2Q92LUtbfed2niO3vYVhtHRcs0arnaWbGQ27pjIxj6VwOsWojsL9J9k5VTkIWQK+4KTgjkKxBx7/hWjCLFTElslq4mQcFd3lY6n9eefSpvGFxbLbriaaFZkljluIT98YztI6YJ25Hsa6qWmrOWs1rGC0Z5VoNv9k1ZZPs4lh+7sYdj1Ne72JtLHwl9ujt4JpoIj5fyZZc8kggdvevK/BVlcXd6ZItsgUbjlR69s17ba6VAfDdxFeuiSsm2NAxUDuSQDgY989awg3KoViOWEVF9DghYaidPgSKzlvrmVWmJ2k7QOc8dhXmXiXwfqpNxqE1lNHAbZbpDL8xkVsfdIyBjOTnGO/PFeoeDPEGs3WtvZwm22CI25cMQ2wnB/Dj2q/wCMJpLTTL+dr2F7WWMwLApyxLMQduTzxhmHbcOc11UUno90cOKlKL5dNT5Slhee5UJ/rG7Yr1PwV4SEdo89zAiyPKF2seIxjpk9T1NY1rpJh1q1uZ5vOcYRmmfgYGFGT0AAAHsK9R8NpFPLHPcq7RojSskSHpjlunGOOvFTVnfREYbDcsueR23hzRtN0rTYkVUclTvKthWz9PwrC8epBdWOxVXdwwctkIF4HB445+lbHiHUIdH82wKNEwAKvMRknr/I1Qt5rPVNH0+G6t0dVlZp543PmSoSeFB4GBx+HuazVN2aPRo1YxlGpvqY3w8kgXVZ5Jmyip8rHk/Qe2K7zV7KHUNFh+eY2sygCTG0jaxyB9M/rWfpmg2ljrSzaRaXE1hcfJbwscvIw4KsegOeSRwAc1d126/szUoLXUJrYgREAWzFo4iRkDOPXipw9GcE1IvG4mnWmpUv6t+p5je+VpetXEnLxo4GyXghezflzVnU9Th1nUJY7VjPEI1Tfj7pOTnHb0/OuO+Kl8slxaz27gy5MU208EAnH4isb4Yan5XjaFZZZIlkUqZAMlGHIbH4VpJKN5ROVq0lz7nr0EDWFraSXcjSlfkDBsyDGBlj24OKq6bAkeuXq6tCj26l4oxuyCwb2zkZBGf1rsbkLqiSWUb2ysyENNECEkwPvHONufw5rjNttZv5V5CJ4FYq5VyOMc+46g59hUqGp0qunB6a2Mfx5qmnxeKJr7SzLHNJbqqwKhffP0YNk8DaevPQevGF8PF09rjxIuo3UdzLYWrakEYEeeCgV0Bbo8ZbI45IPODmr3hExnV7t7jT57pryNo4JTGW5XOXHoyjnPPQg8GuTv57vwd44s9c06ESGJ/N8uQbkmQjDo3qrKSp+tdcZrm5meZiKc3ScYPb8v8AgHvfhDxN4KnhsXe61HT7WTylh1KRHjRZ43V2VXJKxqcYYEfMM5xxWz451Tw9d3Vj4kvp01O3N1JbrZlN8d1bIXQ7D90lWfdz3A6VwMN7pen+K9S1LwbcaXpekX9hBqCjUT5liJ3yGgIThNyl42VsY5x0XHlt/rPleKpodGtbe0guZQGs7O4FxArE/N5T4xtJAIxnjua9DSEHPp+aa/4Y8Kn79VJXuexrY6P4d06/l0fQ9Oh1k6UGlfS7u5lLhpYPmTyJmZEJZl6gny8/dbFeZ+JfEE8ml3kdxLqiM8TgK+oXpTkEcpNGQfpuH1q94J0FLHwV4gu7mbSyl69nDEBeWzMmS8hDLJIu0/KOMhuvoccz4ogjtdJufL6EBRsdCoyw/wCedy4/8d/xrB7GD3Nz9mjSo7/4jm6lVXGl6fPeqhGcuNqLj3y+fwr6j0i1isrGwtbUAiCFIgw4yq8L+ma+ef2URGviHxNOzL5sWmKFBPJBlUn/ANBFfSPglRcwWr3AzJJGGK9OCuf51otIXJ3qWOb+JsEt74q0uyQKbdZImm3dMb1Cj8dzflWf4uWK71LULgxtIjMzqq8lh0wB6mug8XvE+vPK5QxmaOPJ6cD/AB/lTvDlpanVftVxOkUlthvLkxtdSCN2T05x+OK82zlJo9+hUUYJ/wAq/MxPhV4cEiNcarp6pawEtG08ZDSBtwKsp4wpGemc45rZ8QxxaZqdlqUExXVmvGMijlXQtgpj0wQM9+vWtrxPrE1nG9xb2u9ZIjEZA3MRP3XweoBJ/MVw8viQX2m+RcO8d5uRJNv3ZFXoQScqd3JxjtXQ7RjykwlOtUdW2nYZ4s1G1n1Wa/ggwocI2V2tknHbj05rIEdrPNIJQqopPlBVBbHc85q9uEh2ySqsZ/hC5O7uTx9Kz7azEt9LI77UjJQ5bA//AFd65pXbud8JxhGy6FTXL5NNdFt1ckY2k4baRjgmtG7vXMJurG8lEM5EbcCTAx84LN0yw6gcAkZrm/GDW1roc15Zq0ty3yo44K+rY+lYegaq9yIglykYEe54ZDgFs8kj0PFXF2YSpOpDmj03PYE8bR2/jiO7tQs0eoWsUV3E52LE4chHBOSNqltwHA65rl/jfbR6b4zm8QaXPYebDYiG+thKElGc7Wwwwwxs4HzdOMc1g67qOm6kli1qjRiCKRJZIv8AlrJuPU8cDOM+lYurXFlB4Va3vGE2qoJD8rMxkd9myUknGVKYIIOVc4INaTlFp3MMNRlGrFxi77Prvp5f1YdpmrXeoWkk62kVvBLHgGJSFXI2kDdk9QSR2zXHeLLqe+uPIwpBxuGPQV0U/iKLSb+4tRbxC3379zjduBXrg+hrEsJ9OeeVbtpXyoSMhuR7k1xp6bnqSiua/Lp0Os8A+HoIta02S+tm8iNT5kuQABg8Fev58V6ZdSxSTqLDy3tkKuSvy4T0we54/OvPNOvtQfxbpOnbHt7CLzUuUY53YydzE9T29q9TkFvJZzi1KPGScRyKGwAOoxj2qJISbumytZ6YXvpSihHYYk43bAf4cn0rL1a3kSRhYCSOONma5lBJ28f3ccn6V0cMtqzO8X2ktP8AIfkIA78k8nHIz7VW0wXtrM5MYnhnciQu5Dqf72ehIxjHpStZ2FdtNtHkzfD3Sb7UE1aee5uXcLJGs21Y3bGQuAMsfbvXqul2ltJDHOoSO7SMnzVDbMYPykDsfpwajnsbe+tJkghjt7kHO1vuFgQRu9Qag025n023WLVGNtCAxRWOQTnnBz09qqMFJ3YTqJQaWj/H/glTxDrSzy2LbozJHKhVd3PBB59q19Rv3kit4UlVPMIUE/MR2wB6dq86tpLK58XeXIqJp0IkuRKhwWbB28dxuA4x6+tei6Ppj3WoWv2ry4VVPM3MAREDg5z684A960pwaVjzcRJXSXTUeNJ0/UJ7V79o5Li1JECsRksF/udxwB/jmuO8YxXt5qMU6oyzWziWJ7dgG+fh4wevvnr85AruPEMtxYRRQT21vc6c2YftEirhAvKsjLz/ABdfWuMglbT/ABItzeWzX2mXblQpmIZJRgrIx7qenPXmtmlGyFG8ouS+R5Nqmmat4PuvteopPaXt9LJEIIzsCQoeTgcbTxjtWp4Wt7rXLjEtyLKOZmQTsMqFwcg8jniq/wASG17WPEAleOK5ijHkRNChwE3M20Z5wCx6+grqfAdvPNYXGk3e+P7QyqGK7VgKkkMxP+8fwJp1uSUkk7orBe1oUZycbS/R9fkafw+sP7G+G9vfw2Ml9NcTyRRyw43syseeuSvUemR712egPGtttQRxyHG+MDaQSOeKx9ESb/hFrXTYmi2WUj26SRqFwwdiCV7bt248/rVqGZ7jxBBbXds5ghVsoHAL/L1x3HOfxFRUWuhVNpp3WvV/kWtP0SxuZ7qa/EgkklZfMicq6Drk4+8OnH+zXOw6bc6H4nA0q6uJkvS0au2Am0HOSG5JHrgd6637PNawJLbK8sLymPZIx3hV6t9DnHXtVazgk+0G6uTJDDHOJ9lzjkDOMY7DP15rGcE1aSOinVnFPkemxu3GlaPc6YiXyJNKz7SrYGARyQf4ee4rB1XQ9MuhcHylmd1EQE3zfKq7R79B161NHpMdhcX+prdyTSTAFIw+5cDA+UevU1owakml2El5c2skvZeBt4657jnH61urKyWxyKDacrtt/meUQWMunWLPp9yrzQy+U9t5eSFPVgT04x+dQeK7WSa3eJbhoxGqlrcx4Dv8xLBugxkDHfJro/HmpQ3niHTNQ0nTrW1itwyNGp+/vYsS2AMjk8dsmr9oStgZLq5gdQcBNofPONrcdeo5/WonZOyO6HOoxk9L/f6fr8zg/Bujarp1zbahbMiwvnduYLtFd3eQ6zcy3lhd3UVrGsZljZmxvUJuztwMqQcZ7HPtnTFraxWirFFEpKhkyvH+6QPrUMs0lzFd2k9nG08ltIUkzxlfuqp7Y4qKUIp6kV6k6l2jxKW2l0vxpHa6Ddz3qF0RJ2BiPIBcEAngHIz3Az3r0LU/Dqw6eEv5CssLec32h2KHPcY56H8hVfRNLuPD5tEvIRLfXw3SPuDrFEWwCcdDxxVvx9eaZduUj1G0tZssZNzOwVAAqx55AOF3c8knHWtIwcpN7eRnWq7JO/nvt6HnjG3EkDaxvmTauyO2wrAdskjGcY7Guj09pEaMW8iRMxMMiSyEMxIb5cYyBgjk9wa84TWXt2WWN/30ThkAXlSDx+VdEl5bxXKQSzJcPIv+uj5XOM5U/wAicfQUuR6j9slJI7nxBFKLmWTUNlzcABGeVSDJwORnng8Z9qh+HyRLqtkbtriaGGYGYFyUGeQme2cGqmqa/I13pyPm9uzGYwZf4SRgM3uc9TU2h2d7baE1+9q0MV1II0JGNjoSCRg88HGe24+la6TW5CvD3X1O7tdWu7lP7M0u/u7cXWZJ4o1CFZDldgPXhQuSDg/hTdVsm03So7/UIlmxbIIXUDEigYXIH8XH6Vmw38rxnVZ4J2nSLyGlnYfPL03gcHgEHuMj3rNvvH9te6RHFN5N1BZyRtMkTZEhUqAhJ/2VIwPUk9auUk02/l6mdOL51GK069zgLvw1/aV/ci7BhjUOx2/MAx6E/jXF6lZSeG9QIcbLuMBlKn+Rr2XULs6sE1GC4i+eINcICsYV2YghVzk446fkK8q+IFg/lpNJ5wnb92Vk6Ahj0Pp0rmhDdbnoY6re0lo9rdjuvhP4o/trURp+pqudhKybju29P0rqvF9ilprBubKZrmJLYtcKYi4j65Dcem35vevn/wALs0OowFpTEQ+3fg8e/HNety+Kr230OAXl3BMhknt5bPPztFggMxGD1ORnrgVUIpNrocfvzSa37GNYawILu3TT18mdriTKhTmHeMbgc9OWOMYGBXpGqeE49R1yxtb+3Y7JiJIS+GkRmBYKT8oOM4HGa8u8HHSAdQu727uopIGG0MNwlhcqhAx/EMseeMY9OfY9NngvLCxliuGuAUUO8rFmJB4YZ6cAcU36leST/wCHOMX4dixbUV8PXs7M2pxQto80W6O5RWLoJlzhsFcY5/xs3vh46d4s1HVrzT7azvJFSOG3gQJDbLswVVMdcEcDoSeld3dPpdhrEOo6dcvPI8hkZJI/JKvnJUEdB6Y6e9cz4g1QXdxIZXM0uN/nMNr5PUEdOua7E46/11ucTpucrtdN7WZ5j4QJT4cajK8zRC41aNMiR03eXCTg7YpAR+8749s1yHil4zE22W3kYuBmOSNm/SJGr2HW20+w8L28Gh6TH9ibUJ5V+x/aOAYoD+8MdwP3i7ipxuX5eMc58j8aXDyxwhobqEGQnE0k5B47CVj69jVz2PBTvL+uxsfBCTWF8X3UWjBWglsZhf7mC7bcAfNk85VihAHJ6dM19t6DbrBsKKAUhIwOnBx/Na+KfgKLk+N7kwPtthp8/wBr4+9F8vGe3zbK+5NNIDyIpAVAox1JG3OfzIov+7sEV+9ucN4pS30aX7VfMnk27RIqyDIuJ5cqFH/fRP4Cua1xVttb1eztpJTaQg6fLO4DKxaNZduRj5hvXP4VhftW+I/s2m6bp8InE7yRzQSLkKHU7iR6kBl+mapfDWDToPh/J4m1q9l1HXbtry+lt7i5IjjmJ2ZVehchEGD2JweK5+VSutmetSlOlGM7Np30/L9R8etXGtP5d7csk1sdoiZtpjI6FQR9KvItrMzY2x3KYO7GVJ/wrESz1rWLbSZvEFgNCvbvzjGSheRI49vzMvB2ksQATn5TUiMfD8Rub2bz7ctsLRL9054O3J6/pXI5tfEe06cZR5qX3E0z3llqypcQL9nmA/eRZOz8KW9fzL2J4JPLZ05DHIcAY3Y7HFYMXjK3t9RnjvUeO1GCC0ZyB+HQVtz6nb38a/K+5B8jbeCv1oTM5c0WrowtR8TnS9Ta1vvs9zArfOUHzqpHVTjrjqKguJ7PTdPvLzTJbOSaQboMoGLJ23Z7jPIqDxno+nRaVdXBuEF0zeYEySX47fQV5LpDhtTjFzI8duzZYbsA/hUNt3Oym4RUZJOzdn5nt9qit4fNy7xmWQ+WGbATcfYfTjHauc1a1R5DDgtcnCcHAH4ntn1ror24hex0uzQLFBG6OwwMP+P4Vma7ILuSaTTgBMrZZWIGccDjuafK5KzJoVVGbmnbX/hjivHEKWv2aZWl+0nKsrAYEYC4Of72d34YqDwvJaLqNs16JpIwVwsbhCTzj5iCOuOSDwK7u+8Kv4j8L31xcW1/b3emWEl0sz24jhnkSU+cN55YJGq4UD7xbp389023JCSRZ86Mj5g33Tn9eK0kuXUzhJTTV9Vv8z0vU7HUb3xdDBqVyYJ41kmaZV87LIu7HHGCAefSvQ9JvIZZyqPGpIySjZwrAgH6GvMNJna5AxFHLPHHmYeZs+XIHXrjkjjmum0iCHTdff7EkvkT/Id4+/uAII7H1zWEl1NISvaN+h6RYy21nZyKbvzyZR/CcgbSFUA9MHtUE9xFbiKY3k0UOQzKgBGB9fXms0RXVvEby9Zt+3LrGPlwOAevJA9q5h7nVr28EMBGwkHzQuQATknae/brU3NVS5m2n/X3HfCWxfdICCU6qV5+uKk1jRIdV0+NbvDwTICAWw6dcYPauR1W/eHS5rrUrj98vKNFJy5wev49vepdA8RQfYra2OoxCWVfMEYHPHQccg0+azM3SfLeJ5j440jVPCuty2y3BltpVV4nByWUZ69sjn2r1/wVrcUfh+BoWkS4iTy5lxvKqRwzdSCeeaxdXuItYF1putyNa2hjyJWUb153DaT/ALQHHvXnmmaZqnh3V5JoppWugmYIYTkyjIBRgSCQQc98enFaKTTvFmTpRnC01Zr8f66ns+qXck9pH50zXNqqkAgBto9h7elcxhFKWl1PGd8eyJ/Uc4x7+1Yt5qF9FCZLiwurUKd0gIJBxzkgdB71QvdbTVbRY45MAYManPyfT3zV3b1uYcjirW0NOHQpU1B4XnBVTjcD7cfjWtG1ppxMs7zp5xBZwuQxXjmuThvrySEL5q/aE480Nyw9W9/ete01oXaC0ugqzkDd5g3Bsdx2oSs7kScno3odX4fntJDc3PnushOBGG+XAI5x3p9jp8eqaw94mxkR0dHAYgMuMd+MkDI6ccVzP2x44wdsKTQyfKqDAZMYAxUnijxBdaNcxW1szMHUShVbHbgH8atGMnKK93dnfzTw2CMZJHkYHClm+dvfFMttUa5ScTyExOxiODyRxnH5CvGU1DUWaWeMST3zMxyWJ28devA9q0dE1qaK2tbK6eOHzP3rqgJIIPUtR5kwjzabs9DfVohdyMZUia2+UKwwWQDIOO3/ANasrVLt9YhdVd1tzuwy8BgOv4Vhz61bJaTxW1n9qkYkSPIdrMM9c44rPu9aMdlsjgniRiFiDEHaD94E/nzWXPqeg6OyitfkJp0+ppdC0AgvdPRvllYn5xnBwexB459K60Q2txqss32eOKRZNxWNtwX0Ge/I/WvLL/xMLS3RorSacYeQeQvACk8nHsM5qz4Q+IVmttc3OqQtHEkoQSLhsEqSNwH0OD7YrWMW46I561SMKlm7P8z1DTZ55J531CKBhcFl2bdrRkHAA/Lr61qyW16be5DGM2SnBUkB1LAc89+Olc9pPirR7/TLe6syskMzOqO2QGK43rgZKkbh1H8ValzqmbRrq65iaEAvvwQN3HUc88Z9qjSL1N7upG8Nv62POrTxdJp3i6+tFmmvYJYpLZQyqSNw5DY4xuUHI5xXLPoeuQXV+txZNOsUmZR95V3Hjcw9yBniqK3Nx4c16LVUske3upHKI0ivyrYYEjo3Q4PZhWp4j8Z3d1eRtYxi2R/vK7HLMf7x/CtnfVMxhPlkpQWjVn8hNP0CSeN3NgWlUECYEnGMjisHV9NuvDmqWuoXUMbPggKcEkcqTtzwRzjPcV0NpqU9pbzyT3EoYxkyICSA7HOR9etO1a8j+z/Zx5dzbiJGlL5YTSEZOCemTUxRNS1R2WtyzbXccRjunjxFMr+UZ4gBKjfLnac4Pp6Ee1XbnV4LTToVtrHy7WEEMYWLfNgDcc9yAAa5ptSudKez1C0s7SPyy+YZV80OGXaVKnjp+PNbnhSeDW41MUMMcghkacRkg59CCcYAJwfb1Bo80y4tx92pH8SC11DWdat0hVLq6tYTvdbSM+YEbqNwB256ZIqjqNklhaLZixW0HykojtkH0J7k8E579MdK9VvdFgs/CoGkFjqMrrII4j882evAHzdSa8x8S6xFMsM7pHDIsRlaJF43k46Hp0zWdRP2d7nXg6sXX92NkQwaJqV9NJDYukN2y7ginHyopJOemcD9axfinAllrC2FjfNeWGxJVdhyHIBYNwBuB4PArpvhxqizjVGuNU/sy5KRBGklZAY3cKXXZ8zuNwIQADnJOBg0r/SLnW3ktrmNXdMRrMOM4PU+/vU0f3dO892a4u+KqtU3dQtf5rcw9GjIe0uFsLKSaOVXDMCxyvYpuwR8w6jnb9abcWz/AGq4QhpJNxWX1HNbVtoes+HreGZ4BNb/ADN5mduxQQMEnqcntUVvIsmoXMlzsDSgkLzgHv05ovK2pDdOHwFKxto4LUPMoUZ+XPDGvS/h+y3+kBdkiyJIWRiflZfTHrnPNcHYxDVruDTYJ4wTIT+9PyjA9cH6V6ZpF3LYSywvFGHQAAL0U8fpSkrmLm78q3LWqWzwNHKkhdgDvBHAH0rE1JYW3DKhgCWx1wRXXziK/i86ENvxj2J78VxmpPGyMRjMO5MlepPAP1rWM+qFy825g32kWuneDfDWnzXeh3MpiuJ/MW5s3Uh5mAwZgG/h7HHHTOa808ZWttbS2otvJywYt5RgI7Y5idh+eK9L1UzWnhzwhCZ7yK2OkpJsiuWijJeSR84MLLn5ufmP4V5n42dG1CDZIXHlkkmSN+d2MZRV9O4zXfPY+QXxNHRfBGK9/tzVbm2t2e0jsmjuZRnCBmG0emSy4/Ovt23LobyYLtnihVVUdNxUfnyBXyr8AJlHgTxNAlq6ySX9qjXPOJAzALH9VO4/8Cr6iaN7lL9o5vJkjuSwYY52j5Rzx1ptWiEH7+p4R8XtA/tXxiLi81B3WzhR4LYr97eD8w4xgKigjOckVxEVxZQNe2ywtsZt6yDg7+AAPpz+fsK9R8cKbnVyqglUQTTsCAflJCDJ7c9BXM+IbLTNDk82WeK6lZiJT8j+XtAJwuMFTnA9a8qtKUpto+3y6nCFGN92iW/1u7l0GHXtVv5bnU7oCJtybEtVDA/KoHzZG4kDHJzzXnWueMJPtNyyyOQpBA2Dax9cEccc+orU0Ce6uAEn5td7i2gfBZc9WI7ZHStmTwtpJt4VNjbRW+QzS8lgpOMnnJHvWcqnMzsVBUYttadP+GOLfUE1ENPcNKsjoCjKnLr369a6DUIfEWpWeg21tbJYm9cC3zJ5RkTB/eHcflUgdehxxmue1TU5J4ho1hCktpasywtEMbjzg5PsTW5/xOI9MskvbmRprFU2O5ZniAI29eRtCjjsBWnupanMoTlJJWRynii31u3k+zXzMsjrypU8jsTxzWGY3nhRL7ybaUMEzHGVwOzfpXsusWr6jo8esarf2si+UwMMT+WoBJBxg8NwMKOo9hXB3sVmwvGf7MLXbthSNs4x9ec96aViKi5tL7eelyzo1ne3W2GC4nnghAVpGlVVX8SQOx4q++iWn2pvOuZvNij83BIAI6j/AB6VmeAtLn1bU106wuoYrgQiRbWR9stxzgomcKWA5wSCecV3c3hzTreeWO71Kcy+URIvllCXBIKtnlcccda1nJxjdI4KVKEpuM57dLHKeKI7+TR4ZEuriSOMOPsxlYIoOCQo6YbjPrXG6LK8NzIwxtdwTGo5HHXFd9qWkXl3Cr3F69rphj3wvOCCycBQO5BznPp+FefQzJazXNysbvHGxTgY+hx71jFN9Ttqz0t+S0/4c9O+FNjpX2q71PWJxKLadEksZQCsqknJwDljgemBjnrWj4a8a6Tb+LTFcSGWIq0cDzZKRtkEBvY4IzXK+F49Mfwfd6kLvOsu06/ZGcLsiVF2k8fMxYseD2x1qh4ksrK4tNLg0vSZtP1Awr9qluJcb3C/NgA/dJBbJ55xjjm5QfKkc9Ocedyd+3ZKx7rqWrXF5GsOnva+dNE0ZV3PJI/hx6jPQ1PrEMUfyWsa2wCbmTdv8vgZGepOT1r5907U7o6XPp9lNO0kcsciTQdI1+bcACMg5KkEHgg+tdt4I1LXddi1X+09ShitLWNFMs0S7ixbapkYEEAnALc4JGRjNYKE78q1O+VSmoqeyX6/12O2l0vT9V0mPTYgBdlNu4A7nY9gfz5FeC66LvRNZkbTZJ4bq1cqSvBUjqD/AIV7w10yQxXkcsEws7kR3DxuCcDG3aVJB3dM5659Kl+I/gy38T2CX+ltbWV3t815ZFCpJGwH32A6qORVRTvaSMalflj7r0Z80eIvG/iHXJUGp6jK4QBQsYCAgf7oHNbXh3xDql3rGnSz6ncSSrNEoWUhuNw6561reM/hdZ6OLZdM1z+0JCpe43IEMfPGACfQ8Hnp60/wd4Y02PWrdCmZocSPJMdwUYPOAeTkcDFbScUtUcNOnWk7p/16HpfivxRDf6Tc2N/Y6lb3ZIMci7dkoY8PkckY/h4wTXkniPw9quhPBcLM89vLyJFJyrAZOfw5r111ulgTV5brGxSltLMpVhjJBxg8EE9cc0zU7e5v4vJuCs0e3zMyDJZs5DEn68cd6yTbd+h6E4RpU/d36nh0viLUobmLeytjgFhg/mOa29O8WRMFW/hjiaMkrKHzj6+1UvELLL5iyoqIkrH5sdT2HpnA4ri51jWUBVbG7kZ7VvZM8yc5I9ptdYt54J5EZHJUEEneD6YYdKj1XUJL50kLyzSLHwy53jvtJ9K5bwvoEn2M31k0whLMIoF+ZmODhTjv05xj86ydUm1HT5Z49TtrizkjXdsHAcnHUE8cH/63NEVrozGo043Z2Wn6g11xHGgEQ6h/m46/U/WtcaxZRWMscykyfeQkDd9BXmem+J2lH2OGCJVb/lo7AP8A8BJOBmtWHVI5H3ROeGwwcf1z1qXCRcK9K53egatab3uZN+wqEKAqCO2feny2FvJO8sN081s6tiP0yOwriGuYHBjW/WKVuVRkB/WozctbLmO+GAc/IjKSffBqeRWsdPtpRk3tc2tS0zV7XTp/Juorae4R4E8o5Z4n4ZM/w5HHHbI7muauPBsiQwIssf2qRdrIOcUq+NkR2jdZJ5CSCykk/rUseualEizWXkxrMdsc8iZYA9sHitIucVbZGFSNKvLmtdnbfDHwvBooNw8zPcy8OgHPHavQ/EOp2psY4rhEKKDHho+h5PXpnk15VYS6i2wzXsS5H/LNdpJ+oq/DcXkyC3nzKsfXaxYY6fMe5qJtrU6sNGOiT2L3jXSdLt9ItpYbeUCNUlmeORRHHLt+8G53ZHJ56k8DpXCXE8N5KrNDsjCqVlZiWk9WYn8uMV3visRf2ImnyB2dz5jKP42PAAx+PA9q8k8U6fNDdWyx6ibndGWZCWUxYz8hGOuFB7jnrWsW5rQwq/utX1Z1WtalbT6ckT3sI8lXZDFFgs23gFsZPKgc8D2yah0q6utQtQsM6BEdJIIFO4Qk5O0Z5wCx49c0mkjT5tP01LQyXOoalE8L2EMBZ4HRl2SMxzkPgkqMYwO1aGmt/Z11NfQwLBL9pOyOOPKnIAYc8kZH3TwOcd6cr8pnh7Komuj6mj4ltIZtMVdO8ze9xseN4sNjaDtznk5B6D8ecV2HggaDb6GToujs12UK56ySsuSd244xXK33i2LSLG6nk0gNd3amG3Z1CqpwMsMc5DYP6Vo/DnUxb6fJHcysJ5pFlwDtwQcggjpyT+dYqz5bHZiFJXW70/rQ0v7X+yx29zq0U4jVDGs27rtwWUHoCAwwMdxXknj/AFAXN1LthSKdwWHlnqCcqTyecda9S1K0g1E3fmPiNmLOM8dOpHrXkwsI5tamG0vBbAhzu4PZcUSumaw5ORvVP/M7v4W+Gr5dF+2XWpC2t1j+0IgCudrfu2xn7pPTHcAdhXq+iaIILIXtvbPdW1vGzPvUI5LgrnPJOMZGOmPxrx3w1qEUFzbw2pcgj541yykA/dwa920PxC6afbQiZJ7XLh7TaVyDnG5vTPOPrU0m72mY17xV6Lun5W+//hzG1SW2u/DkyrYKAsghBhRgr7hncQ3I5wPTrXzz4rjlXVZY2jkRo/lKYKsp9K+stM0601u1mhllRbiGIlcYRQd3yDPfknn3WuM+KHgNr7w9LqV1ADeW8f7qZGBZiB/q2APIIz7gge9b8rZiqkLuGzPnbQ5por6N1XaU5Bz0PvXp/h3WftF+jXE6K54J25xXll9Y3UUqiSN4XChto9CMqfcEEHNbfhtBHLHLdtJ5P8T55X8a5p6HVGF48x7eNWt7Tcwwd3UqM49DVCSO1t9MmurnEssj+YqqcEN2GK5DTdXV55vKPn2vAKu2HYA9q072/h1iZYoUKwqFXG7BAz196mMnHfYFDmskXPGKyNPYPBo8MOzTbQARWeoLGn7lTtVoJtpALED5c9jk8nwnx5NLLr+Jk2OkKjaDcHGST/y3+cdfp6V7P8RNOs7jxTqip/ZTvFKIeRppb5FCnJM6SZ4/iGfWvDfFUaweILuJVVRGFXCBQB8o/uu4/JiP5V69TofGx1bPUvgRJqQ8PaiqBRpaatYnef8AnqZFyPfgKa+tFPkxXYBAVpXIz3IwR+tfInwU1UR6Be6eSQv9pW1w/wAw5HmRAYHXjByfcV9dxEXiyK+wQ/Orr6ZPJ/QdKtr3ERBrnZ5P4kuRZeKHgaGa5lljMXkjGQN3AGf4hjI/3vasO60IahDqEjsGhs1/eqGVmXGMAqo+gz65rZ8XX0a63EyXSwQxqHXamZJH+YLz1P8AFyfU1xV1DcxSSNCM3EoO6Rm4Azxx3xivKqWUmmfc4NSlQi46aI1L+G+jsobi4trWGBhHEzbEUSqpHClehHQnPJz61E2uLPp982oWdpJHbwiNpUZY5IwxwCM8MOc7QCe/HWtPVdFs00TCOJbgx7twfcFZueB2wTnFedXYD3A01BLHHt3XMhO4rj/E1Kdnc2i1Vjbr/XmcvpX2JtaluZJXhtZBIqqvztGxB2kjIz/CCR6n6Vfj1HUpCS97NK8jkv5h3O5PUknn9fWtLQ9H0O8mna9vpUjYmFBbp8ytjJZicZHbgevTjNPWrBLXXfsemBrm32xFmgI3gE/dY9AxGDjtnFU035CU4wvu2/ILrStUuLCL7Ekl1OylxbopZsdSdoGMfyzWz4X8E32p+GJrm4a6gureYpDFI4RIBwHZ8g5PPQdhXZ+CdK1WFroowshtFsjONxIPOCcdcDms/wAT+IZLa7ttKja7EacuYwFBwxAcDuDzkVF2loJ/vNzO1P4WWCPbXuJ7m1aMCYpP8xkx94fL0PPGajvdF1OzVdWTV4pIrWVGjW9YzvKFAwjAclcDGfw4rshq93JoEk1xC0hVMW8ZXZujG3Hy9c9TntiuDvNXm1K7hhtxJHbtl/Mxlt2PugHgflRztLVkQo8706dTag8WWet6NbzXFp5U1oHiy8QMbIW+UKOwVQo9etZN1puj6rCphuVhlkJEsbfLg+o/SnQaHqJ1WMavOyW4hUp5KgFcnjjpmr+rWum2unumo3cwljRmigW33GQHGATwAct79D1yKG5yd2i/Y0YpRhJv01/QxPDcWmaJq72mqB2dELwJgfOCC3mAtznaOFxkhuOcA4fxO8W6bqcNnb6Yjx3JO+4dSQrLjgLn0wfQ8VZ8Q2R1jRb6ARTf2hp+JrdpIj57MXVXiJAyRyWAb7u3APzEHip9GmuNMidjFHC7B2kCbnzjGAeuPbOK3jZJM83Ewkm7bof4Q1QJ4nsPs0rwwyko5LdRXpegXFvpkWr/AGiS3ula5gleC4k2tcL+8DdwTtYqSBz37V46bJbLUrYndFCCAXHUDPWusi1u7s7q9TQLie5nu7cicwWxLYHzbMHnAI5I4I6gjinZOSMqNd04S5vLT0d9z27StGspmS9lPkeHnvEiZYiF3SMmVAOSTyfy9M1ua1aT3UIsbmUQabsZpEWUBhgcYweh+Ufh7Vw2nXJ1X4XECIW++IPCtuOBNsxu5PAyMkjnOPQViaV8S7K5S1/tYMBDEZWMm1iyhtqg9Mt0OAOeuKUKcb6GtXFTtdv0/rueiR+HtPbQ5JZgst29wZFW4kXzHROG3kegZTjjJB61ySw+GPC+s3EBuJriUI0i5YhnydwPH3TjFQReIZf7ayJI5L6bY0dtnzpWyfusq5AIGCVYg+1eYeOfEUkviWa5ksXtLuPMTxhwQGHBHGR+Ga1lSi91ocscfVV3z3fqeteJLuZo4wYpry3tEw8skflvJu+cdug3DnqcHkZrQ07WGv8ASZLexU3l+5ZnZQFWNQchQffqe2BiuATUbG78LWNmdT82xhgR3+cRuT3jYdcg5HfjHasG31+18N6gLqxvZTGXAMCk+ayYUsC+Nqg5IBAPToO+apWvZm7x3tYxTj8/M67R7T7PqErT3kVxfNueKILvW2Y/ex2DHavI5+XmtDXA2oSwPcWdlqN3tBknmhQuxA78DIx2Jrk/C+rWKXE99DOY5SxKWjuSNjEk4B5JHHOe1dJdRNo8/wDaMV2J47pQZYtuTH749QDis1FyvfQ0qVI05R5VzJ/n/XmS6pcW2m+Vay6mLZLp0BEEYRY1JwXO0dB1/CuLGqaNdx3VvrltM6y25Nv5Zw6yg5V8n7ynBB9ie4rpPG2nizEFzZspuli4LD7y5+6F981wE9leXV0wijdTHGdkYBZlX+7jsOa6IwSjpucUqz57Wun/AF95Jfa1p8ejSWll4d0aOYAp9odZzcYJPPL7Cccfd/CuesLF3xLFlVJIYq+NrdcflXTx+C7q+1cW1ndG9tvMfdcwoAzBEDybEYjc+3JCZBYrircXhGVrC5vtMlJEaGYFxhnAAGGBPXGScZ5OKp3UbMw5XOd16swmk1TTZIZIp4pml+VVKguBnA5x/U1Z+y3urTJHewfZHkA/fMGAOSMggDnGc4x2OKZ4M1y007xppt9r8EktlCWLRxYLKShCsAeDgkHFe037TT6at59sFrps7kpGyIrKGPdiv/1hWDaTOmlScvy/rc4Twj8MLlr221O11uKzMUnmQyhAZAVbrsycdjz71gato/iKLz7UabcvFbOzeckTBX5PzAY6GvQtXvrG1uobAX+9vIBV0tcByOgY8c+4qtqy6tp2jT3k1tqRtJpBEtzllgXg8BSc5ODQ3fY6oU+TV6PZHI6J4d8Q31sk5SERkZXzHJPTpx0+ldbpLT2c85Se3kS2Ty38vOBz12tjHP41s6Dq11Fo0JmWzhmhgQRGMgkoFzzx1weSe+R2Ncx4jvNJ0vSl1HS5ri31CaQF7cEkMpyS0bDpg9ie/FZ6Pbc6Ixldc70PVpF0C5tJsS291eJGvnIXCOBgZYIeQe/HPvXknj7ToUd57m6vLm4iO22V2LEAk5JYnOMHIHr9a5ex1Z01CG6KzRxyPmUhvnK/xHnv7mrHifXJL9VS1uPN8thsyo3MDn8OMD65rSlLlTuc1eDqNJbGhYzRTeG48SAG3Y/MyDOT6EYI+nQ4ps15aJqCpDa+ZbW9x5geQEGVc4wecjI7Z/xrM8M6dd3tjezyK7RJKkChBhizBm3Ae23kdOe3FNvIb+1mKzBkSQYZmGOB3pOVlZGlNLeT1R3Pis6TqGhWSwCRJoJWaFZlydrHBXcBgnoe3Qil0WCSae206AwpcSMo8wtxGucEt7d65q01K91+WDS0Tf5IPlmNfmdsdT68Cug8OWi2OtiW4vI1aDy1ZMEN8+Rz6YIwalN2FUSlP3TY8SXlxp8ctmihwUO4pHnzjyAQfTvXAzaXLpNiGuXxKxLbMENye9er37QqBdJmQB8Bhzggc1514mZtQvrxrqV1JiHkgLlc56H0/WhWlKyM51pU4NPfe5B4XmWTxNZS6ZNbW7mRYQbk4jBbjcx7CvX/AApLK0FxJN5ccwkPywsGVSDjg/hn6V434G8O3Bme9nfbGpKsnct2Fdjpki6RcSXZmlSJnLN8u7nPAbnpSas3Y6FL2kUurPQJ5rn7WJ0mYHq8eRz2/Ktux1gxRSw3Vt5ysnlwsSSYsnnjv1Nctp93HqbeYI0Kqu5txI49PepLvU0sbVJZI2AP3Qxxk1cZPeJDa+Ca1KOpeDtI8+S5aMQRsDyDhAcnsegz1xXInTLnUZPsEHkwm4PlJtIEZcYPJ6gYIOeh9eDU3xK8Uz2trpiWruN8uXRM5GRx05612fhSXTtV0Rbp7IWbkbBMYuuOMBiOcHIqJO0krHRy/uudu+v3djyDU9Il0uGKb7G6yo7RSSpkKjqcEZ6ZqTwzqdmmrwrd3UkSPkFweVJHH617HqmlafPoFzbX7mEYLP5PCuBn5sc+3HvXhtzb6ZJqU13ZWbWmnICoWSRjvkAHCk87e/PIyBS9kqi0M6mLVJPm/A6fxxqNlca/q00l3EztdynbI65xuP8Afss/mT9TXj2vSRy6jdSRbdpkO3aFAx042hR+QH0r2TXptRS6k82GeEFyeTrUff8A2i2K8N1GZpbu4kJJLyMxySepPc8n8ea9Ko1c+Qppm34C+0t4s04WeTIsySlQ2NyowYj34XP4V9y/b2htbwqVCPEzBl5Id1BwR+VfB3g611C+8Q2tvo+RfPu2MG27QFJJJ7ADJNfbvgaRtU8P2txcALNcWql/9lth3D8xQpNQ0KcU5WZyuoSQyRx28jpFcSsFV3XJ29SB71U1fRo1eOa2uCxhQqISehz/ABE/T6c1mfEyOS3spJYZHilhberDgjBrQ1NbePRdKu1eRftunpMxlwVLbQGHBznJzz7V5lVKTcj63AVXTpRXTVf18iDWD9j0dfOEKfajsWZpVIDYzkhckYrJsNLgvrO2/tCeGLU7iMxxxREnADY+YZw7Ejdt7ZH4b/hSbw/9j3QW6SyTPskkCK7yuQMLnPPfAAFM13Sr+S7sfsOiahYPaNJMszxLFnIA3DJwOAfrxxQk09TaVaLWmjRmXv8AxJ9dWOxhiNxMqRwxtCFiIA5Py9WBwear6J4dvrLxU17Oz6i8lwJmjXbGrSDJ6AY45IHpVbVdS8RyXs8tjbiIzKVklmdfNYEgknbwMkDgelanhtrmyW5czRQy3LYVZZDvyF7DoB15pyk0FOmmtbXa/r0OJvvEupv42TVpjLFcW8qzKjL5e6MjCgA9iD+Oc118/ibw3ealJfLb2kF7IwaZZM9e5A6ZqtZ6DFqfiSNb5/tEwQATfeWMDATHqoGOPzrmfEnhK51XxPKkFojSFMxqB5CBFwAc+/HXn1o0k7im3BcrfT8DsLbX4Neu1htvlkjUkyZ6D8ePSs7WbaXTQZLOJLh2yUZhzn6VL4c8F6pYJbpqnk21rGn+sgRS8pyeCwAYnPfmuf8AHs2o6VJHbs06ruYoZ02Buhx7kZ6+9XFxvr0OarGdrUmlf5nR+Fb8zaVPcXEl1B4gjulERC5jMGBuPIwTnI4Oea1dZs5W8MXt7btbpql2zQzFMfIpkyMAjA4OBjpgEV5XaeNLm3tWhk2RkHOVXkn69K9B8B63YahFKPEJ+x2Zjwzbt5Yt0YYGRjHv1oqz25UYYaE4t87u/wCtP+AcHqupmNZbe0hlaaJiTmPDnHO5gCe3J5I4zWGbpf7FhWAKVJKsWH3TXqvjLSYNI0ubxF4b1uLzbMhZI45f3vluNucqeeoz04z9K8Yu7ueYMzNEss3AVOcHHGRUwd9Trrv2iul/w5h6vM6XEX73e2eMGvSvDGi28ujW97HNeWksV1CjywqTJE4O8+U4I2se3X+L2ryO8jlgvXjuQBMpwSCGB+hHUV7b4GgSy8P22pXM0sdms6uqyDdvbGMn6nmqqSdOzRwYeCrNwl1sdbot097aaXp9pBF/p935VsiKVWB3kZmZuMkbcj8Ca8V8caFNoetzabdlRFaXBKTxsHJjZgeMHHHJA75Ne6ePrqW00HwZP4TaePXDfNHaLGqsrH5T8vqNz9/7zA1xWq+E766v9eufF9qtleXNuJbS0spF2LI5Y5wMgKCpGzIPzjmqp6e892XWhGcUto62XXey/wCCea6xqjhLO2Gq3Nybe6uJpGZUK7m2ruVhkksE5zkDAI6mqtprEt3dNNqcYu2B3MHChm4IbJxyxDdevHsKyLqJ4LhoCCHVipz1yOKbDCxJ2ZDHj3rolUbR5VOl71krl+7iie8tFN0FjkYbykbEQgnGcdzjnA/PmqV8gS4KRuJFXKKwyM4J5wQMZ64PPNXF0uZIxI+SD6d6nt9Mjkikk+0LG2OEK8k/WslUi0dk8FiItXibaeNLy4tNK0fVorf+wbf7NHPHbQx+cUTCl0kILLIVABwQDjkVv6P42jg0g2WpRg7cwrcxDO+POQdpHykY6+h6VwV3pz26xlmXzcFgvT8fx4qxp6LJeWlrczJbQzyqkk7jKxoSAT74zVyqNpEUcO4ScZI91mTT30TRH8qO5u/JjnS4mkJ3k53ALnlM8f8AAc8Z5z9Y0u3S3uPIkQSsACJDwvfANXL7RbGTWlXQ1+ww2yBrO1wZIyCVz5mctyoycdGrUktrPUrOS5Nu2y4UKyAZDEH7wHb61HO07M7PYpxU02r/ANI5bTrcaNdWmoaVcyWsaxMtwGC3CPMyPGzAEDAKvwDnGT170PEd3qsE1xq1lZyzWMly4nn2DIJQYJUcL1PPQ5Hfiu0j0W1sdHkgSKSaJnDk4BZfpV3w1A8gulliEcTxCIbG2h48/Mp9c+9XKo3ZPYxhSjC846yX4o+ZJFF5rqhUO1pPmHTjOT+lfQt1o1rd6WWhH20SxRTWodyotdqkEHkhicjORnIGMVm/ED4e6fFdT6z4YtJYjEglWKaRctIu52yo7bFY/L3AFM8LeKl/e6bAkDTEkLOrMFlOMZOQCBgdSB74rnqw1Tlsd+EnLll7Lf8Ar+v+AbF3YWui6G+oz2C332YB5maXMi54DBfTPcdOO1efXerrLrCTQzSLY4EohDE5b0IJ+td/4h0PVr5Xh+zyxyywKyoj4iZXGRk9s46H0rzG/wBFm0rX2sr9cTQtkrGS6sMbsqR1GD+HfFQ01H3VY68POCl7zuz0XUJLYaBZS3DhJXw6AS5J4xt2YPGD9c+1YttpU15LG9zbWtvcxzrcC427jtJJZXRjtwMjAC+uTVDQrPUbm8gna3ItEO9RKvyFR0xXo0+nrfETx7Ss2DL2GB93Hf8AGnCbatYzrQpwlZO/9bHOWnhP+1re6l8+ALMx2TCIRpx0+VRwM+nvXNW/w/1mw1QpLbrJbx7SzRHcCSM4BHoePwr0+CeLSkt7UROY1xEgTJ/Mn8604dS0+xtZLq/eWDMhhBkQ7Wxg8dj3/Sm/eXvEe0lTdoR06af5HEeENL/4R7TtWt9at5Ir5ZyohQl2YKMjGBjByec1w3i3XTNqbiKDbbjjbICcflX0RpWriVorvT5EDRjKs6fd4x0NcL4m0GG5u5Lh0WeeZy00svLOT1P1rVJcmh5ymvat1I6nmnwzuo18XQyfKHuFaMMGwucE7foRW94sktLXxJcO0K/vXTL5LbCBk4wemcZBrC1XS4tFvrS+t4WBt5vNVS2N2PX0rtLS0tdUtLO+uUjuYbgZzE2Pm4HTnpkjHGfwrJ7WZ20n73PF9CyfD0lzpCanpU8rWlwCPs8TjCN3IFctq2ly6bd2z6lFOttIMB2QjPQgj1HPavZPDunabp9q0MIEMQJXnKjI74J4NaN1Z2oj3yRRzRgbcYzx2HPaqcVozhnOUrpnlehX9jpsPlPPaA5ykhk2soznn3ouj4cvhPD/AGiIvk3Lg8Fsdvx969YstG8N6nqdxHJp1lbrNCFKCFGXpjIyMAnuevrXMax4A8NaddIIYHsJ5crbfa4hNE69Q+B93uDjtjg017ybXQdCooy5ZXXocz4YvrubT7fFu3lQRmMyYH745GAo78YqbUbqy1PS3klDgpIU2FTnI6Z/H0qx4dv7BtPmtt6JLE2HWQnA57N0I9KnvzHdRLaxExqGJDqACSeu0ds8VlTutDprq1R9Di5vKs9t0IHivWkB3xSM5OeAgByRz3zW9Z6zqv8AZsxlHMGW2SPuODzgDIxk88etQLYIXkt4YDI6N5nzHAyP9r16Vz2r6/Z6e8n2jysLCY3CMSpbHXPfHtV+9J8qKk4QjzvV+eouu+LLy0YyGVluLhfnWHgoOwP+Fctqcd7qdxZ2q2rx/bQJUdhjKE/eHqD613f/AAgi6jpUWoalqNrbXV3bpd20P2lIraG3YHaZJG+9I+OFXhQOTzUvw10uK8Q6lcR7Vc+TboeiRqcAD6tnmteR0oX79fP/AIb9Dz6mJVZuotbdDDvdBnjRprfSLt1UFi66RcIqgZySUuTjGOteJ3uCdynqc17brNlbw6dqM7xaUxW2kIMceklgQp6eVNu/75BPoD0rwqViwXNdE731PIgux3HwXh87x1CVljimitLmWFpBlfMELbcjvz2r67+G9wLjQ7eW0IjinbzY+BhFcKcH/vs18QeGdRl0rV4ryCOOSWNXCq4JGSpGeO46j3r6z+C+rh/C2niF9yQlYmU8D/VR8/nVppwsTyv2jl5E/wAWrY/2NrDTMHkjRsMB945/xq34s0dV8KPZxD/VWkSISM7WVQhGPcqa6TXtKg1RVglfctxIjOCMAIDlvwAFed+MtY1Owu2soYzI0AysoIJkJBLbh0A5yPbFeXWiqcZc3U+kyxzrOKhpy6/l/kYHgjwxbW1tp1wLr7O8sz/aZklJELq3G5P4doK8/wC0evb2TxrqAhtJdKubiK3uI9skZmViJhjoG7HOfXrXjHhWURwai08ouJbjbLKoUqYi5I2nPU5VTxkYNaWsa1qviO4jvLrzpbqCBkkjjtyR8vYAdB0JY9z9K6cPJKNicwhKVXmctE3/AF+hp2Ottp3nS29tDcAsYzK2G28fdI9Opz/hWUusQCJ0aSEx72C+Y3LEc4FcZPeXUMrXFuJoGHDYJH4EnitGy1KG8th9ut7eWZlIRehXgjdkHg85/Dn0qnTuRGrye8judNngnguY764jVnjIXceEzj5xjrj071zdvrT2ly9kLi3nTBIEfOCD2OOcjnms6K1iv52tpJtReOTCRC1Ub0AbJbaeHO0MMZHY9sVg2kVxaX8Lu73MbEDGdhdARwTztJ6ZHSmqehFSo5NmhrfjO/sJjJpbSRwRuVO4Fv0PT04qvf8AxPi1m80/7dp5hFpENo3BizZHzIcZVh1BzkY6mt698OQWWkxC2u5riG5jw8gTG2XqyMCSCV3D5uAR9DXK6r8PGa+AsJIpIG2kTBeeRyCOzD2JHpWDThc7VUhUSfXz/rcfr1pa65a3S6TpeY7CM3Ms8CgyFWA3O7Zy3OPoc8da47S3vrQx8XMaMco2Dj8K9Pn0tfDen2t5NZT3MIB3XIGxiQBkZOQMcHpzmuxtL+Fl01tOsrhJ7EJJaLdWoMsK8MCV6ZY85HrxUtc+mxaqqiueCuv6v+J5ho+sRW32pZ3kzNbm2ctHx5bdR+PrXPafZ29xqTfNFLBCHz8vQA8f0rq/izZraWVtdRjy5UeRZyI1Qs7MzEnB55OB6AAdq8mXU5od+T8g5x0yamFLl0RdXFRlHnfUn16SBtQl8qONATuKqOEyc4FegeGPENp/wi9tpOqxGSzkYKzAncq9cj3FeVafBdanqcNraq0t1dSrFGo5LOxwB+Zr2j4seDY/CEUllap5nlNBCrYOciJMt/wI7iaqtB8uhzYCtTnXtPs2vkR2OuJB4os8XLS6daP5lqrctCM5GD2PAJxjnmut8b+LbLUZmvLSQy3MjCQFRgBj6+wryNdImKxupMcgG8MWznjt6967eHwZPNmGe4jjzCskcgbgZH3T9K541JJ2jqevicLQqJTre7Zaefc8t8QCJ9SnlBJdyWB6g5PPParVpteK38tYzgEHA569Sa7h/AM8EXk3Mcr3MsvyPHHvQLtzkn19uK09J8OW2nR+aIg44Ks6ZH5Zroac1Y4KTp4apzx1uYjTONJWzmtIggOQNmC3vmnQ+Erny/PUpsVgSrKWAVu5x6V3j2ESG0huVlcKSY3IDbh3Bz261flm+zW00DvG53ZYKwyFPGDWMaUpPXY66mNhCK9mtXueA6gx+0+VBCZNr743OPmAJ44qWztbq91KKeWFXSPLNCF7fxH61NfiSy1aS3WQuYZGWMPwTluCPQ4x+da/h2e8lvkxbyC4jOWYfJle+eKuTaWhjCEHUad7Pb+keoJA1vHJZSicF0WR5VbqT/CR9OMe1WLCWZJokHFmsRxsPzIQepHpXMan4mn054r+72q6RFY8AOzg8Ant2qp4W1B4DJca7A9q+T+5lyHbPPA9OnFXGXUh03K8N35anZ+JbsWMEkhDKBHlGyOp45NbHhqeK+sre6Tf5SRlJAf73GP8a59LWbxYtqsULQ2KKpkiYYYDt7dK6HxFu0mztYdKtgsIcGRByVAHX3rTm59tjzXDllyv4izrD2ctrPHfZjSSIxh+QArEZYYIJ6dK858RfDS7a5trvwnHNcWMkImtmfPmFFX5yeACueADgnPQ4JrqNdivGt991LCLLKhvLfDsT6d8DvV65sb+58PXMIuJlkt7VpoVhBO4gZAKkjA9cZ+lVJRa5X1NMNKpSlzRdteu3qYekeMXbT/s97K4mjUAozZR0UEqqueeDnAPQcVk+ELGHVvtWqvJFMxkktjDJkGBdqkyA5xknKheuCT2pINVttWZ7bxHZ3dnLc2nmebJGY3LEYjlAP3h7Dgj35qXwfqGl+HdLuLeZ5YLiWFGVkTaJXBbLSFs5+9jjHAGRWNOVkk3od1ei5tunGzdttV5nTwxWoiM0irKqYWJWJIXHHQdelWIb/7WsT+c0cZcRbTHtYMeOM9AKZpGo6fc2w8qWOMOfmjRgecd/atKRs6axhto4ZNpKsf4Tjr/AEqWr6hGyfK0RW9qljpdwYJnmYlgWJwv15602G2l+xW9sl00kKOJhDN865x1wensaRdVtlsYVmlQMfldeoz6/SucuJ/Iu2uopwiEDjzM9qqD0VjGrdtpms8l5JG8Ajgkui20OnyAgHP51atlunt5ba8xlG4CfMT9K5WDxBLNexQ2CGW43Eh8gbSRjIzXWpFcJaLPO6PMIgpdjt5zTlJX0MnRdkpHB+JdDju8ztuJPZjkn6/4VkeEZFstahSaZorJmwyopJLY4AHTcTgZPHrXqDaekkLTFUZ8ct/Dz7Vkw+H1nF3ZpZeZcHMwm3Y2KoO/C9DnI+mKShz6msasYJxuTW13KdUnisb83MBVSvmxhjkHkD8K6M2Mw/eteTbeo2ngfUVxFrby6ZZW4uILqGOR2VJ1QEMQegPt6fjW3Gjm0jkTU7yWVkLbSQq4+nr+NZaqdmPEU+ZKUWWY9Ui+1BvNkVoHVshOG5qPWNdtb8/Y7SZZL6XOxVUkqT1/ADOeaxEuYZhcJftPNKSPLWPgkfge9ZsGmzWOrxyaZBKkzD5Q7E7c+uacoveJmoJb7/11NzxNpcthDbW9lGJFVctHGQWJ9T+tZ2lWqQj7XfSNbKT92ZhkH3FaWuWU1npEt1cztFdtHy6seT7mvP8ARbBTeLNeyzx4G7MTEsfqaJvkirhhozqppS/A6fWtXs7tBp2kXNtLeXMmxC7hIk/2nc4VR9aw/DPw01LWrsXGv3QFsDgRwnOcejdMV1R0jSVtknnEVvASGEsrhCxz3B4rH8aeNGtoxoPh10uS/wArSwjK8/wgjj6kUKrzqy0Xc0dDkSUHeRF8RdJ0+413TdJ0JIUZIwJooSWSFVwF6k898etd5YWSaJoYEKMVgjGxQPmO0Z/Msf1rH+HPhg2MIuLwCS6lcl2YZPA6D2613FtcW988qJFJi1m8ooVwdy4b/A0pT9o+bpsjhm2koLVI8c8e6ip8L6sTeJOxtyAP7atbg8kD7n2VHPXswPvXz655HNfQ3xabVrXwTqS3Z1IW8vloTPDqMaklwQP307xnp0Iz6c188sOlenUavoeLS2LNi4juYmcZUHkZxx3r379n3UN0V5azShIYnVwM8kkEAAfUDntxXz3GOld38MdXfTPE9hMsnlq7+VIevB7ke3B/CovbY2gk20+p9kxXUS2rSzITEY/mkAO9VJHOR26Vy10tpq+vyWunWkVzbtCifaGU5AHJOe/GBk+nfGav+Hr13sp1UjzIPmAzwR1x9Mg1StdaS2t5rm3CSRlfk2d2JI2/nxjtisa6s9T0MtleDUVqcfq+gpaeJ1e8uhBEDk7v9WEwcBm7Hp1/Sqh1h7GW9EYkuiY/KSAlozIuAQeR0xnB9+K7zV7eO7sIG+SUfZy0hIJwxPIIPof09K801HXpoy8OpzG8kt4fs0RJ+ZUHQY9uKxTcNFuelOMa0eaT20/r/hzBvdKF5cxz5l3upkXgnI7DB70+ztJ/MnjubV/MRfk6Lz2JqydeiZY0tZ9zqhPXBXPYfnWvoJa8tpZwIpHiUKzO/LZ9e9aqpdHG6U4u72exhwW80Y8u9V2+U5ZEyVPqD/jV61trO4sj9t1SDzox8ikFW+nb/IrrnvVZMyvunKqW2ncTxjB9hgVqeHdR0W1ttR/tq2tp7e7VbeKGfYiFyGB3N1C4z83b64qk7vcE2ovT7jzPT9SM3mWiXIadAY9rHAb8e5rahf8AsiCLfdiEF90m05ORztx3qr4l8PzalLa/2LMZriJBGJZvLjDogCoFUfMMAfeJy3HArkvEkuq+FtQt4tSSAXTR5KrndGc8q6sAQe/cEHINZ6wvc7OWNe0Y6N9Op1niTUTq9tGLyaSGwkHPHH4gYz2pbTWzp2lQ2ejs7XmRullfLSL22gVwV9rr6jFC0t/CjIc7FUqMe/c1Zs/EdppSM8MaXl3kbSqkKv581jKT5tGdVLD8tJxavrov8zvvHdtEfDf2nWMyyCPlC20nPavnu8sGlm/0ZTICM4A5rr/FXiLVNeVUuFZUByBnge1cpGbuBZCjsqY5AIzWsZX2Zx1cP7OFqivft0O1/ZytRcfF/RlCo0qJcSQ+YMqJFgcq34HB/Ct/Rop9Th06C9vZWnkjmlBuZhIZZlYvIpAOVGwjBI5bP4cP4C1i88CeNtI157RpEgcloz/y1iZSjgH1KscH1xXqmj6cdR8UWmuaTqmn3ejGMWUNx5Yja0LElUuIzyjAZ+bkNtOCeldSs4PqeVGNSnVutP62+ZreJZ7XSNXNpDDZXMMixAp5eCgDK3DDpjb192rc1m2jSwfU4CjzPjML4UMoH+eK5a/0691Ce7vo4U0qRc7IpEaQu5TdnABxG2Cdx45yMjJHN+I9W8WWNtNFcTWlxbqzhprb5xJnqQ3cH2rn5OV6rQ701UhHkkrrfU9AtL6NooVWRJI7pNrIRwTjpUOoxi008xOTFsdWExc4U54BPcVxHg67ikNl5EscluFLsxyWRiOVwehHtXQ+J9UuNkFnsaWG8IZoVXDPEDknJ6HA96NtzSMW5e56/carX0VxCzXMZVwuVYPgL9e3JrP0bTbZ2kt5XEczF7me435PlDsM8bj0Gf8A61TDQV1OC0iaaOC3kiEkUUZ2DOOmO+MVp6B4U0dZ2WSJmuQSWaSZvw4z2puMktBQqUlo3r5HB+LtEuotSudTKoRdbTHKEG5PlUqOOh5HPrXDahrUmnTSpKkomYYaQHad39a+gPFtuungR/Z5GsrhVeacJkxSZ6Z+8U4B+teEfEqy0ptQsJbC6a4vGknjuoeSkaKwMbA47hmBHP3c8ZpQhdvmKxNaUYRlSW+mh1Xw206DWlTU7+6trmG5ZrI2wVzJZHhhKMjGSFIBBwCwz1Ir1i+0W3urnzL8xmOIAL8vfjuep7mvIPBNzY2qTOquiCLAYRkOWLfcQgNkDAI3bT157n0d9Ukm0hLi7aSJYgqlZIupOeCCeOhOcdjQ2r2BU58qld3N+TUVku4beKWOGVcYcrhSOmPrUVxFIRDKZ/NlZsqd2Mjv0rB0aQ3ryfvpJs4PTAGTwR+tb73NvZhjOXXAJJJzn3+p9Kd+hHJGKVtzndY0y6uCiW80CmNWcRnKlsAsMHnnjH4itJJdWaVE+0wujgICw3BMjG4MMZFTSRz6jaobQxxsQTgkB0z0+hxViyszp9tGquZNuCBIobcc5xt7g9Pfmp03Ro5NaS6Hmvibwte63rUIi1qXU3t7QefeO2VWQcmOPnhBkAZ9Ca7bRdN0+8WNLm3h1DZGImGcK524Cpk5BJ7jv61mXcr6N4gn1C3slvDevsu4fLw8a4yWjx0I9vatxb6IPYW1vBMknlBlMsZVtxJzz2PGPwrOavO52c7VFdrbr8f60PP73wncR2E9+4a3kilZHS1fLKFwNxGcHJI6H1ra8Naref2BPbXcDtdqD5bSAgPxxk+tdJMILe0kiuJo1faTs2c/h71TkSJ9N3TyTNLgOzMvLD0I7VfKo67GKrzqq0tddDhLXQbqe2Mt9fyp1+WM9Mdenaq9voenyyuh1B8rxvZjtye1eg2lok99H9mEZ4AYHgE9cGjT9O052nt5Ujjincs+F+6wPbB5HXvUqnG2hcsXNS95teSsca3hc2XiHRodNv7lheTxQusa/vFDEZAycE+nvXofk6Xf6jNZytLZ2kkixiVnErWxORkZ4IBxuPrkg1U1a1SJIxFuSUMvlOP7+eDXOTfbWdJo4N8kEhDBxsBbPXI45460+Xk+Zmqjr2be2lyZrC609hHDdu8EjP5UhOVlCSNGWHPTcp/Su91KO401YJJjvuBA8UqqSBtYFTj64zn3rgfEtreXkFnbW0a2sFsWmhTfnDOyswDdT8wzg11l1qcUjK98Nkjo0j7MlQTzir0TbiYSTnZt33NWxstJvdNjXU4ro2ZGVMMuGjb+8AeDn3rlte0a6tLpU03V4Z7BgCDu2zQnsrr6+4yKn0zVopbSVYpSEmbEY9M9sdqj0pXE8kN1EsqyElcHlm6HOablFx1RCjOEm76dv66liy0NoriO4mkMmCCcjA+ua2XigMhlkKh1bIYfwgep9KpXNy8NwlsW3SKu51U8BfX3psCNqBaJkSONcNhxnzAOcGsnC5nKs07tnNa/4lj8Rau1nYlPsCYjxIOZMHlh6egrs9L0C1uNFvJTEY47eHzFwoJdh1Gaz28NWMVxc6hHEkKzssgVRhI2xyF9s8j610Wi3Mqo7TCNbGM4QEnE3p/9f16UpKMZr2mpE6icb0dEjjfCXhULqH9teJhb6ibgotpYSxloYtwDMNrD7w4XdjqSa0r3w7pKeMNW1O2tYLextSUQRIFTKr87Ko4Azniti41Ealqt1Z28EwFsFEdyf4XYfcA4AwMkkdyKr63otrHDEn26e2nlIQRLISs2fvblz/dyc9+/WlOzXKlcmm5Sq3qSauvwNXR3iOnxTjao8oPg9s881Rn1RLPRtQ1GNUWyt7eS5eVCCJ228Y/LGe9VLia7uNa+xPEsmkpHtYeWMSt0G7PYdhV3xtpI1LwHfaVbARGeIRLtGAACD/SpovnmovpuViYxoU2+r/Bf5nhHxbt7W38LBoG01pHuo1/0a106NgMMfvW0ztjjoVA984z42wy3tXtvx8vQ2jaZbfbb25Z7ppCtxO0m3amM/PbQnPzerfQV4ketepV+I8SlsPUcVe0yUw3CkHkHI+tUl6VoaElo2qwjUZnhteS7Iu5umcAep6fjUWvoXzcup9Q/DXWlv7RGLEyeWoPPXAyM1vPplppljefYo4oYYnE7BpCAQ5xx9P6VxXwi022Gi3OufbEi0+FvIgjkkXzZG3YGR24ycd67XUZoJ7eze3dTcqCRGG/1g7r78j9ayr6WbR34SSVVqL0ZlW+oy3puLfTE3fLsZmkBjJ9Bk475/wD1Vz/iTwtPa6iLOc2UcxjaRrqVmEb5Gfl9T2HbitPUYTNKhhb7PGy7UYnC47A4/KtLVbrUL+Lzr14xIsaxpL13ADGcGsVtdPU9Ks1JqNtDj/8AhCrPR7Uz3VyspI37R8gB/wA+9VJ3e0tLeRLUgXAZVVOp9CeldZr5t7fUv7Ke4EuqQKGkhJB3fKMZ+v48Vlzabdy3kUl5JtlY4SBxnaT9OMVnBNNpoVSV0pNmRpWnT3UbXJARypVEDZJOP55qzptpNpbww3MyxtA3mSwSH90XAYgsNwBADHjuc/StIl9Ptit1G6PIS8QijXc/bOc/dzVDw9Zrrup3tvNcTRX0SlY7ZIjuuY8NklxwB0HJ6mt41LPlSJ9neDqN6FHU7l7Iz6ZaW8cEsr+aJ5YJE+zqv3QpfnBB+79B2rjNdvr2/lF3eWtzqEyr5DPPuyhXgDHbGOlbXj14pLiwtJNQjisUhVz5cnmOELbcAE/MwHOCRxXK6ZqF9YXdzarAzJAhmUyjZwcbSfXOQe/WqUHWTjLQmti5YFxlBJ3W71ZPaWkF1tjmjiW6bqmPu59a3tF8MvEWcW6hF4LN1PrjPeuLTVr+6vJ5Dst7vAdiowxwf1+leq+FvEd5qGjPZzrbo9tE0zzHCBgoxtz3J7eprldBwklLZnpU8d9apudH4luv1Qui6LpM8F9dOIrO105gJb2V9x3t2Cn/AA64FZ154LtL9ftduJ7mV5WEW9TErxL0dAeSCQwyeOOK3bLwBqOo2sl7HYyDSLnEvmSTMY2O7GWGeMEHJOMAVFohuNGvoIfEA2ILcy2isQwWMlgrDrx97APer5VbaxKqe9aMrvt1/r+rGTYaCZtTS31WzTygBtG05dVIyoJ+6cHmp/HWlP4T1L7X4XhAtrq3aC8gT51K+474IBDDuAa7pdKsr+1tJZZbqae4XbkrgxfKVABzjrj04NauvafpthouLWG7htQ7DzbhSFRcH5Awz97AGO2c1FKMr3uPEVoK1l6roeIeELfXJ7lYLXUJ4hdxqwKSlGlTJCqTnlcnBB4H4Vc8X/uXe1Z432ZLGNsgMM8ZHH5VhaVr0K+J76Gxto4oLibyreEtxECeFDMeByTzXo0+j+FptKC+JLTVbW92GQ3M1vJGk4CjakZHBznOQD0rtu5qx47caEm+5wHwo0yO91m6uvtAZLTa0tpjHnq2Rnd0BDFePr2Fe06/ptjcWy6ldKhubURloidw2qwO1e2SOoPFeX6VbQ+EPECW5jEVhdQxTswmV2SKRgUkP+1j+E8jNeiazq9q8lraL5slm20xykj5kIyORxn2rNwfNZo6FU9zmi9/6scxp+q2UepILy6lmkmXzCgX/Vei59fp9K7DTyLnyru1SMzRNu+ZsCQEYwT3xXkMrFdRu5ra3dESQ+X/ABHj0r0XQdQkXwvvZ0CXKMMlfuN04rZNW5WcdRNT54nc393FLMsMLvLPMGR02kxxY6YJPI6/SuX8SfDOw1x1ZJ/J1LZgSqOD7H8+tO8EapFLeQ6faoTcJExO5s8KCev0zXXwzrKFdgV2nkN61zt3Z2Ri4abM83tNMh02zh0YhbS/ikHls6jrnGcnqCfyrQ0y6vpRb2WntdpG8zvcOYwV8+NtuAxycDjOCB613OtaLp93pq6lK4vZEbABQLInJwV79R1z/KvIfGdnc2V8Z9OvrizmCNNA8LeYHd/vB2z97B5POTx70cnJqdMK0ay5H+XU0Tcro+stZ2oVFuNz+SOPKIYg4/2SeQO2SOmKo+JL0TT2yQH7X5uR5Cudu70OPTFclLp+t6jqdre6n9pa0gGJFtWUSlcchc8E8Z5+lYPh3Wbuw1Vgy3dsYtxOEwQMEMD6ZGR71UkraHPTnaXNe1v63PYfCepTrpEVxO9vboHI2EEuoBx19a27m/gur6yIjligYsfN8vg44Zlz1AzXjU+uSxzW0kMkDw3KuI3km4BHOGAzg56cc5Few6jf6aNFjYyytmNIbaVY23RyYwqMo5w2MfljOOZjDoOrUXPzMh0O4+za9JeSbJGiheN1UgggkHJB6D5VPXP51HqF9JeGFpLlFRX/ANSGyU+U4f34rlPDk76nY/bbi/FvB5jwyFW2yTnGSOnQEgZrVhnNvfQypGkivE0WJE3BR0Le3/16STubSaV+pnmcyzNf+bIzjCFWPT0IFJLNf388CIUWFSHndsBX/wAKcuj7J3WC7MBLFsY4C+1aqQrFb+REkVwBlWdyQGyDxkY5rKSadm9z0KdSMo88Vqixf3LOYjABuCbTycN+VQtYTO5aOQoFYMxByF4yR+Va3h+00qTS531+9uLZIjGkAgVWLA7t2fyHPvWFohezu5oo7tH82Qt5TjAZc8ECtXBpXZxKsrtR3RvRr5Tw29wdyoPlOcnOehpb23huYJEhnILckLySRkcjvVXUzOk8CW0KFnO0HON3tVG+t7jTtQidBIhwQfm3EjPOfrz+VEpcpyNOWt7MrXMF1/ZdtFatv2SYUk8/T6VsabbyX928N/H5HlqpVWb7w5zg/WpLC8hmiuJ4dsrA5CFehHtVWPXoJJbaZW8vYSNo9T7VD11T0NFOesXHXuR31jc6dqBgtVUxlM5Ztu0Z6fhipbg3Fpp00wn3IqZDkZzx6VpzPFdqsqzs5lO7pgj8PrXm3xA8U276nFBZTuYrRdjOrfK7d+O/pTWuq2JcnJpW1LVlrF/JctJcsqZfPlueSM8Z/wAK7S98SabHbSTyXUS3gUBYY23Nk8Y4rx9Zri/dXaAwwSfd7s/viun0lIYdkECRrt5bHb3J9aiNTl3OevGLfM/wOy03U7zUJVF6hZNwKQj5V9efWumv5Lq+8pY5Vg5+ZlUHaB/d7A+/aue0W5EcixBx8w5BHX6V0qmMLkEBO5rDmu7s5ZVOVpkC31wb63tdHiimfkSyO/yW6jucclie1TDTxPrC6lfusjxLtTbnGenAqhfa3p2i2cqW4VWkflUxvkkY9B7n9K1NOIgtUa7ZBcPhnI6L7D2FWomiq2jeKstvN9y9bWKfJLM5IVt5A6E1rMEddrkKFBY56njoKyftySMkhkCwr3IxuPt61bhZZG8xhwfuqe1b4aned+xxYzENqzPm79odrhZtCt7kXoKrNIBdRX0Z5KDgXUj+nVce/avHD96vVf2hfk8U6dCLVbYR2QbYsFvFnMjckQSOp6dSQfbGK8ldsMa76vxMxprQmBpwYqwPSo1PFLmsyj0Dwf4m/s21a1nVntJHEhCnoR0NeueAte0yeNs6osbyyfJDMmFEgPykHsT0NfOenS8bT2rVt7iSB98TEEdR2NZ1LtWOzDzg5e96XPpa6W5gv5mSKIoztsVmzkegHrnNZF5qlomt6fbRygkyFriJh9w4GF5+p/Ssjwf48tdSt7CC+EiX6fLJKMYBGArg56nofzrqdOihkvtStisVxFJOtyHZBuSQDB598n8654xs7NnpqWnNJdP+Aef/ABCt9R0vxHp+vuZpbIKLcIWz5K5JAHouSfp+VdtpGrww22x41lcIZCrfMcAZJPoAKreOdRhsrK3Elq8ySbkO0BuvTr07dPSrHw308rbajNqXmSiWHyYtrYAOc8+oGOnTJrO7lPlbOi9NYZVJLXUWTTpLu3uruXUAl3EkczIDtZFbOYsHuFUEex9cVW03Rv7Vs59ejEQso+PsJnbfPtbPlrjknjPBz0NX7vw7NqAvLme7k1AeYY4hnYWfOVBOO6hjz0UFj/CDB8P9T1e0aeeytbC0hhZoldYjI08mwvt3Ejy0CrkseBwcEmuqlTXNd6GNfEJUeWk+1+nyKuo2/hywm0rVzp82mefP5dy10i3Ugx94qjqeAccMMnnGK4PxDYzQSXt9qv2661J5lhgCqBA6srZYOOwIG1VGBt6167q8s1vrFn9rls2vZtt63kgOIy/IwT7c/TB61z/j1J77TrmSONRKpJkMa42r0zx3rWNZQdrHFXwntop31+88X0O+n8HeK9N1OF8ajbtuVGXduyCpyPQgkV714Y0Uaj4e1jV74mbyLEQWvmxrGwlVQVQJ7IvXAzk9815Bonhe+1Sf/SQvlgDBfqueeD1zxXdadGbfQre2064jkv7NmNxuYlixAAU+wwSPqaiVXmdmtDXDYZYeN1L3nv1sjtdF1XSdL0XUItT1KFb7iM2plf5o2OJIpUAGBgk9fXoa8m1vxCjeI4pw4uES6CbyS/7sZwPm5IHAGewqC+jaW9lYZnvLtiJHfkhu5Hr9frR42sbTSfCOl3EcMyXUspRpSwxIwVS+B0wGJHGeMHPzYGPO5r2a6HpulTpWqu7cmeiRaxLcg2Wns9zbTBCAxVPLTODv9yfcAVpX96ZvC2rwzlUgRELBhuJ+YDA54Pv/APrqj8JPENreabBp6WiwxI3nKQoDOcAMGPU/dHvVL4reKLaOO8tbKHy4vmaZ/vIXOcYz7E9KiDvK9xVY2Xs0tup5Bfhda8YSRaYqI8SIVYn5TGiFST742D8DXb+C/C+q65ceRb+I20a7cFRFJevD5m3BJAHQAHIHscdDXmPglorrx9pccrstvNcqkpU8lCeR+VeyfFHw1qnhnUbbWdFdo1tJxcWs7KHBVG+Q55DHpmu2E3HrY8SdKNSbilfsYOo/DmWwsi95cz/by7YUx7sBCOcHhs8EDuCOeanuHaHwqqWV/NcSQxR7jMg8oQ/3lTG9RubqcduTxXY2XjjX/GEFu97o1vbWEG06xf258x94wFZUJxGG3Y9Tg9l44nUkTTdQiuGeYRSEh4QwxLFuO5ckEKM5xxjNTVkou973OzCUnPRR1XTuQeEtIFzp9je6bqjrJLdS213AHCy27Y+Ur82SjKTzgchhzXpN7oiafYLZ8kRt90kAmuP0G4sLy9MtqgU+YAzx53OB3JPJPua63U9YSeRYygQA7fmH3/cCpumtyKlN+021H6fD9gNrq2mW7rJIrxTRkclTxVyzvJReu+oSdRgEcLzzwuevbn0qOS/T+zocuitwMBcY6cY+lMu1Z2KW0eNrCVJByJB3FRJWRvSlraXoa1v4ouILwWAtBe2FwyvLIQVVQvIGevqCferGv22iapplkbCzuRdSH5jndHCORtOevTNcxbzSI03lx5VwckfKVbv+FX9FvYd5itp/kUcjJxn/ABpc+lmaTpxT5oqzX9am3o/hi3vILmKGWMXFsFYxy/Kp9MEgg9OncVzWuWMt3apqM8zQNGj2M07R5yRv2Fhj7pXbHxgqVGc7q2E8SW2mSSL9pkWUFnyrH5OOee1bujarH4q8N+JLYY3CJJyJIyu9lwWYnpk7VHqSM1pT5dI9TkqqpFOaWh8++F/BWp2eqxNLaO0EL71byG4O4/MT045B+leh6vr2mWMhu9IkNzcxq6R+WVIWTBKv0OSDznjBFdLfeI4brwnpN1dyxpdW18yOiYzKpTPmMO3QA+pzXPand6Vb2b3CiK4tJlLPblGEKjOWXB9Tz8pznofWbJS5k9zT2TnDlnDa6OU8LzyanY6GJLyynu2DuYpI3R3PmsxZiRtcbiwyp9jyK9GudMn8qJmhjZ1/gPCn8a+dV1VbfWfs8CmO2jYiNGcgx85wD1HU/wBa9I8NeObm3uUi1G4uJ7M4Xc75KDHqaUpvm1KeHTS9nL5HYaho0kV3DegQ4Kn5AuQpxjFMVraWxdZwkSxkkx5GQe341S1rxLpzvA9tcPcxuceVC4BPua5seKrAvJbabanyro7bpLmbJKg544IGO3pWMpq9ztpUKjhbqdDEi31uyRiRcnABP3RkYJ9zzWVrxuI7a2tbgGeG2JaFlPzx7jz9R0rsND1jTTY6ZDbW9tqFtbXBL7ciVlI+WNj1IBP0PFJ4q8PeZfQW2nra3OoNMCk8bMNuRwhYkLtA5JxXQnzwujikpUatpr+v0MjTkuriSzv4rlZomYoIyTkY6mtm633U26RCItu1ivJK5zVLQ7FreeO01OAWpglKTojfOct8yqenPqKuzXJtvNiDK4TCKp+Xd6CsYN9dwxEU5LlIbULaYhtrdEjJIkmJ5OfUetZniHR9MWJ7oTrak/xt8uCO4FbGpXMQiBmXyYjhpiRnYAOuRXj3xC8TQa1OlnpSySWqsN0rD5pW/uqPSmoLlt0IjObqJxepa8XeNzb2Kado9wWKpsluwMEj+6vp7muW8M+Hr7WpYpWiIgB+TfkKfc+tdP4T8DmUpfa5GSANy247f73+FehlbbTreIEs0j/LFCowzewHpWb+Gy0RNWt71oaswLbw3b2ieTLNLdXLjDbeFHtx0Famn6Yi/u41Xy4jg7V+UH0J/iNaDQTXQ8glYsH960Z4T/Zz/E36Co9b1S20i3MavHEsS/KCeF9yfU1lBOb5UjkqNxWr1ZJc3cenxjzpAozgDqT7cfyFcj4l8bRwI0bXn2fHAiiGZD/8T/OuD8S+KbvULmQWchWLp53Rj9PQVyLXgtyxTmQ9XPJP411KgkzC6jruzs38VtFeR3dpaSCSL7pnfOCe/PSnXPxJ16UKN0Ax2wcflXnk9/MzFmfk+tRLeSZzvP4irVCKKniak7X6Hsvh34nqLmM63byBwcCZGLqufbtXtGga9bajaxz2s6TRN0ZDkV8ewXRJG6uh8P6xeaRdC40q7aB8/MoOVb2K96pLk2OWpSjU1TsyT4wa3pOu+LBd+HZJnsBbRoPNtoYGDDJYFYVVDyeuM/lXBtknJqR6jJ5rWTu7lQVlYVDg1JuHpUNGaRVixbzmOYHPB4rdhkDAVzYGTWrp8uQVPUUmiXpqjXgmkglWWBirqcgivbPhz4rtr6xkMrJFfxKAylseauf5jPFeFo+RU9jPLBdLJBJscd6zlHqd1GrzLkezPqCJLPV4UmQZRWKMrdVbjg+hrT0tEEUkQMdukIyskgyideoHJ/D8a8s+GPjB9Skksr3Z5hTzA2MHKjBB9eMc+1bh1SeTXJIAHhg8sgSDkNhs89s89qy9naXMVZr3G9NzcuNV1C70mWEKMJC6xQoMNkrhjuHJY4OT6cVzsqaiPDWn2WhXX3VWQzwsQ7MVww3A5xnt61FqGrG6mltkhyhG0Ox5Pc4x3qPStUeNppopYYjKAnlldo3DgHAwBwK6LyS8xr3nboc/p1pqNpe5uZnIhC5yegBwFB/T8K6PRb+7hvZS8zmKQ/xdvakh1KG1EhnMYeJ+SI94PPBPrz3rVtLeKWyjnVl2uMlx1+vNcjUpTuew5KnTtPqOs7m2s9Innm8syjLxFhw3XA4qDQrGTS9EmubqO3hn1JBfByQx2v8AMqkdvlxxXPa4Fs4LyOC5jlliiBCE/Md7BenfrnHtXqur6TZ2Hhe0tJS0skNtGDKRgsVXOeenb6YrSUXaxytxir/zP+v0PJLeNnuftl28MCmQrGmcZP8AnHSpPGmjLqumyzORbLawu8UhiJR2znbkcKCen1+lQ6lFFfyC8EoSS3GVgkIQk4JOwHggY+vTrU2j+OWstIle6KvEGxjGRuxwcH04waxpx5Za9TtxEpTjePQ5LwZ4lSCwaOSOQXEOXQoOQO9U9Sl1XWbOVy6SQTkuQM/JjuaseCQ13qU4ECul4zh/KVQwznJUcAAZ6cCvRdK0e00i0EN7G9tM23ExOUY88f59ab912iRD3r8x4DoVw+leJLG5cmMwThgxHQg8Gvra28faF4o8M3ekat9ve+jt2nQxoZGUEbQUbOMDI5f1IrxDxr4VF+00yPHBOOkbty5+vqOtbfhHQ9X87SUgWyinh3Fbm5cRCdAAwyW4z2HTOa66M+6PJxGHSfuvT8jU8J6ZL4WS8g1COWWKeCSKWNmPl+dgmNyvQlW7npmsHWUuxaNsRpEJAyBxg9q3tevb/TdLudausLZG9Fm6bwzeYys3A6Ywp5zg5GM1Bplxaa1plmkGo2EUsxYyQs7B0weM5GMkcjBP4VNV8+nY6cHGph4ub1uYWl3V4t/5t1vBVUgDKgXaFUKM4x0AAzXWXWqiwktbm8USW7YO4jO36isrWdHurUXUdhJC64DiaYkFu2AOmP8ACjStNvNSjgtr+4jbBwwDfJzwPm6AZPOelZqDjdpmspxrTTdkvxOzF3pWoLMiXW+Kd18tABnPTj0/+tWS9rrljdiwtJwLdsgM5+7z19q4hdLu9LuPtOn3ADxSHMDuM8HqD3HuK1T4gvry5QXe6GdsAOOnTv8A41Epp76M3p4aUXaLTXn/AF+RvXmlahEWa9uWlUcg9ifTNT301rYWDi0iZpVVWaNR8xOOdv41k6brTyNPa6k8kijhSp6e/Pao7xhdWjeXMdqceZnqB3qXZf8ABLXPtLW3bZmJpou9Q1BnluVtsv50ayEkv9PXArSvvFiy21ylwrmRAuBE2FkHufb0rjpL/wAu7UXas0cLkoY2OR7CpZt2uXarYweWqjaUUdvelRUV1ub432nOpNWS7HpXgUWWt2kjtGkVyfl2o5O3I4OCfrW3q/h+XRdIt9Xkna7toZf3y+Wq7RkYZRnkZJB9OD0Oa5zw0i6JbRqtuuGIWSUDJz7c11OrCXXNBezuiWjiBVCeQh9qI0007oiVdKopX91vXrocL4o+HcGtNbPoMsKCZHu4S0SxlkJyy7gMswbPBPAIArlNQ0fV9C0G8lurZXt9xhDOeQw649cf1Fd/Z2ep6RdjTbmS0nhttwWeGQyZU4ztI/kcY5NJ4+QW9jPFPkRbchdwfeSMZyOPXt3op1G3ae6KxOHpqP7ppp6/ieceDbmG/wDJtZZGsoFBjZ41+ZnOSCTjp29ea9e8PQaatuWs9OtY4wxVzEuenUZOTnnrnNeCXVzFaRlLGSRW4YgHr9a67wD41ubITQztsinIcInChvXH4de9VyvexyOtGXu3s/wPV7l7IXdkbOOdp3mVZPs8RLeX3YscgYx6e9aOsXURiurXRLq7+xIRI4lILswGC2RgEYOPpWc/iGO90KARxoJHKlyoI3LkDt65NUtF1No1cI0W3zmaV/VB0wO56VcJW2OfEczWvT+v+GEgtL8SpNZX7y7eQX659AenStHU766t9Eu7u62ieNGmJZQQAB3PSrJljZi1rGYWcb8MOM/TtXI+LJ7rxDKfDunygWa4bUrsdAc58pfU9Caaj73NcipXvBcyRwlxr+ueLoY9PtkIgPMhQlQ/ux7Cu98D+B7GzC3M7C5uVHJx8iewq94Y8Nw26rBB+7tU65XG/wCprZl1u3SU2GkxiSTO3co4H0qajuryehyc86rcaS0/rcku9kSyR2duiTdQxB49zWba2FvZHzpppbi/ufl3g5d/9hPQe9T3s8WlWxErGe7Yb/LByM+rVz+qeJl8L28mp6iDca1cKUtYO0Yx1I7VgoyqNL+vVmql7ODt/wAF/wDANLxRrdj4dthC0kYugm51Q8Rj0Hqe3v1NeH69r82qzNLckiPJMcPYe59TVHUdUubu6mub2Qy3MpycnpWPPLk5J5rvhFRXLE4Kjs+7H3FxJJnJwPSqDHOcD8ac8hbikAqtjHciMWTk04Q/lU6jilxRcYxIwFz6VKj7TwTTMUnegkpP1qMmiimWhKKKKBksdWrQkS8UUUEM0YSelPJIbiiipKhua3hy+msNbsrm2IWQOM+jDPINeo+ILyW3t7eSIgFX6duTiiiiJ1buJNIRDq1sVUEbs7T0qvcqsurWaFFATf0HLEnqfU9qKKJ7G+H+L5GrFFGtveEIu5AcHufrWpLPJbvAImwpKkr2JwOaKKxjsdtZtvXzGeBYLa+u7yW4tbcyx3jSM4jGZCSThj6AjgDFd3r9lGiby0j/AGq3EjqzZAJZlIA7DAHFFFKp/EE9Kasc1rFtFBorXCxxmW4tMSFkU8MATgYwOQD7EcV458QI1tNKtFhVVWa2hkYbRwxXJIoooS0L7mr+zlZxX/iMRXO5kEkaAezSAGvYfHNuJNb1a1ndpog/G/BI+QHjjHeiihbMyj8a9P1OOsrOC40+J5Yw0inG8/ePHc11nhqztJb6ZLi2SeKK0aeOORmKo6ocHGeegBByOKKKuHxIiu2oyt5nj3xW1G4nZrVyBCcPgccjOP5muO8MWsc1pfXjl/OtpkWPBwMFSf6UUVL1kzoqtxhS5dLnp8Wnw+IPDAuL9pRNEDsaNyu3n0/xqloqfYL23tYiXimKlvM5PI9aKKJN3ChrCV+h3Gv6faf8SMmCMvMkKu4G0lS20jjA989c96rfHDQrDQfEsP8AZcRhjltVmEe7KoSWBC98fLn6k0UVrWivZt26HJhpy9vBX7nldjfTCR87WZxyzZJ6mutigjj02bC5wFPzHPUH/CiiuRq8UehOTVV2MvR9OtbxWlmiXfwcj1x1rL0eRo9Zu3HJhcBM9uaKKdBLkMsZKTq6v+rHVaTcyST3DHCsx3Erxz9Oldhps7nRbhmwSjKACOD9aKK36Iwlrf5EkpaGfzIm2uTywA9PpV650u31nwvrEl7uLRw7l24GD83t7CiisHujth8F/M+X763WNrVgzsZIg5LHp8zDA9uKuXK4NkQzZ2LH1/hB4FFFanI0rHS6HqVzbXIsEk3W5lMYDclQfT869Bs7NIJLi2VnZYpWQOxG5gOmT+FFFJ/ZMovSXqSeILicRWkEczxC9uFt5HQ4YKc52nseOtbdrYwaVHFZWSbLaM8Lgc+5Peiiktzlq6tJmR421S7gEdrBII4pCA20YJ/GtfRoY9PsovsyKrycO5GWb8aKKwqa1dex2zSjhYW6tmFq+oS22k3N3CkYmSTIJGcn1Oe9eK6hfXF1JLd3MrS3Dnl2OTRRXZBWgede7ZhysTkk5Jqk5JPNFFaI5nuNFSDpRRQxDqWiigBKQ0UUxH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1320=[""].join("\n");
var outline_f1_18_1320=null;
var title_f1_18_1321="Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity";
var content_f1_18_1321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Nancy Y Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Neil D Gross, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Scott Okuno, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Shyam SD Rao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1321/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1321/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/18/1321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of locoregionally advanced (stage III and IV (",
"    <a class=\"graphic graphic_table graphicRef70195 \" href=\"UTD.htm?38/12/39117\">",
"     table 1",
"    </a>",
"    )) cancer of the oral cavity is discussed here.",
"   </p>",
"   <p>",
"    The anatomy of the oral cavity, the epidemiology of oral cavity malignancies, and the treatment of early stage disease are presented separately, as is the management of patients with metastatic and recurrent disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32217?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The oral cavity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral cavity extends from the skin-vermilion junction of the lips to the junction of the hard and soft palate above and to the line of circumvallate papilla of the tongue below. The anterior tonsillar pillars and glossotonsillar folds serve as the lateral boundaries between the oral cavity and oropharynx.",
"   </p>",
"   <p>",
"    Specific sites of oral cavity cancer include the lip, floor of the mouth, oral tongue (anterior two-thirds of the tongue), lower alveolar ridge, upper alveolar ridge, retromolar trigone (retromolar gingiva), hard palate, and buccal mucosa (",
"    <a class=\"graphic graphic_figure graphicRef54845 \" href=\"UTD.htm?3/27/3509\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The tumor node metastases (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to classify lip and oral cavity carcinoma (",
"    <a class=\"graphic graphic_table graphicRef70195 \" href=\"UTD.htm?38/12/39117\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By definition, patients with stage III and IV disease have tumors greater than 4 cm in greatest dimension, invasion of adjacent structures,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of lymph node involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are inadequate data from randomized clinical trials to define an optimal strategy for patients with stage III and IV oral cavity cancers. Recommendations and treatment planning are based upon trials that included large numbers of patients with primary tumors at other head and neck sites, observation data from series of patients with oral cavity cancer, and an analysis of individual patient circumstances.",
"   </p>",
"   <p>",
"    Decisions about the integration of surgery, RT, and chemotherapy for each patient should be made with multidisciplinary input. The management plan should take into account the likely functional consequences of treatment, as well as the expertise of the treatment team.",
"   </p>",
"   <p>",
"    Locoregionally advanced oral cavity cancers are aggressive malignancies with high rates of recurrence following either surgery or radiation therapy (RT) alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, a combined modality approach is generally indicated when permitted by the patient&rsquo;s overall condition.",
"   </p>",
"   <p>",
"    Surgery is generally recommended as the initial therapy for locally advanced oral cavity cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/3\">",
"     3",
"    </a>",
"    ]. In most cases, simultaneous resection and reconstruction is feasible with acceptable functional outcomes. RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemoradiotherapy are alternatives for patients who refuse surgery, have a technically unresectable tumor (carotid artery encasement, vertebral or brain invasion), would have an unacceptable functional outcome with surgery, or are medically inoperable.",
"   </p>",
"   <p>",
"    Although there is a strong rationale for induction chemotherapy when surgery would result in severe functional loss, the intensity of mucositis induced by concurrent chemoradiation in the oral cavity restricts the use of this strategy for first-line treatment, as does the lack of a proven survival benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291357030\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delineation of the tumor size and extent of invasion prior to treatment is critical in patients with oral cavity cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32217?source=see_link&amp;anchor=H88481456#H88481456\">",
"     \"Treatment of early (stage I and II) head and neck cancer: The oral cavity\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with locoregionally advanced disease should be evaluated for the presence of distant metastases. A CT of the chest is often a convenient screen for lung metastases and a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    can be considered to rule out distant metastatic disease. Small, clinically indeterminate pulmonary nodules are often identified. These are statistically likely to be benign and, therefore, rarely affect treatment. Computed tomography (CT) is also an important tool for detecting cortical bone erosion of the mandible or maxilla.",
"   </p>",
"   <p>",
"    All patients should be seen preoperatively by the surgeon, radiation oncologist, and medical oncologist for preoperative treatment planning. Assessment of comorbidity, speech and swallowing function, nutritional status, and dental and psychosocial evaluations are also important steps in treatment planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initial surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is generally preferred as the initial step in the treatment of locoregionally advanced oral cavity cancer, although data comparing surgery with RT are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6292878\">",
"    <span class=\"h3\">",
"     Surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral cavity cancers can be accessed through a transoral approach or a combined transoral and transcervical approach. Traditional surgical techniques are generally used for locally advanced cancers. There is no advantage to minimally invasive approaches, such as transoral laser resection or robotic-assisted surgery, particularly given the complexity of the reconstruction that is often required.",
"   </p>",
"   <p>",
"    Every attempt should be made to ensure negative resection margins, since there is an increased risk of treatment failure in patients with positive surgical margins, even when postoperative RT or chemoradiotherapy is used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/6\">",
"     6",
"    </a>",
"    ]. If positive margins are identified, reresection is indicated when feasible. Postoperative RT or chemoradiotherapy is indicated when positive surgical margins are identified.",
"   </p>",
"   <p>",
"    Surgical procedures (eg, glossectomy, maxillectomy, mandibulectomy) can result in severe functional defects in speech and swallowing. The functional loss associated with these procedures may be mitigated by reconstruction and intense speech and swallowing rehabilitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Postoperative RT and chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative RT with or without concurrent chemotherapy should be strongly considered standard of care for patients with locoregionally advanced oral cavity cancer since these patients are at significant risk for local recurrence after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/3\">",
"     3",
"    </a>",
"    ]. Randomized trials that included patients with oral cavity cancers have confirmed the benefit of postoperative concurrent chemoradiation compared with postoperative RT alone for high-risk patients with locally advanced head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25719?source=see_link&amp;anchor=H6#H6\">",
"     \"Postoperative radiation therapy in the management of head and neck cancer\", section on 'Chemoradiotherapy versus radiotherapy alone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors associated with a particular increase in risk include extracapsular nodal spread, positive resection margins, N2 or N3 nodal disease, nodal disease in levels IV or V, perineural invasion, or vascular invasion, all of which are indications for chemoradiotherapy (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ). The presence of T3 or T4 disease, without any other high risk features, is an indication for RT alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25719?source=see_link&amp;anchor=H6#H6\">",
"     \"Postoperative radiation therapy in the management of head and neck cancer\", section on 'Chemoradiotherapy versus radiotherapy alone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative RT is generally preferred over preoperative RT for patients with locoregionally advanced oral cavity cancer. The administration of preoperative RT can delay surgery and increases the risk of postoperative complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initial radiation therapy and/or chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional organ preservation approaches are widely used for patients with locoregionally advanced oropharyngeal, hypopharyngeal, and laryngeal cancers. However, this approach has not been widely applied to patients with oral cavity cancer. Data are more limited, there are concerns about increased toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/7\">",
"     7",
"    </a>",
"    ], and no survival advantage has been demonstrated for patients with stage III or IV primary tumors of the oral cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Two trials in patients with oral squamous cell carcinoma have failed to demonstrate an improvement in overall survival with preoperative chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 195 patients with resectable disease were randomly assigned to either three cycles of preoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      followed by surgery or immediate surgery. Postoperative RT was used for high-risk patients in both arms of the trial [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/5\">",
"       5",
"      </a>",
"      ]. There was no significant difference in overall survival (five-year survival 55 percent in both arms), although the use of chemotherapy prior to surgery resulted in a decreased requirement for mandibulectomy (31 versus 52 percent) and postoperative radiation (33 versus 46 percent).",
"     </li>",
"     <li>",
"      In a second trial, 256 patients were randomly assigned to two cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , and 5-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      followed by surgery and postoperative RT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/9\">",
"       9",
"      </a>",
"      ]. Planned treatment was completed in 222 cases. After a median follow-up of 30 months, there was no significant difference in either overall or disease-free survival (HRs 0.98 and 0.97, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy is an alternative for patients who refuse surgery, have a technically unresectable tumor (carotid artery encasement, vertebral or brain invasion), would have an unacceptable functional outcome with surgery, or are medically inoperable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combined modality approach utilizing both chemotherapy and RT is appropriate for patients who are not surgical candidates but whose overall condition will tolerate the potential increase in toxicity. Approaches that may be used include induction chemotherapy followed by definitive concurrent chemoradiotherapy or RT and immediate concurrent chemoradiotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      RT without chemotherapy is appropriate for patients who are not surgical candidates and whose medical condition will not tolerate the increased toxicity associated with chemotherapy or concurrent chemoradiotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients where a nonsurgical approach was originally undertaken because of either the low probability of surgical cure or the morbidity associated with resection, complete resection may be indicated as a salvage procedure for residual disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oral cavity subsites",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although squamous cell carcinomas are the most frequent histologic type of lip cancer, these tumors generally are more related to skin cancers than to other oral cavity cancers. Because they are readily visible, most lip cancers are diagnosed at early stages, with T3 and T4 tumors representing a very small proportion in published series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32217?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of early (stage I and II) head and neck cancer: The oral cavity\", section on 'Lip'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, definitive RT may be functionally and cosmetically preferable to surgical resection. In cases with bone or nerve invasion, resection with postoperative RT is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Floor of mouth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locally advanced cancer of the floor of mouth is typically treated with surgical resection to achieve negative margins, followed by postoperative RT, with or without concurrent chemotherapy. The combination of surgery and postoperative RT has been associated with better local control than either modality alone, as surgical resection alone (with 1 to 2 cm margins) for stage III and IV disease results in five-year overall survival of only 46 and 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cancer of the floor of mouth has a high rate of mandibular invasion and cervical lymph node metastases. Furthermore, anterior floor of mouth cancers often involve the geniohyoid tubercle and genioglossus muscle anteriorly. Thus, surgery will frequently require segmental mandibulectomy as a marginal resection of bone is generally not possible in the coronal plane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Oral tongue",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral tongue is the most common subsite for oral cavity cancer. Cancer of the oral tongue has been associated with a worse prognosis compared with other oral cavity subsites in some but not all series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Typically, five-year disease-specific survival rates of 39 and 27 percent have been achieved for stage III and IV disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Partial glossectomy is commonly required for locoregionally advanced disease. Total glossectomy is occasionally required in cases where bilateral lingual arteries are involved by cancer. &nbsp;In those cases, total laryngectomy may also be required to prevent aspiration. The addition of postoperative RT or chemoradiotherapy, appears to improve disease control compared with surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary treatment with concurrent chemoradiotherapy or sequential therapy may be preferred when total glossectomy and laryngectomy are indicated, given the overall poor prognosis and functional loss associated with surgery. Patients considering this option should be aware of the potential trade-off between oncologic and functional outcome. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Initial radiation therapy and/or chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455663481\">",
"    <span class=\"h3\">",
"     Lower alveolar ridge and retromolar trigone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical approach to resection of locoregionally advanced oral cavity cancer involving the lower alveolar ridge depends upon the status of the teeth. Patients with good dentition are often candidates for marginal resection of the mandible, which can be performed transorally. In contrast, edentulous patients and those with loose teeth involved by cancer require segmental resection of the mandible to ensure adequate clearance of disease.",
"   </p>",
"   <p>",
"    Similarly, locally advanced retromolar trigone lesions typically require segmental mandibulectomy followed by postoperative RT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Resection of the ascending ramus of the mandible including the pterygoid muscles is important to ensure eradication of disease. Microvascular reconstruction with a fibular free tissue transfer provides optimal functional and cosmetic rehabilitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32217?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of early (stage I and II) head and neck cancer: The oral cavity\", section on 'Retromolar trigone and lower alveolar ridge'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Upper alveolar ridge and hard palate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hard palate cancers are rare. Locally advanced lesions typically involve the underlying bone, and primary surgery is used more commonly than definitive RT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/21\">",
"     21",
"    </a>",
"    ]. Resection is generally well tolerated. These patients can be reconstructed with either an immediate surgical obturator or microvascular-free tissue transfer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Buccal mucosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buccal mucosa cancers have a high tendency to recur locoregionally. Consequently, patients with buccal mucosa cancers have a worse survival rate compared with patients with cancer in other oral cavity subsites [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure of a buccal mucosa cancer can be difficult via a transoral approach, which makes it difficult to obtain clear radial margins in an en bloc fashion. Furthermore, the thin distance between the buccal mucosa and the buccal space permits early invasion to deep structures or to anterior cheek skin. Exenteration of the buccal space, parotid, and skin is needed to maximize outcome, although this is achieved with a considerable cost to cosmesis.",
"   </p>",
"   <p>",
"    Cancer of the buccal mucosa can be treated with definitive RT. However, deeply invasive cancers should be managed with surgery and postoperative RT. Regardless of the method of treatment, there is a high risk of severe, irreversible trismus. Aggressive reconstruction and rehabilitation is required to optimize functional outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822571#H3822571\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Trismus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455663491\">",
"    <span class=\"h2\">",
"     Supportive care measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic tracheostomy is generally required for locoregionally advanced oral cavity cancers undergoing surgery, except for cancers of the upper alveolar ridge and hard palate. The tracheostomy can usually be removed within a couple of weeks of surgery and prior to adjuvant therapy. In some cases, tracheostomy is maintained during adjuvant RT or chemoradiotherapy.",
"   </p>",
"   <p>",
"    A feeding tube is usually required after surgery. A nasogastric feeding tube is feasible if the impact on swallowing is expected to be minimal and of relatively short duration. A gastrostomy tube is advised for patients in whom swallowing will be severely compromised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage III and IV oral cavity cancer either have clinically involved lymph node(s) in the neck or are at significant risk of subclinical nodal involvement due to the size and extent of the primary tumor. Treatment of the neck is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/3\">",
"     3",
"    </a>",
"    ]; this usually includes unilateral or bilateral neck dissection with postoperative radiation therapy (RT).",
"   </p>",
"   <p>",
"    The extent of neck dissection remains controversial. Limiting the extent of dissection reduces surgical morbidity, particularly if level V is excluded (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ). A selective dissection including levels I to III, a supraomohyoid neck dissection, is typically sufficient for clinically N0 oral cavity cancer, as level IV and V nodes are rarely involved without clinical disease at other levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. This dissection includes the submandibular gland but preserves the spinal accessory nerve, the internal jugular vein, and the sternocleidomastoid muscle. Some cancers of the oral tongue, however, involve level IV lymph nodes without disease being present in levels I to III, a phenomenon known as \"skip metastases\" [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with clinically involved regional lymph nodes may benefit from a complete modified neck dissection.",
"   </p>",
"   <p>",
"    Contralateral metastases, and hence the need for bilateral neck treatment, are more likely for tumors that approach or cross the midline [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, oral tongue and floor of mouth cancers are at very high risk for bilateral nodal involvement. If postoperative RT is planned for the ipsilateral neck, some groups advocate RT to the contralateral N0 neck rather than neck dissection. Bilateral neck dissection combined with bilateral neck RT has a high risk of significant lymphedema, although surgical sparing of the jugular vein is the most important aspect of preventing edema in patients undergoing a bilateral neck dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients receiving definitive RT, irradiation of the neck should follow the same indications as for neck dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both surgery and RT can have a profound effect on the quality of life, given the role of the oral cavity in speech, mastication, and swallowing. Thus, careful patient selection and surgical planning is required for all locoregionally advanced oral cavity cancer patients. The use of a multimodality approach in locally advanced oral cavity cancers increases the risk of serious complications.",
"   </p>",
"   <p>",
"    Potential direct surgical complications include infection, bleeding, aspiration, wound breakdown, flap loss, and fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Irradiation of the oral cavity and neck may result in mucositis, skin reaction, xerostomia, loss of taste, and dysphagia. Late toxicities may include skin and soft tissue atrophy and fibrosis, osteoradionecrosis, xerostomia, and trismus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recovery from xerostomia after irradiation of the oral cavity, even with modern conformal techniques, is more limited than with other head and neck sites because of higher doses of irradiation to the submandibular glands and larger volumes of oral mucosa and the minor salivary glands in the treatment fields [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/31\">",
"     31",
"    </a>",
"    ]. Xerostomia also exacerbates other late complications, such as difficulty swallowing, impaired speech, and dental caries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteoradionecrosis of the mandible is a particularly feared consequence of high-dose radiation to the oral cavity, and one of the primary reasons that surgery is often preferred to definitive RT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adoption of newer reconstructive techniques may decrease functional deficits from radical surgery involving the oral cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, these reconstructive techniques do not restore motor or sensory function. This is acceptable for smaller defects (eg, hemiglossectomy reconstructed with radial forearm free flap) where the remaining normal tissue can compensate well. On the other hand, larger defects (eg, total glossectomy reconstructed with rectus free flap) may result in permanent debilitating functional loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Surveillance, Epidemiology and End Results (SEER) Cancer Statistics review for the years 1975 to 2007 reports a five-year relative survival for locally advanced oral cavity and oropharyngeal cancer of 54.7 percent, in contrast to 82.5 percent for early-stage disease and 60.9 percent for all-stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/36\">",
"     36",
"    </a>",
"    ]. Although stage IVA patients have worse outcomes than stage III patients, it has been suggested that the subset of stage IVA patients with pT4N0 disease may have similar outcomes to stage III patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymph node involvement is the single most important prognostic factor for outcome in oral cavity cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition to the presence or absence of lymph node metastasis, other factors include the number and size of positive lymph nodes, the presence of extracapsular extension, and the ratio of positive lymph nodes to total number of excised lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. With regard to the primary lesion, higher histologic grade, the presence of perineural invasion and increasing size have been correlated with worse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1321/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTTREATMENT EVALUATION AND SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of oral cavity cancer both to detect recurrent disease and to diagnosis second malignancies that may develop. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding, and enlarged lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=see_link\">",
"     \"Second primary malignancies in patients with head and neck cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences will occur within this timeframe. Because of the higher risk of recurrence and second primary malignancy in those who continue tobacco use, many schedule more frequent surveillance visits for these patients and also continue surveillance beyond five years.",
"   </p>",
"   <p>",
"    All patients treated for advanced stage oral cavity cancer will require intensive functional rehabilitation in addition to cancer surveillance. Patients should be counseled in smoking cessation and referred for dental, speech, hearing, and swallowing evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43959?source=see_link\">",
"     \"Overview of treatment for head and neck squamous cell cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Posttreatment surveillance of patients with head and neck cancer, including screening for treatment-related complications, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/38/5731?source=see_link\">",
"       \"Patient information: Tongue cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral cavity squamous cell carcinomas include tumors originating in the lip, floor of mouth, oral tongue, lower alveolar ridge, upper alveolar ridge, retromolar trigone, hard palate, and buccal mucosa.",
"     </li>",
"     <li>",
"      Locally advanced oral cavity cancer typically requires multimodality treatment due to the relatively high risk of locoregional recurrence and disease-related mortality. All patients should be seen preoperatively by the surgeon, radiation oncologist, and medical oncologist for preoperative treatment planning. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with locoregionally advanced oral cavity cancer, we suggest surgery as the initial component of therapy rather than radiation therapy or chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initial surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with locoregionally advanced oral cavity cancer remain at significant risk for local recurrence after surgery. We recommend postoperative RT, with or without concurrent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend postoperative concurrent chemoradiotherapy over postoperative RT alone for patients with positive surgical margins and extracapsular extension (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Postoperative RT and chemoradiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive radiation therapy (RT) or chemotherapy plus RT are options for patients who are medically inoperable, who have unresectable disease, or who have resectable disease where surgical resection cannot be accomplished with acceptable long-term functional consequences. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial radiation therapy and/or chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with locoregionally advanced oral cavity cancer, we recommend a modified radical neck dissection and postoperative RT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The optimal extent of the neck dissection is controversial, and is influenced by the extent of the primary tumor. Tumors that approach or cross the midline and oral tongue and floor of mouth cancers are treated with bilateral neck treatment. For patients receiving definitive RT, irradiation of the neck should follow the same indications as for neck dissection. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/2\">",
"      Oliver RJ, Clarkson JE, Conway DI, et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev 2007; :CD006205.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/4\">",
"      Robertson AG, Soutar DS, Paul J, et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clin Oncol (R Coll Radiol) 1998; 10:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/5\">",
"      Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003; 21:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/6\">",
"      Liao CT, Chang JT, Wang HM, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol 2008; 15:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/7\">",
"      Turner SL, Slevin NJ, Gupta NK, Swindell R. Radical external beam radiotherapy for 333 squamous carcinomas of the oral cavity--evaluation of late morbidity and a watch policy for the clinically negative neck. Radiother Oncol 1996; 41:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/8\">",
"      Stenson KM, Kunnavakkam R, Cohen EE, et al. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope 2010; 120:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/9\">",
"      Zhong L, Zhang C, Ren G, et al. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/10\">",
"      Salgarelli AC, Sartorelli F, Cangiano A, et al. Surgical treatment of lip cancer: our experience with 106 cases. J Oral Maxillofac Surg 2009; 67:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/11\">",
"      Gooris PJ, Maat B, Vermey A, et al. Radiotherapy for cancer of the lip. A long-term evaluation of 85 treated cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/12\">",
"      Guinot JL, Arribas L, Chust ML, et al. Lip cancer treatment with high dose rate brachytherapy. Radiother Oncol 2003; 69:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/13\">",
"      Rodgers LW Jr, Stringer SP, Mendenhall WM, et al. Management of squamous cell carcinoma of the floor of mouth. Head Neck 1993; 15:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/14\">",
"      Nason RW, Sako K, Beecroft WA, et al. Surgical management of squamous cell carcinoma of the floor of the mouth. Am J Surg 1989; 158:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/15\">",
"      Zelefsky MJ, Harrison LB, Fass DE, et al. Postoperative radiotherapy for oral cavity cancers: impact of anatomic subsite on treatment outcome. Head Neck 1990; 12:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/16\">",
"      Bell RB, Kademani D, Homer L, et al. Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg 2007; 65:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/17\">",
"      Sessions DG, Spector GJ, Lenox J, et al. Analysis of treatment results for oral tongue cancer. Laryngoscope 2002; 112:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/18\">",
"      Fein DA, Mendenhall WM, Parsons JT, et al. Carcinoma of the oral tongue: a comparison of results and complications of treatment with radiotherapy and/or surgery. Head Neck 1994; 16:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/19\">",
"      Mendenhall WM, Morris CG, Amdur RJ, et al. Retromolar trigone squamous cell carcinoma treated with radiotherapy alone or combined with surgery. Cancer 2005; 103:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/20\">",
"      Huang CJ, Chao KS, Tsai J, et al. Cancer of retromolar trigone: long-term radiation therapy outcome. Head Neck 2001; 23:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/21\">",
"      Yorozu A, Sykes AJ, Slevin NJ. Carcinoma of the hard palate treated with radiotherapy: a retrospective review of 31 cases. Oral Oncol 2001; 37:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/22\">",
"      Diaz EM Jr, Holsinger FC, Zuniga ER, et al. Squamous cell carcinoma of the buccal mucosa: one institution's experience with 119 previously untreated patients. Head Neck 2003; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/23\">",
"      Andersen PE, Warren F, Spiro J, et al. Results of selective neck dissection in management of the node-positive neck. Arch Otolaryngol Head Neck Surg 2002; 128:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/24\">",
"      Byers RM, Weber RS, Andrews T, et al. Frequency and therapeutic implications of \"skip metastases\" in the neck from squamous carcinoma of the oral tongue. Head Neck 1997; 19:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/25\">",
"      Dias FL, Lima RA, Kligerman J, et al. Relevance of skip metastases for squamous cell carcinoma of the oral tongue and the floor of the mouth. Otolaryngol Head Neck Surg 2006; 134:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/26\">",
"      Ferlito A, Silver CE, Rinaldo A. Elective management of the neck in oral cavity squamous carcinoma: current concepts supported by prospective studies. Br J Oral Maxillofac Surg 2009; 47:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/27\">",
"      De Cicco C, Trifir&ograve; G, Calabrese L, et al. Lymphatic mapping to tailor selective lymphadenectomy in cN0 tongue carcinoma: beyond the sentinel node concept. Eur J Nucl Med Mol Imaging 2006; 33:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/28\">",
"      Capote-Moreno A, Naval L, Mu&ntilde;oz-Guerra MF, et al. Prognostic factors influencing contralateral neck lymph node metastases in oral and oropharyngeal carcinoma. J Oral Maxillofac Surg 2010; 68:268.",
"     </a>",
"    </li>",
"    <li>",
"     Frank DK, Sessions RB. Management of the neck: Surgery. In: Head and Neck Cancer: A Multidisciplinary Approach, 3rd, Harrison LB, Sessions RB, Hong WK (Eds), Lippincott, Williams, &amp; Wilkins, Philadelphia 2009. p.181.",
"    </li>",
"    <li>",
"     Koch, WM, Stafford, et al. Cancer of the oral cavity.. In: Head and neck cancer: a multidisciplinary approach., 3rd ed, Harrison, LB, Sessions, RB, Hong, WK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.250.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/31\">",
"      Gomez DR, Zhung JE, Gomez J, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys 2009; 73:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/32\">",
"      Pauloski BR, Rademaker AW, Logemann JA, Colangelo LA. Speech and swallowing in irradiated and nonirradiated postsurgical oral cancer patients. Otolaryngol Head Neck Surg 1998; 118:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/33\">",
"      Oh HK, Chambers MS, Martin JW, et al. Osteoradionecrosis of the mandible: treatment outcomes and factors influencing the progress of osteoradionecrosis. J Oral Maxillofac Surg 2009; 67:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/34\">",
"      Curtis DA, Plesh O, Miller AJ, et al. A comparison of masticatory function in patients with or without reconstruction of the mandible. Head Neck 1997; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/35\">",
"      Urken ML, Buchbinder D, Weinberg H, et al. Functional evaluation following microvascular oromandibular reconstruction of the oral cancer patient: a comparative study of reconstructed and nonreconstructed patients. Laryngoscope 1991; 101:935.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/csr/1975_2007/ (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/37\">",
"      Liao CT, Chang JT, Wang HM, et al. Survival in squamous cell carcinoma of the oral cavity: differences between pT4 N0 and other stage IVA categories. Cancer 2007; 110:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/38\">",
"      Shah JP, Cendon RA, Farr HW, Strong EW. Carcinoma of the oral cavity. factors affecting treatment failure at the primary site and neck. Am J Surg 1976; 132:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/39\">",
"      Gil Z, Carlson DL, Boyle JO, et al. Lymph node density is a significant predictor of outcome in patients with oral cancer. Cancer 2009; 115:5700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/40\">",
"      Gross ND, Patel SG, Carvalho AL, et al. Nomogram for deciding adjuvant treatment after surgery for oral cavity squamous cell carcinoma. Head Neck 2008; 30:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/41\">",
"      Myers JN, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer 2001; 92:3030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/42\">",
"      Fagan JJ, Collins B, Barnes L, et al. Perineural invasion in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1321/abstract/43\">",
"      Arduino PG, Carrozzo M, Chiecchio A, et al. Clinical and histopathologic independent prognostic factors in oral squamous cell carcinoma: a retrospective study of 334 cases. J Oral Maxillofac Surg 2008; 66:1570.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3389 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1321=[""].join("\n");
var outline_f1_18_1321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H291357030\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initial surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6292878\">",
"      - Surgical technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Postoperative RT and chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initial radiation therapy and/or chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oral cavity subsites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lip",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Floor of mouth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Oral tongue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455663481\">",
"      - Lower alveolar ridge and retromolar trigone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Upper alveolar ridge and hard palate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Buccal mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455663491\">",
"      Supportive care measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT OF THE NECK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTTREATMENT EVALUATION AND SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3389\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3389|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/27/3509\" title=\"figure 1\">",
"      Anatomy of the oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/3/8244\" title=\"figure 2\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3389|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/12/39117\" title=\"table 1\">",
"      TNM stage oral cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43959?source=related_link\">",
"      Overview of treatment for head and neck squamous cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/38/5731?source=related_link\">",
"      Patient information: Tongue cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25719?source=related_link\">",
"      Postoperative radiation therapy in the management of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=related_link\">",
"      Second primary malignancies in patients with head and neck cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32217?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The oral cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_18_1322="Clinical manifestations and diagnosis of hemophilia";
var content_f1_18_1322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of hemophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/18/1322/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1322/contributors\">",
"     W Keith Hoots, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1322/contributors\">",
"     Amy D Shapiro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/18/1322/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1322/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1322/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/18/1322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/18/1322/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/18/1322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemophilias are a group of related bleeding disorders that most commonly are inherited. Inherited bleeding disorders include abnormalities of coagulation factors and platelet function; the most common of these is von Willebrand disease. However, when the term \"hemophilia\" is used, it most often refers to the following two disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor VIII deficiency (hemophilia A)",
"     </li>",
"     <li>",
"      Factor IX deficiency (hemophilia B, Christmas disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of these conditions will be reviewed here. Therapy with replacement factors and the development of inhibitors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link\">",
"     \"Treatment of hemophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophilia A and B are X-linked recessive diseases. They exhibit a range of clinical severity that correlates well with assayed factor levels. Severe disease is defined as &lt;1 percent factor activity, whereas 1 to 5 percent and &gt;5 percent of normal are defined as moderate and mild disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Males within a family have the same level of deficiency because they share the same genetic defect.",
"   </p>",
"   <p>",
"    The combined incidence of hemophilia A and B is 1 in 5000 live male births. Approximately 80 percent have hemophilia A, two-thirds of whom have severe disease. In contrast, almost one-half of individuals with hemophilia B (which occurs in 1 in 25,000 to 1 in 30,000 births) have factor IX levels above 1 percent (ie, moderate or mild disease). Hemophilia A and B of comparable severity bleed with similar frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with severe disease have a milder clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Leyden phenotype of hemophilia B is characterized by severe hemophilia in childhood that becomes mild after puberty. The mutation at nucleotide-20 in the promoter region in this disorder disrupts the hepatocyte nuclear factor-4 (HNF-4) binding site but not the overlapping site for an androgen response element, which may explain the recovery at puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. These patients also may have less disruption of the HNF-4 binding site [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coinheritance of the factor V Leiden mutation and other prothrombotic markers occurs in a small proportion of patients with severe hemophilia A [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. The presence of such prothrombotic conditions partially counteracts the bleeding tendency of hemophilia, resulting in fewer bleeding episodes and a later onset of first bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial presentation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bleeding may occur anywhere in patients with hemophilia. The most common sites are into joints and muscles and from the gastrointestinal tract. Approximately 80 percent of hemorrhage occurs in the joints; the ankles are most commonly affected in children, and the knees, elbows, and ankles in adolescents and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/12\">",
"     12",
"    </a>",
"    ]. Spontaneous hemarthroses are characteristic of severe disease. This pattern is different from the mucosal and cutaneous bleeding characteristic of platelet dysfunction or von Willebrand disease (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 1",
"    </a>",
"    ). Mucosal bleeding may manifest as epistaxis and gingival bleeding, and bullous hemorrhages may appear on the buccal mucosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The settings in which bleeding occurs vary with the severity of the disease. Bleeding occurs only in response to",
"    <span class=\"nowrap\">",
"     injury/trauma",
"    </span>",
"    or surgery in patients with mild hemophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/2,13\">",
"     2,13",
"    </a>",
"    ], to intercurrent injury or surgery in moderate hemophilia, and spontaneously and at an early age in severe hemophilia. Female carriers of the disease have variable factor levels; bleeding does not occur in those with near normal levels, but those with less than the expected 50 percent reduction may bleed more often than unaffected relatives or matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients are known to have hemophilia because of the family history; in one survey, for example, 25 percent of affected children had bleeding episodes before the diagnosis was established [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of newborns with severe hemophilia traverse delivery and the first few months of life without detection, despite the presence of severe factor VIII or IX deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/16\">",
"     16",
"    </a>",
"    ]. However, approximately 3 to 5 percent of such patients develop significant subgaleal or intracranial hemorrhage in the perinatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. In a multicenter survey, for example, symptomatic intracranial bleeding occurred in 4 percent of 744 patients, with 40 percent occurring within the first week of life due to trauma as the major precipitating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/18\">",
"     18",
"    </a>",
"    ]. Seizures are common during the acute intracranial hemorrhagic episode and there are frequent long-term complications such as psychomotor retardation and cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Most episodes of intracranial bleeding in newborns occur in sporadic cases with a history of difficult delivery or use of a suction apparatus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a study from 12 European hemophilia centers, involving 508 children born with hemophilia A or B, head bleeds occurred in 18 (3.5 percent) within the first 28 days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/21\">",
"     21",
"    </a>",
"    ]. Mild hemophilia in the mother and awareness of her carrier status were protective against such bleeding, although this was not statistically significant (OR 0.24; 95% CI 0.05-1.05). As noted before, there was a significant association between the use of forceps or a vacuum device during delivery and neonatal head bleeds (OR 8.84; 95% CI 3.05-25.6). It was concluded that vaginal delivery assisted with forceps",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a vacuum device should be avoided when the mother is a known carrier of hemophilia and is known to be pregnant with a male child.",
"   </p>",
"   <p>",
"    Early bleeding also occurs in approximately 50 percent of undiagnosed hemophilics in association with circumcision [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/22\">",
"     22",
"    </a>",
"    ]. Once diagnosed, the bleeding is controlled by infusion of factor concentrate or the use of fibrin glue or other local measures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link\">",
"     \"Fibrin sealant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More often, children with severe hemophilia A and B become symptomatic after the newborn period but within the first two years of life. In one study, the first symptomatic bleeding leading to the diagnosis of severe hemophilia occurred at a median age of 0.9 years in children not also carrying prothrombotic risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/11\">",
"     11",
"    </a>",
"    ]. In those carrying prothrombotic risk factors (eg, factor V Leiden, protein C deficiency, the prothrombin G20210A gene variant), the first bleeding episode occurred significantly later, at a median time of 1.6 years.",
"   </p>",
"   <p>",
"    However, some children do not bleed before the age of four [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. The major manifestations include abnormal bleeding in association with procedures or injury (frequently in the oral cavity) or excessive bruising, hematomas, or hemarthroses with activities considered normal for age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/15,25\">",
"     15,25",
"    </a>",
"    ]. Thus, early diagnosis and treatment may preserve the joints [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of hemophilia\", section on 'Prophylactic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of disease occurs later in patients with moderate and mild hemophilia. In a survey of 140 boys from Sweden, for example, the mean age at diagnosis of moderate and severe disease was 22 and 9 months, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/15\">",
"     15",
"    </a>",
"    ]. Moderate and particularly mild hemophilia may, in the absence of an informative family history, go undetected for significant periods of time (age 14 to 62 years in one report of 10 patients with mild disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/26\">",
"     26",
"    </a>",
"    ]. As many as one-third of patients with mild disease (factor levels &ge;5 percent) have very few or no bleeding episodes, which, as noted above, occur only with trauma or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sites of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;As children begin to ambulate, bleeding episodes occur more often and begin to involve joints and muscle, as well as other systems. The factors that initiate hemorrhage are not known, and the onset of hemorrhage often is a random event, occurring either spontaneously or after minimal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial hemorrhage (ICH) is most frequent in neonates, although it does occur in older children as well as adults; in most studies, spontaneous ICH is reported more frequently than trauma-induced bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/18,27,28\">",
"     18,27,28",
"    </a>",
"    ]. In one study of children, the prevalence of ICH was 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/27\">",
"     27",
"    </a>",
"    ]. It usually presents with headache, vomiting, and lethargy; however, some ICHs are silent and detected by magnetic resonance imaging (MRI) alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for ICH were determined in a nested case-control study of persons &ge;2 years of age enrolled in the Centers for Disease Control and Prevention Universal Data Collection project. While this study did not include all patients at every hemophilia center, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Of the 10,262 enrolled in the study, 199 (1.9 percent) experienced an ICH, for an incidence rate of 0.39 per 100 person-years.",
"     </li>",
"     <li>",
"      Significant risk factors for ICH included a high titer inhibitor, prior ICH, disease severity, and reported head trauma.",
"     </li>",
"     <li>",
"      Prophylaxis was associated with a significant risk reduction for ICH occurrence in patients with severe hemophilia who were negative for HIV or an inhibitor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hemarthrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemarthrosis is a painful and physically debilitating manifestation of hemophilia. Bleeding originates from the synovial vessels, and hemorrhage occurs within the joint cavity. Distension of the synovial space and associated muscle spasm markedly increase intrasynovial pressure. In addition to these acute events, hemarthrosis is the initiating event in hemophilic arthropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=see_link\">",
"     \"Hemarthrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H29#H29\">",
"     \"Treatment of hemophilia\", section on 'Hemarthrosis of peripheral joints'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H31#H31\">",
"     \"Treatment of hemophilia\", section on 'Hemarthrosis of the hip and iliopsoas bleeds'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H35#H35\">",
"     \"Treatment of hemophilia\", section on 'Chronic hemarthrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations vary by age. In infants, early signs of bleeding include irritability and decreased use of the affected limb. In older children and adults, hemarthrosis is manifested by prodromal stiffness and, in some patients, by a characteristic warm sensation, which is followed by acute pain and swelling.",
"   </p>",
"   <p>",
"    Bleeding episodes often affect a variety of joints, particularly the knees and ankles, which are the major weight bearing joints. One joint is usually affected at a time, but multiple bleeding sites are not uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Skeletal muscle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding into muscles with hematoma formation most often affects the quadriceps, iliopsoas, and forearm. Iliopsoas muscle bleeding episodes may be large and may compromise neurovascular structures and produce a compartment syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/30\">",
"     30",
"    </a>",
"    ]. The hemorrhage may be localized with ultrasound.",
"   </p>",
"   <p>",
"    Untreated hemorrhage may lead to the formation of a pseudotumor with hematoma surrounded by a fibrous membrane. MRI may be useful for diagnosis and therapeutic decision making [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/31\">",
"     31",
"    </a>",
"    ]. Recurrent hemorrhage is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Head and neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding can occur from numerous sites in the head and neck, leading to manifestations such as epistaxis and bleeding from the oral mucosa and teeth following minor trauma or dental procedures. In addition, coughing or vomiting can produce bleeding into the posterior pharynx, which can lead to airway compromise or airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of lesions in the gastrointestinal tract, such as esophagitis, gastritis, polyps, and diverticuli and swallowed blood from epistaxis, can present with blood in the stool. In addition, bleeding into the abdominal wall can produce severe pain that often is misdiagnosed as an acute abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/33\">",
"     33",
"    </a>",
"    ]. Computed tomography (CT) may distinguish hematoma from other conditions.",
"   </p>",
"   <p>",
"    Patients with hemophilia also can develop hematomas of the bowel wall, producing symptoms that mimic acute appendicitis or produce obstruction or intussusception. The diagnosis of \"pseudo-appendicitis\" usually can be made with CT scan, but occasionally surgery is required to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/34\">",
"     34",
"    </a>",
"    ]. Bleeding into the retroperitoneal space can also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Genitourinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria is a frequent manifestation of severe hemophilia; usually, it is benign and not associated with progressive loss of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The bleeding can arise from the kidneys or bladder and may persist for days or weeks. Ureteral obstruction with colic may occur when clots form. Other etiologies should be excluded if a particular episode is associated with pain or is not responsive to therapeutic intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Posttraumatic bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hemophilia seldom bleed from small cuts or venipuncture, but hemorrhage out of proportion to injury occurs after larger injuries. Delayed bleeding is common; it can be massive or may persist as continuous oozing for days or weeks. Delayed bleeding can occur in patients with mild hemophilia after minor surgical procedures such as tooth extraction.",
"   </p>",
"   <p>",
"    A potential explanation for this delayed bleeding was provided in a study performed in mice with hemophilia B (HB), animals which do not bleed excessively at the time of wounding, but rebleed hours to days later. Immunostaining of unwounded skin showed strong staining for tissue factor (TF) in both wild type and HB mice [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/37\">",
"     37",
"    </a>",
"    ]. However, TF was absent from around vessels near wounds in both wild type and HB mice, returning to normal levels by eight days in wild type and 10 days in HB mice.",
"   </p>",
"   <p>",
"    It was hypothesized that TF is normally down-regulated during wound healing in order to prevent thrombosis of newly-formed vessels, but renders those with hemophilia vulnerable to hemorrhage during the healing process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Late complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three important late complications that can develop in patients with hemophilia A and hemophilia B.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Joint destruction due to hemarthroses, leading to a number of orthopedic abnormalities",
"     </li>",
"     <li>",
"      Transmission of blood-borne infection",
"     </li>",
"     <li>",
"      Development of inhibitor antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hemophilic arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors may contribute to synovitis and joint destruction in patients with hemarthroses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/38\">",
"     38",
"    </a>",
"    ]. These include tissue deposition of iron and dense fibrosis of the joint with contractures, pain, and limitation of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/39-41\">",
"     39-41",
"    </a>",
"    ], as well as a possible linkage to HLA B27 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/42\">",
"     42",
"    </a>",
"    ]. This latter observation will need to be confirmed in other populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .) The number and type of hemarthroses correlate with function and future quality of life.",
"   </p>",
"   <p>",
"    Primary prophylactic treatment with factor VIII or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/61/8151?source=see_link\">",
"     factor IX concentrates",
"    </a>",
"    starting during the early years of life can markedly reduce the risk of subsequent arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. This was shown in a randomized controlled trial which compared three times per week prophylaxis versus regular on-demand Factor VIII replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/46\">",
"     46",
"    </a>",
"    ]. Results showed clear superiority for prophylaxis over on-demand treatment. The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% CI 1.5-24). Further, results from this study suggested that, in a few individuals, previously unrecognized subclinical bleeding may induce low level arthropathy evident only on MRI. It is still true, however, that many patients are not treated with primary prophylaxis and receive treatment on demand or courses of secondary prophylaxis. Thus, orthopedic complications remain a serious problem.",
"   </p>",
"   <p>",
"    The outcome after hemarthroses has been evaluated in numerous studies. In a report from the Orthopaedic Outcome Study Group, physical and x-ray examination scores of the knees, elbows, and ankles increased significantly with age, with changes that were related to the number of joint bleeds [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/45\">",
"     45",
"    </a>",
"    ]. All six joints were normal at study entry in approximately 10 percent; only one-half remained free of disease at six years.",
"   </p>",
"   <p>",
"    The orthopedic outcome also was evaluated in an epidemiologic survey of 116 young adults (mean age 23 years) with severe hemophilia who were born between 1970 and 1980 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/47\">",
"     47",
"    </a>",
"    ]. The patients had an average of 16.3 bleeds affecting the six main joints during the year of evaluation. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All six joints were normal in only 16 percent on physical examination and 4 percent on radiologic examination.",
"     </li>",
"     <li>",
"      A history of orthopedic surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rheumatologic procedures was present in 54 percent. These patients had undergone a mean of 2.3 procedures, primarily synovectomy. The knee was involved most often (42 versus 24 and 21 patients with elbow and ankle involvement, respectively). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=see_link\">",
"       \"Synovectomy for inflammatory arthritis of the knee\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limitations in moderate physical activity such was walking up a flight of stairs, taking a bath, or dressing, were present in 2 to 7 percent. However, 18 to 30 percent were limited with regard to more strenuous activities such as running, going up several flights of stairs, or walking more than one-half a mile.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another series of 139 patients included those with mild and moderate disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/40\">",
"     40",
"    </a>",
"    ]. The combination of clinical and radiologic features led to the classification of definite and possible hemophilic arthropathy in 42 and 14 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The completed Joint Outcome Study in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/46\">",
"     46",
"    </a>",
"    ] has demonstrated that prophylaxis with Factor VIII at 25-35 units per kilogram body weight every other day is superior to intensive on-demand (eg, 40",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    initially, then 25",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    at 24 and 72 hours) factor replacement therapy in preventing joint disease in previously pristine joints at age six years. The 80 percent lower incidence of pristine joints in the on-demand arm was confirmed by validated physical exam and radiographic scoring as well as by follow-up magnetic resonance imaging of ankles, knees, and elbows in the 66 children randomly assigned between the two arms of the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of concentrate-related transmission of infection has been reduced markedly by improvements in donor screening and virucidal techniques and the development of recombinant products (see below). However, patients treated with older factor VIII or IX concentrates were at high risk for infection with hepatitis A, B, C, and D and with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/48-53\">",
"     48-53",
"    </a>",
"    ]. Most patients were infected with hepatitis C virus (HCV), and HIV infection occurred in an average of 50 percent of patients overall [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/49-51,54\">",
"     49-51,54",
"    </a>",
"    ]. Coinfection with HCV and HIV is a concern because the liver disease may have an accelerated course that typically does not respond well to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .) In addition, patients who progress to cirrhosis are at risk for hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current use of donor screening, virucidal techniques (solvent-detergent, pasteurization); the insistence on safety testing when the product is first used, and the advent of recombinant products have led to a generation of products that have an extremely low risk of viral transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    .) In one study, for example, the prevalence of antibody to HCV was 83 percent in patients infused for the first time before 1985 compared with 6 percent in 80 patients infused for the first time between 1985 and 1991 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current screening methods for HCV have produced a further reduction in risk. Similarly, no documented HIV transmissions from antihemophilic factor concentrates have been reported since the implementation of improved viral inactivation procedures for plasma derivatives in the mid-1980s. These procedures kill HIV, even if it is present in high concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parvovirus B19, a nonlipid envelope virus, is an exception to elimination by dry, wet, and steam-heated methods [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/58\">",
"     58",
"    </a>",
"    ]. Parvovirus has also been transmitted to hemophilics in factor VIII and factor IX solvent-detergent-treated concentrates and has even caused mild hypoplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogen inactivation of blood products\", section on 'Pathogen inactivation of fresh frozen plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some concern regarding infectious agents for which there are no screening tests or methods to remove or inactivate the transmissible agent. Such agents include Creutzfeldt-Jakob disease (CJD) and new variant (nv) CJD. CJD and nvCJD are forms of transmissible spongiform encephalopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link\">",
"     \"Creutzfeldt-Jakob disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Development of inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important complication in patients with hemophilia is the development of antibodies (primarily IgG) that inhibit the relevant factor. These inhibitory antibodies, which occur in approximately 25 percent of patients with severe hemophilia A and 3 to 5 percent of those with severe hemophilia B, complicate bleeding episodes because of diminished responsiveness to factor concentrates; in addition, anaphylactic reactions can occur with factor IX inhibitors. Inhibitors are much less common in patients with mild or moderate disease.",
"   </p>",
"   <p>",
"    This topic and its diagnosis and treatment are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Maturational delays",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the increased risk for bleeding, the presence of inhibitors results in maturational delays. This was shown in a study of 333 HIV- children and adolescents with hemophilia followed at six-month intervals for seven years. When compared with those without inhibitors, the presence of inhibitors was associated with delayed bone age and Tanner stage transition, lower maximum growth velocity, and lower serum testosterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Protection against CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and carriers of hemophilia appear to have a reduced risk of coronary heart disease (CHD) mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. In a report of 717 Dutch patients with hemophilia compared with the general male population, the mortality due to ischemic heart disease was reduced by 80 percent in 11 years of follow-up; most of this reduction was not accounted for by conventional cardiac risk factor adjustment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protective effect against CHD is also present in carriers of hemophilia. This was illustrated in a report in which 965 Dutch carriers of hemophilia A or B were compared with the general female population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/65\">",
"     65",
"    </a>",
"    ]. A significant reduction in CHD mortality was found in nearly 35,000 person years of follow-up (39 deaths observed versus 61 expected, standardized mortality ratio 0.64).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DETECTION OF CARRIERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hemophilia typically begins with a careful review of the family history, particularly on the maternal side of the family. With an X-linked disease, fathers cannot transmit the disease to their sons. Screening tests are then performed and the diagnosis confirmed with a specific clotting factor assay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most instances, the mother of a male patient can be identified as a carrier because of the presence of abnormal bleeding in other members of her family. However, approximately one-third of patients with hemophilia have a negative family history; thus, lack of a family history is of little value in excluding the possibility of hemophilia. There are at least two explanations for a negative family history:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient may have a spontaneous mutation, which occurs in 25 to 33 percent of cases of hemophilia A and B [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. The size of the factor VIII gene and the presence of hot spots predispose the gene to mutation. Hot spots are recurrent sites of mutation (usually methylated CpG dinucleotides). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=see_link\">",
"       \"Genetics of the hemophilias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neonatal deaths or the passage of the trait through a succession of female carriers can lead to a negative family history despite the carrier status of the mother.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic hemophilia has been well-documented in females [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Three possible explanations for the expression of the phenotype in an X-linked recessive disease are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-chromosome inactivation may occur at an unusually early stage of embryogenesis, resulting in low levels of factor VIII.",
"     </li>",
"     <li>",
"      Mating between an affected male and a carrier female produces homozygous disease in one-half of female offspring.",
"     </li>",
"     <li>",
"      An abnormal karyotype as with loss of part or all of an X-chromosome in Turner syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/71\">",
"       71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Screening tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients presenting with a bleeding diathesis of unknown etiology, three initial tests should be performed: platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .) A normal platelet count, normal PT, and a prolonged aPTT are characteristic of hemophilia A, hemophilia B, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 2",
"    </a>",
"    ). An abnormal test occurs in individuals who have less than approximately 30 percent of the mean normal concentration of factor VIII; however, patients with mild hemophilia B may have normal or near normal aPTTs. Thus, in undiagnosed mild bleeding disorders, a factor IX assay should be performed even if the aPTT is normal.",
"   </p>",
"   <p>",
"    Other disorders prolong the aPTT but not the PT. They include acquired inhibitors to factor VIII and IX, and deficiency of factor XII, prekallikrein, or high molecular weight kininogen (abnormal bleeding does not occur with these deficiencies). A similar pattern (normal platelet count, normal PT, and a prolonged aPTT) is seen in patients with antiphospholipid antibodies who have a tendency to thrombosis rather than bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of an inhibitor, which does not occur in untreated patients with hemophilia, the elevated aPTT should be correctable by normal plasma, which normally is done by performing an aPTT on a 1:1 mix of patient and normal plasma. Specific factor deficiencies then are determined by assessing the aPTT in mixes of test plasma with commercially available plasmas deficient in known factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Specific assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific assays for the factors that can produce an isolated prolonged aPTT are performed in the order of their statistical frequency (ie, factor VIII, IX, and XI). A specific clotting assay for factor VIII may be either a one-stage or a two-stage method. One-stage methods are used most commonly because they are simple and readily automated. Two-stage methods are more difficult to perform but are less subject to other variables. Borderline values obtained with both methods always should be repeated.",
"   </p>",
"   <p>",
"    Several mutations have been described with higher values using the one-stage method than the two-stage method [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. In some of these patients, the diagnosis of hemophilia A would have been missed if only the one-stage method had been performed.",
"   </p>",
"   <p>",
"    Another method for the measurement of factor VIII is a chromogenic substrate assay [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/75\">",
"     75",
"    </a>",
"    ]. This test is based upon factor VIII-dependent factor X activation. Highly specific but complicated assays using immunoradiometric methods and enzyme-linked immunoabsorbent techniques (ELISA) also have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Distinction from von Willebrand disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with von Willebrand disease tend to have a different pattern of bleeding from hemophilia (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 1",
"    </a>",
"    ). The most sensitive laboratory test for the diagnosis of von Willebrand disease is the ristocetin cofactor assay, which is difficult to perform. Von Willebrand factor is an acute phase reactant and plasma levels increase in response to factors such as stress, pregnancy, and hormone replacement. Thus, normal values do not necessarily exclude the diagnosis in a patient with a suspicious history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type 2N von Willebrand disease, in which a qualitative defect in von Willebrand factor that affects the binding site for factor VIII is present, presents a different diagnostic problem. Bleeding in these patients is caused by low factor VIII levels (5 to 15 percent of normal) and mimics the findings seen in mild hemophilia. Differentiation of this disorder from mild hemophilia A can be difficult. Type 2N von Willebrand disease should be suspected in females who present with isolated factor VIII deficiency (with normal levels of von Willebrand factor) and in families in which an autosomal (rather than X-linked) inheritance pattern for factor VIII deficiency is suggested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Carrier detection and prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carrier testing is unnecessary if the individual is an",
"    <strong>",
"     obligate",
"    </strong>",
"    carrier, such as the mother of more than one hemophilic son or the daughter of a patient with hemophilia. Several methods of testing have been used for carrier detection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean concentration of immunologic and procoagulant factor VIII in the plasma of heterozygous carriers is approximately 50 percent that of normal women. However, the large scatter in these measurements produces significant overlap with the normal population [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/14,77\">",
"       14,77",
"      </a>",
"      ]. Thus, the demonstration of subnormal levels strongly suggests the presence of the carrier state, but the presence of normal levels does not reliably exclude it.",
"     </li>",
"     <li>",
"      At least 50 percent of obligate carriers of hemophilia B have a factor IX level below 60 percent. Once again, considerable overlap occurs with the normal range, and carrier detection based upon coagulation assay alone is much less sensitive than are available DNA techniques.",
"     </li>",
"     <li>",
"      DNA-based techniques are the preferred method for carrier detection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/78-80\">",
"       78-80",
"      </a>",
"      ]. Initial studies identified the causative mutation in 90 percent of individuals with moderate or mild hemophilia A but only 50 to 60 percent of individuals with severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/81\">",
"       81",
"      </a>",
"      ]. The discovery of an inversion in intron 22 in the factor VIII gene accounted for the previously unidentified 40 to 50 percent of patients with severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/82,83\">",
"       82,83",
"      </a>",
"      ]. Direct gene analysis for the intron 22 inversion is recommended as first-line testing for carriers in families with severe hemophilia A [",
"      <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/79,84\">",
"       79,84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic analysis of the human factor VIII and IX genes also has resulted in accurate prenatal diagnosis based upon either informative DNA polymorphisms or detection of causative mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Studies are performed by amniocentesis or, less often, a chorionic villus sample obtained in the eleventh to twelfth gestational week. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Bleeding in carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of factor VIII and factor IX levels has been observed in normal subjects (median: 1.02, range: 0.45 to 3.28 international",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    as well as in heterozygous carriers of hemophilia A or B (median: 0.60, range 0.05 to 2.19 international",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/87\">",
"     87",
"    </a>",
"    ]. Extreme degrees of X chromosome inactivation (lyonization) and other genetic factors may lead to very low clotting factor levels in heterozygous carriers, with associated bleeding phenomena.",
"   </p>",
"   <p>",
"    This phenomenon was explored in a postal survey among women tested for carriership of hemophilia in the Netherlands prior to 2001. Twenty-eight percent of the carriers and zero percent of the non-carriers met the criterion for \"mild hemophilia\" (ie, clotting factor level &le;0.40 international",
"    <span class=\"nowrap\">",
"     units/mL).",
"    </span>",
"    While clotting factor levels from 0.40 to 0.05 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    were increasingly associated with prolonged bleeding from small wounds, tonsillectomy, tooth extraction, and operations, increased bleeding was also noted in those with levels between 0.40 and 0.60 international",
"    <span class=\"nowrap\">",
"     units/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Since factor levels appear to be independent of the severity of hemophilia within the family and vary from person to person [",
"    <a class=\"abstract\" href=\"UTD.htm?1/18/1322/abstract/88\">",
"     88",
"    </a>",
"    ], it was concluded that clotting factor levels should be obtained in all carriers preceding a medical or surgical intervention in order to assess their risk of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/24/29058?source=see_link\">",
"       \"Patient information: Hemophilia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23971191\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophilia A and B are X-linked recessive diseases. They exhibit a range of clinical severity that in general correlates with assayed factor levels. Severe disease is defined as &lt;1 percent factor activity, whereas 1 to 5 percent and &gt;5 percent of normal are defined as moderate and mild disease, respectively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common sites of bleeding in hemophilia A and B are into joints and muscles. Other sites include skin bruising, and genitourinary and gastrointestinal bleeding. Spontaneous hemarthroses are characteristic of severe disease. This pattern is different from the mucosal and cutaneous bleeding characteristic of platelet dysfunction or von Willebrand disease (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sites of bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most commonly, bleeding occurs in association with",
"      <span class=\"nowrap\">",
"       injury/trauma",
"      </span>",
"      or surgery in patients with mild hemophilia, to intercurrent injury or surgery in moderate hemophilia, and spontaneously and at an early age in severe hemophilia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two major complications of hemophilia include hemophilic arthropathy and the development of inhibitors to factor VIII or IX. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Late complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Development of inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Protection against CHD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of one of the hemophilias is made via a family history, screening tests, and specific assays. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis and detection of carriers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Screening is done via the platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT). Only the latter is abnormally prolonged in hemophilia A or B (",
"      <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"       table 2",
"      </a>",
"      ). Specific assays are then performed to determine the type and level of factor deficiency. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Screening tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Specific assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional testing is required to distinguish among the hemophilias and von Willebrand disease. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Distinction from von Willebrand disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of the carrier state and prenatal diagnosis can be performed via a number of different methods. However, DNA-based techniques are the preferred method for carrier detection and prenatal diagnosis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Carrier detection and prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/1\">",
"      White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/2\">",
"      Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/3\">",
"      Walker I, Pai M, Akabutu J, et al. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995; 35:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/4\">",
"      Santagostino E, Mancuso ME, Tripodi A, et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/5\">",
"      Crossley M, Ludwig M, Stowell KM, et al. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 1992; 257:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/6\">",
"      Reijnen MJ, Peerlinck K, Maasdam D, et al. Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter. Blood 1993; 82:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/7\">",
"      Kurachi S, Huo JS, Ameri A, et al. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc Natl Acad Sci U S A 2009; 106:7921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/8\">",
"      Lee DH, Walker IR, Teitel J, et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000; 83:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/9\">",
"      Shetty S, Vora S, Kulkarni B, et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007; 138:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/10\">",
"      van Dijk K, van der Bom JG, Fischer K, et al. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004; 92:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/11\">",
"      Escuriola Ettingshausen C, Halimeh S, Kurnik K, et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/12\">",
"      Avi&ntilde;a-Zubieta JA, Galindo-Rodriguez G, Lavalle C. Rheumatic manifestations of hematologic disorders. Curr Opin Rheumatol 1998; 10:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/13\">",
"      Venkateswaran L, Wilimas JA, Jones DJ, Nuss R. Mild hemophilia in children: prevalence, complications, and treatment. J Pediatr Hematol Oncol 1998; 20:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/14\">",
"      Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, et al. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/15\">",
"      Ljung R, Petrini P, Nilsson IM. Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand 1990; 79:196.",
"     </a>",
"    </li>",
"    <li>",
"     Rizza CR. The clinical features of clotting factor deficiencies. In: Human Blood Coagulation Haemostasis and Thrombosis, 2nd ed, Biggs R (Ed), Blackwell Scientific Publications, Oxford 1976. p.238.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/17\">",
"      Eyster ME, Gill FM, Blatt PM, et al. Central nervous system bleeding in hemophiliacs. Blood 1978; 51:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/18\">",
"      Klinge J, Auberger K, Auerswald G, et al. Prevalence and outcome of intracranial haemorrhage in haemophiliacs--a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr 1999; 158 Suppl 3:S162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/19\">",
"      Kulkarni R, Lusher JM. Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol 1999; 21:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/20\">",
"      Tarantino MD, Gupta SL, Brusky RM. The incidence and outcome of intracranial haemorrhage in newborns with haemophilia: analysis of the Nationwide Inpatient Sample database. Haemophilia 2007; 13:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/21\">",
"      Richards M, Lavigne Lissalde G, Combescure C, et al. Neonatal bleeding in haemophilia: a European cohort study. Br J Haematol 2012; 156:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/22\">",
"      Koch JA. Haemophilia in the newborn. A case report and literature review. S Afr Med J 1978; 53:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/23\">",
"      Martinowitz U, Varon D, Jonas P, et al. Circumcision in hemophilia: the use of fibrin glue for local hemostasis. J Urol 1992; 148:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/24\">",
"      Pollmann H, Richter H, Ringkamp H, J&uuml;rgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 Suppl 3:S166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/25\">",
"      Gilbert MS. Musculoskeletal manifestations of hemophilia. Mt Sinai J Med 1977; 44:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/26\">",
"      Kitchens CS. Occult hemophilia. Johns Hopkins Med J 1980; 146:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/27\">",
"      Nelson MD Jr, Maeder MA, Usner D, et al. Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. The Hemophilia Growth and Development Study. Haemophilia 1999; 5:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/28\">",
"      Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 2008; 140:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/29\">",
"      Witmer C, Presley R, Kulkarni R, et al. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011; 152:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/30\">",
"      Fernandez-Palazzi F, Hernandez SR, De Bosch NB, De Saez AR. Hematomas within the iliopsoas muscles in hemophilic patients: the Latin American experience. Clin Orthop Relat Res 1996; :19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/31\">",
"      Jaovisidha S, Ryu KN, Hodler J, et al. Hemophilic pseudotumor: spectrum of MR findings. Skeletal Radiol 1997; 26:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/32\">",
"      Bogdan CJ, Strauss M, Ratnoff OD. Airway obstruction in hemophilia (factor VIII deficiency): a 28-year institutional review. Laryngoscope 1994; 104:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/33\">",
"      Jones JJ, Kitchens CS. Spontaneous intra-abdominal hemorrhage in hemophilia. Arch Intern Med 1984; 144:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/34\">",
"      McCoy HE 3rd, Kitchens CS. Small bowel hematoma in a hemophiliac as a cause of pseudoappendicitis: diagnosis by CT imaging. Am J Hematol 1991; 38:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/35\">",
"      Small S, Rose PE, McMillan N, et al. Haemophilia and the kidney: assessment after 11-year follow-up. Br Med J (Clin Res Ed) 1982; 285:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/36\">",
"      Prentice CR, Lindsay RM, Barr RD, et al. Renal complications in haemophilia and Christmas disease. Q J Med 1971; 40:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/37\">",
"      McDonald AG, Yang K, Roberts HR, et al. Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia. Blood 2008; 111:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/38\">",
"      Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008; 143:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/39\">",
"      Madhok R, Bennett D, Sturrock RD, Forbes CD. Mechanisms of joint damage in an experimental model of hemophilic arthritis. Arthritis Rheum 1988; 31:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/40\">",
"      Steven MM, Yogarajah S, Madhok R, et al. Haemophilic arthritis. Q J Med 1986; 58:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/41\">",
"      Hakobyan N, Kazarian T, Jabbar AA, et al. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 2004; 104:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/42\">",
"      Ghosh K, Shankarkumar U, Shetty S, Mohanty D. Chronic synovitis and HLA B27 in patients with severe haemophilia. Lancet 2003; 361:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/43\">",
"      L&ouml;fqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med 1997; 241:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/44\">",
"      Petrini P, Lindvall N, Egberg N, Blomb&auml;ck M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/45\">",
"      Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/46\">",
"      Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/47\">",
"      Molho P, Rolland N, Lebrun T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr. Haemophilia 2000; 6:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/48\">",
"      Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993; 64:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/49\">",
"      Troisi CL, Hollinger FB, Hoots WK, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/50\">",
"      Kumar A, Kulkarni R, Murray DL, et al. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol 1993; 41:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/51\">",
"      Kroner BL, Rosenberg PS, Aledort LM, et al. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994; 7:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/52\">",
"      Soucie JM, Richardson LC, Evatt BL, et al. Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males. Transfusion 2001; 41:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/53\">",
"      Arnold DM, Julian JA, Walker IR, Association of Hemophilia Clinic Directors of Canada. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 2006; 108:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/54\">",
"      Tradati F, Colombo M, Mannucci PM, et al. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998; 91:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/55\">",
"      Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/56\">",
"      Morfini M, Mannucci PM, Ciavarella N, et al. Prevalence of infection with the hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation. Vox Sang 1994; 67:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/57\">",
"      Horowitz B, Prince AM, Hamman J, Watklevicz C. Viral safety of solvent/detergent-treated blood products. Blood Coagul Fibrinolysis 1994; 5 Suppl 3:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/58\">",
"      Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997; 37:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/59\">",
"      Gaboulaud V, Parquet A, Tahiri C, et al. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Br J Haematol 2002; 116:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/60\">",
"      Morfini M, Longo G, Rossi Ferrini P, et al. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus. Am J Hematol 1992; 39:149.",
"     </a>",
"    </li>",
"    <li>",
"     Evatt B. Creutzfeldt-Jakob disease and hemophilia: Assessment of risk. World Federation of Hemophilia 1999; No 15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/62\">",
"      Donfield SM, Lynn HS, Lail AE, et al. Delays in maturation among adolescents with hemophilia and a history of inhibitors. Blood 2007; 110:3656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/63\">",
"      Rosendaal FR, Varekamp I, Smit C, et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/64\">",
"      Rosendaal FR, Bri&euml;t E, Stibbe J, et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990; 75:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/65\">",
"      Sr&aacute;mek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/66\">",
"      Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/67\">",
"      Foley CJ, Nichols L, Jeong K, et al. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 8:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/68\">",
"      Thompson AR, Bajaj SP, Chen SH, MacGillivray RT. \"Founder\" effect in different families with haemophilia B mutation. Lancet 1990; 335:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/69\">",
"      Lawn RM. The molecular genetics of hemophilia: blood clotting factors VIII and IX. Cell 1985; 42:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/70\">",
"      MERSKEY C. The occurrence of haemophilia in the human female. Q J Med 1951; 20:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/71\">",
"      Panarello C, Acquila M, Caprino D, et al. Concomitant Turner syndrome and hemophilia A in a female with an idic(X)(p11) heterozygous at locus DXS52. Cytogenet Cell Genet 1992; 59:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/72\">",
"      Mori PG, Pasino M, Vadal&agrave; CR, et al. Haemophilia 'A' in a 46,X,i(Xq) female. Br J Haematol 1979; 43:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/73\">",
"      Keeling DM, Sukhu K, Kemball-Cook G, et al. Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954--&gt;Leu substitution in the factor VIII A3 domain. Br J Haematol 1999; 105:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/74\">",
"      Rudzki Z, Duncan EM, Casey GJ, et al. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/75\">",
"      Kleinveld HA, Andersson NE, van Voorthuizen H, et al. Determination of coagulation factor VIII activity by a chromogenic substrate method on STA, an automated coagulation analyzer. Scand J Clin Lab Invest 1999; 59:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/76\">",
"      Hellstern P, Miyashita C, K&ouml;hler M, et al. Measurement of factor VIII procoagulant antigen in normal subjects and in hemophilia A patients by an immunoradiometric assay and by an enzyme-linked immunosorbent assay. Haemostasis 1987; 17:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/77\">",
"      Klein HG, Aledort LM, Bouma BN, et al. A co-operative study for the detection of the carrier state of classic hemophilia. N Engl J Med 1977; 296:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/78\">",
"      Goodeve AC. Advances in carrier detection in haemophilia. Haemophilia 1998; 4:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/79\">",
"      Kazazian HH Jr. The molecular basis of hemophilia A and the present status of carrier and antenatal diagnosis of the disease. Thromb Haemost 1993; 70:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/80\">",
"      Poon MC, Chui DH, Patterson M, et al. Hemophilia B (Christmas disease) variants and carrier detection analyzed by DNA probes. J Clin Invest 1987; 79:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/81\">",
"      Antonarakis SE, Waber PG, Kittur SD, et al. Hemophilia A. Detection of molecular defects and of carriers by DNA analysis. N Engl J Med 1985; 313:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/82\">",
"      Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/83\">",
"      Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/84\">",
"      Jenkins PV, Collins PW, Goldman E, et al. Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling. Blood 1994; 84:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/85\">",
"      Ljung RC. Prenatal diagnosis of haemophilia. Baillieres Clin Haematol 1996; 9:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/86\">",
"      Peake I. Molecular genetics and counselling in haemophilia. Thromb Haemost 1995; 74:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/87\">",
"      Plug I, Mauser-Bunschoten EP, Br&ouml;cker-Vriends AH, et al. Bleeding in carriers of hemophilia. Blood 2006; 108:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/18/1322/abstract/88\">",
"      Knobe KE, Ljung RC. Haemophilia B carrier detection by factor IX:C analysis; no impact of the type of mutation or severity of disorder. Haemophilia 1999; 5:238.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1310 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1322=[""].join("\n");
var outline_f1_18_1322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23971191\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sites of bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Skeletal muscle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Head and neck",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Genitourinary tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Posttraumatic bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Late complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hemophilic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Development of inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Maturational delays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Protection against CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS AND DETECTION OF CARRIERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Screening tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Specific assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Distinction from von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Carrier detection and prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Bleeding in carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23971191\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1310|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 1\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/45/43740\" title=\"table 2\">",
"      Causes PT and PTT abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=related_link\">",
"      Genetics of the hemophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=related_link\">",
"      Hemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/24/29058?source=related_link\">",
"      Patient information: Hemophilia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=related_link\">",
"      Synovectomy for inflammatory arthritis of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40728?source=related_link\">",
"      Variant Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_18_1323="Manning criteria for IBS";
var content_f1_18_1323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Manning criteria for the diagnosis of irritable bowel syndrome*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Pain relieved with defecation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       More frequent stools at the onset of pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Looser stools at the onset of pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Visible abdominal distention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Passage of mucus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sensation of incomplete evacuation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The likelihood of irritable bowel syndrome is proportional to the number of Manning criteria that are present.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1323=[""].join("\n");
var outline_f1_18_1323=null;
var title_f1_18_1324="Progression of fetal acidosis";
var content_f1_18_1324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Continuum of respiratory to metabolic acidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 176px; height: 168px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1324=[""].join("\n");
var outline_f1_18_1324=null;
var title_f1_18_1325="Tricyclic antidepressant intoxication - Rapid overview";
var content_f1_18_1325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tricyclic antidepressant intoxication: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sedation, coma, seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tachycardia, hypotension, conduction abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Anticholinergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dilated pupils, dry mouth, absent bowel sounds, urinary retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Electrocardiographic changes in severe poisoning:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        QRS duration &gt;100 msec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rightward deflection of the terminal 40 msec of the QRS complex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deep S wave in leads I, AVL; tall R wave in lead AVR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        R wave in AVR &gt;3 mm; R/S ratio in AVR &gt;0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Serum TCA levels do not help to guide therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Manage as indicated; many patients require tracheal intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Breathing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Administer supplemental oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypotension: treat with intravenous crystalloid. If hypotensive despite aggressive volume resuscitation, consider pressor therapy with alpha-adrenergic agonist (neosynephrine, norepinephrine).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conduction disturbances: if QRS &gt;100 msec, challenge with intravenous sodium bicarbonate (2 to 3 meq/kg IV push) and assess for QRS narrowing. If QRS narrows, begin continuous infusion (132 meq of sodium bicarbonate in 1 liter of D5W to run at 250 mL/hour in adults or twice the maintenance fluid rate in children).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Gastrointestinal decontamination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Administer activated charcoal if patient presents within 2 hours of ingestion, unless gastrointestinal complication (ileus, obstruction) suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treat with benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do",
"        <strong>",
"         NOT",
"        </strong>",
"        treat with phenytoin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1325=[""].join("\n");
var outline_f1_18_1325=null;
var title_f1_18_1326="Single LDL outcome";
var content_f1_18_1326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Event rates versus LDL-cholesterol across studies, plotted as a single line",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 320px; background-image: url(data:image/gif;base64,R0lGODlhrwFAAeYAAP///wAAANnZ2YiIiO7u7kRERDMzM7u7uyBzOSIiImZmZpmZmREREXd3d8zMzKqqqt3d3VVVVViWa2afd6zLtbrUwi58RfL389bl23SohEqNXuTu54KwkDyFUp7CqRAQEEBAQMDAwGBgYPDw8KCgoDAwMLCwsICAgJC5nMjczlBQUNDQ0B0dHRJAIHBwcHR0dAYVCoKCghpdLhxkMTo6OiAgIJOynXCff+Dg4EeKWwIHAyt5Qzd/TZCQkGWZdSpPNrbFu9Xf2EKGVyJrOYGljJ+5pyBtNwQOB8HMxU6MYXymiby8vGGUcKiyqz1NQjiATSsrKyJBKyRnOFmSawgcDqq/sVyUbIisk66urg4yGJS4nwojERA5HFaPZ5+fn0BKQxhWKs3Sz2eadhY2ICFuNwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACvAUABAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx0QH09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyNAfsQDyIkqEBHFYxYkYMxa6mIoAA3oGIAA48DGBA0YcNaqUmHKVgQYAGAwA0MAAypU4Wb4ikGCBgwAERrY0NDSn0XRFTSkIUECooAMBRCpKerTqOKqmIij4GRSqoRP4BIgdS7as2bNo06pdy7at27dw/+PKnUu3rt27ePPqVYs11IIIggwAlknT5qK+VhNzQ/zJgQGQIkkGMHlTseWrDy9rBsfYVufNoJt9pjU6tOljpWWlPs062GpYr1vLBhVCBAgRIRAVqLjgI9OTg2K7Ej67eCYSAT6A+BCAhKGlEAkEeACAQIQFhIiz0m68+6QPJUYAGFHiQ6GaA6IHmHmIuyr33uMzChHAxCATAXILGpAAwgLeuwWgQFDBZSbfgaLQZ58g+OkHQAL3EELAS9kZiOCFnoAnHnnmGfLfSAWcNCF7gsCHiokYYoiccsw55yFEEERQD2AVWpTijZvUdpuDk6Boio84BtmjhUIWuYp2DxCYZP8pQBrp5FSYSEcdABSS0uSTWG50yQCPGeBlADBZmeWYogjXwD39MUnmmp4QN+EBBBCoJpt0ZqIdBA3k2cCUixAQoAFBQUdPZXUWSombvtET5iIQFBBnAjMpoMAjVxoaJHEPCPjAplI9YkCk9CRwAKGWltoIcRBMRwmXhSjAAKmmxoqIdgYUoCefjCgAaCFeFQLWPXsFK+ywxBZr7LHIJisXEDfwYANebt6zqCIQGDDpIAacpEBTh8l6YwUZWIAAAhqkgAmSA2z6QKeK/FdPAgDIGEC2sHpr3AUUTDAuAhNQsIEm2kH3E3Zi2mvcBh5IMK4FGVRwQSfE/bTbhNOGUqn/wepggIIG43bAQQUWY5JpqhTPiTFoKXDQwbgacIBBwZb8lF56BI9y8cnhgCsuuR78+2MmghoGM85G4avvuP0+nAp3CzQwgJw2E50Twkcz7HAr2tkKwAIhmSz1RBh4wDECHoMMGyZQAZdAxaDc/PUzGKjcscukiQxUYGx/4vbbyujMcs+3oBpABA/Q7DXf5+AbLtL+6hJwPUJHjbg5G+S7cNK9cPeA01CXOfk4CI9ttWuZfLr059/EPbbHL9uIydqno65NBXKTi0LrxWT9Up64hiy7NX4jIAHgyURrT95t/i6N0ftizgyS6q57uPLJUL1ww0o7w50DSfbuO/XIhL36/8fUPB7AwNODD0zcK5NNtzURMwVUlX3+2VVJwEGpfjDgtq8B8djAVFTmh7xCNOpRMyFMTeq1v1sobmf98tk24jezANTMEZ/iilO61UBcMA8BFnCeN8w3r0iwqldQYVd7OliL0F3PbOJgGucgoaugaLBXhPiVPZTFwx768IdAbAsQlCCEcfHgBlUIohLhoh0CDGCGjajWtQShwMjNioWuYB/LbqcOWkGuc4hwV6hGgj8GYnEUwfufBLtotz3NLH1n9ITRIEiB7LUDVQwgEP08F0dQVK5qGahjRGgVgTwloJDeg5h8/JQ/3fDGNyHyhQtB2LCMGE9akvPObhjQyFYNSv9K1bnOLlQ3N9xZMhPRU5cKk6fJenDyEOhRD4lyQTv/ecCUKtmbIrsTIFd2kj/+ARA9BlSL4A1vjTnRJSeUiY5e2uOVg4CQPSS0x1Z8kF+CVAwzAWYcP+WDAaN6EYhEZLpWWI+SV9PMNu3Uymd2chAfitGMWDHJDlTSNPAZwFbgyJpeQjMXWnQfLkOTT3pEAIy7bOU/bVHLvw30NCbyjwLC+b3uMNIWFwjeBABonO1172csvKYI42M+9A2NeghTGDpvFL+JVbNt4BPf3GAoiRDwSBCSGkR6BASAdx0AKpMBQNAoiplLjIyA/JRaQFlnCRIwJzkuwukUATAAblmQqq//6lVOhXq+clBwPVc96df69zdkToI+JTCBCUqQn0FsdT9Wxc5PIKDVKRbSq0CDHEilltHF8YujlxDBB8Qzng+IwK1TrWqJsKMAeNVVp9wqqlGfmC6EsvJkIs0mJ0AAAkJwFrGEUGxPQ3WSxwriruSI1pRemohMuXWaHLRXSl8oCsESdgSGBS1kF0sI0y5lld8QDpfm9aUCFiJAuj2Vt2TqPnORAq1qZauDBAVWnoZVKEEN2js5c4kz2SNNjsAhdERlxjUFtGUPFYVT6fGBqCbGTQaAk2UTgUO3viq2dEojYFNh081wJ05xgkR9n9ISHdZjiQimSwxYMBYv0IPBNKjH/wsEUI8lxKAeLJiwsMJgAx/sYFxTsAESEkziEv+QhGB6BA7pta3ymmMB8BpErwowqbT1dFQw3g9hMvHBEGr2a/FLAAMeM0tF9BI78qIXfteRYxlXhMZUxE4AcBxjqlpREpMcHeoEyKpyZpIdTSawIKD8H5FMeWtVHvAjNDY+5/5OgAODnVjTEeYNHrlEVNbplRdx3veBT3BVpccFK8rkKtt5qjdGs44HnQj9mrUT/TXETgcnEulU2R7skSY9gJvMTASFAA1gNEzdIcbqwgvKwdm0GHuyiAcy7tGdWC9UCdEAyjRqVFwCJ28zFRRW+7d0RZ7zaXo80gQFIK1rbSsVvf8Hqa1edQD39bU6MyHnU6xTHFm+JypsKwjcHrZEKoQKAUgSFMiFU9NRsYzubpXUxLB5bm5WxWcHMe+YDJq6UvYJA6Yk7ctcUlHtzoVjQsWeMxFs0l0rNaKjFMlE9Dm92x5st3MriFqPqlEP2Pd+bHLVjJ+k3+pGZfQ4nVBgQIAB1xoAYDxSAG7xB2+KBsUm3+noWUA32TwSlAJ6M4hUmRSY6Cb5Sq59CaJXglWF6E2qRPJynsykzpzw50lcjU1Yv0LW7cWS0Sux9Uno0xBaK8BMJn0thW/CmToYQxcu92NLrOAEJ1gBr9It1Kb0ciYDn9egI611Iv3i5YRI1buoCi//XQkC6pkI0BGyIINxGYEJNM2ECOzxbQJLpcVQTluVvl4oJClpvsscxslppHKke6RwMbZWzDdBACdwofEImEELqKBrTiBHBCMYweSjmkKc2v1aDOBaZC2lWpgLmxcHeMy8+EMiBUQA8BCAlNktEVAZtAAG9FioJlRQA0LUQAVOtsfvtxYVB0Cn4XUSbpeKG3BzOFrqn6g3AOrd+7oD4M6EMHznu4smoW+i671AdRFECDMHCi4QAHIHACsQAC7gZJc3fthCMC22f5fwJgG2V+hAbG0nCBcFCjjwAR/gAi4AgjjggL53f1PlXfPif05yJ3qyJ+23DdkWeauwAipADyqQ/4BvFiWJkmLHZwwO4CiT8G7N1UevIEAKoEqP4FpPUUZLlgzRNy+gVwgPZ4SxIDiJtAjIRUUzsUBPeAxRCBJTWHNWqBqlYyu8o2IVcUN9AYCaEIZfZAh9RUdWV4bbESWYFF4VgUJ0lwifgQ9AdRL/UWqDYgpwaA+7AgAaaEd2OAvQo4R6KAhs+BVhERcvQANjEQAswGAXNhY0oGE9hAUskA9Q0ARXkATjsgM+UAQm1oqu+IqwiBYeRQBZiAg4VEUuhgii1VPQNgAfMmbBRgqHCAM/kAPwtgAL14i1UFLXpYX1gB2SQRlfuAi7aEEVNAhitwrRBwMtMAMs8z5AlYzKaP+GlyAxSPWDuhhZFsQThXh/wQgJQTiFhQAuTzAuUqAFawRUw5R0gDgZgUJj9zB848hORjVAJYOOh1CN2OEu2PiOjhCFiZgIc4g0RPAFnaOP9ZCM2SgUCTApE5hoA1lylCAzYCVql/UICikIENKQlQCHEUkImcWI4YcPC7eRUPEfB/CRZxaSoYcJQYOBsnCIUjgI56RlipAp+UAjBMgeKVQAHamORMWT55IJ/gFFCJkKQgkSQSA2MyVgNHkINll+9ACVUvl/eFgAJjlqs+AA6BYA3DgEpUQJGCmOYSkSS0GWZUmQl6B8KMeCelkJ8bgJUbgF3TguObBfkhCOiVCXAJD/KniZl0WnCQ7AHz74ZZMAkfLoCBUgBmQwLmDwA0HACcgImeR4CX/hGw7Zk5TgkpmJCHM0LlYQBTrwkqT5PHi4fNulNy3ZlrTJCH/0Qg8TmLX5DAETlVd5CFk5lL7JlWSjbcNZPp3QmlM5CWyZD13jcBsTl88ZQHtpE58iHcZllqvJm5Z1Xly0ndogHF4CnuAZg4jAmoZAhtlBMB8yaSsXIDuGnsKgnoACJu15nImAmYSgUY0zK/QJES8XfU9kGAsgkPrpC+qJD+HJTeUohDGJEgdKeKelADXhlw+KCxGah5ZJCT3mnCgRIS/nAMFHAK6idx9KOhUIYBcIoIqgL/ZE/4OnkqFkx4/S+aJn4zqXkAIQl6OHh6CG9nyHl0c+CqF+tx06amiUORnGuaQgOgvUlYtUihFu+FZYmqU6IQvjNaVa4qVH4Yb21aVkGg9mKma+Uomx+KZwGqdyOqdu4YYs5qBEkaZG4YZJlps1oqdD16SAOhFrSimDGqhAeqhaKqiKqqaM2qjvUKiOIKmQ+guUiqaVeg6XOo2Zyg6bqj+d6qiJGqru8Kl+SKqiup+oCg+mekWrWqqP+qp4Naqyig6tukK1ug63mqe5yka02qupFavAGlyzEI1+WiDDqqmzgIucmqwjJAuT2KzOuhiywIf+t6vTCpStEK05hA/ZGqyywP+soPqt3FWtTjiu5Pqsv5qu6Sms7FoN2Pqn70qtFtEQ9nqv+Jqv+rqv/Nqv/vqv/LAMhTqwnlGwy2iwMYSwjqiwpbmwBytZDls3DyuxFBux4UCwE2uxDbuxVwiuFcuxP/qxHZux4NBZtWCytICys6CyssCyseCysACz8zqzNFuzNnuzOJuzOruzPAsPglcPEFAtgsYKO0UvQtuMpsCEgnByFBUg4vgJSouf4eS0p6C0V3p/+5i0FfGzm4a1PKW1OgUSwEG12fByEQAYvKYKP3ESrHK2AJC2p7CFVEUP4cQfBHBytRh17TgIC2S3eFsKcsulfqtxpCC3OgUvg5u3Z1f/iGtrZYR3t4RrDR6BHYS7k6iQKSfBFZUrpqEwYDuJWhtJCmqmFfESJqE7CuIVKqMCuqnJCQM2uaULjKbQK5gLAFzButjghTuJtFmRfUCxu2kJCp47teyBaqLLEf+RJhtpvKjbEq7ijmP2tJ0wYF64vNLruhchLx/hJ8V7vcyQKuG0ua4AbTExJZY7uynxuabbupugZma7vuhrCF6Bu6VQX+B7WvBbvy1BvvRbDREQWW4Lt6tAEjMRwHeDCsO7HwkAuYrbvlvbNQ3wKokbv4GhLU0xwfpLCP97uAxMwTJGGBhMDTa2tMoXvKIAHexxtCbsCXe2o17rvZpwZNahumOW/7WF+4zxIrY1/LU3PLQjvMMwnHg4jMLYaMM9e8RInMRKvMRM3MRO/MRQHMVSPMVUXMVWfMVEcyat+0ajwMWiICOKW51KSX7rYQg/ARgycqzAAG1Qkx4TaipgHLYzIhI/sWeGoMXUWMaM4MaroseJsL2WEMdG1lWEwACGRghnnMNqzAl4/AmHVAh8DMgnI8hzCxMZt8B13AiNnAherAh87HV+jAiSTAmUjAiPATXSYceJnMbJkCm9E8kHjDGU/MlanMmGMMP0sDlM8RH3GSrU8UYwZlC2q3znYw8EEMyD87bEBSgBkgC/HMrywhTyBHDwJE2AcSYFwMs45bu4kncFMP/NqkJF9XDMvgEYq3w+3jQZ1PERdMUUWIsr0iHBydwluRxa6xHPBci3uywgMvJKO/URixIBVeYuAB0TsWwws+yDbmzLhSAjJILHH+EAYMwTeTQzmbwUXHNdfHzRFoSU8zLRQuZEoTwIDm3QUMPRTVPGEZ0eaBzOKplHUGETo2y7JZTJC53MaQzSeSQjyMgADJAqefRFASDPgPEYDnBy97Uf9zzUczvGEB0V/7EVQfXJHsEeP4G4KTbT9pLQYVLLJWQIo4zHRg3Ij1E46zFpiiJGgMLHaA0mmUIjZD0dnRylWX3QbZ0nZWzUeEzJmSwdQDHTNp1imZItOH0+cb0pAtL/kQLCwxzI1CxNJV01yjMTz8rs1CoNFG/92J+cHlLx1pVs0jjD1W9ryATA0Brsx2J9Pjot0gNg2thijTxl2p6dw0kS0l78E/IME+yMyF9dcXl9Pny8G7gS0jEN2oOQyYHdAOcs0dNB0UHh01EhZOdbHUMt0kV9PlABpUv9KrPt2wmE2YNT3J+cAJEl3nXdo2sSzYOD1gdF0/aQP7g8HantAOlsAM/8dJoGbRlZHcp3zPk92/V936c9Lym2U9OCzOsx31g7ZC49zGMpEoD91b2xj8sd4NtceEF1x2M5z0M9GY002Uzd3TRx2bSYzN71GDABFbhy4nVdD+yLxb1g1KOw/xuMdcgwXg0y/gnEHCYM8MY3/uNAHuRCPuREXuRGfuRInuRKvuRM3uRO/uRQHuVSPuVUXuVWPrMAm+UJceWuWq5cPqZe/uXIGuZi3lMJW+ZjTqxoXiJnvuaxsYuPcLogy+WfYZ9Uhada+OKSoHucdQKEZahrbuYoCS8KCueOIOeZgFsBAAJsFR4UEeiC7giApxWKJSjQKE0DcLSTUgDKNylH6+OHMHkLghw98OiBXufwoqILAOeGl5+ke3JBaM6qbc61Jwny932m7uaQsKOKpd+TsXTRZA8Nyh4W5GtoSQmMTggfAH6AruuDHlrfrCq1FhMkQrosOTJu+xOcuwhgUf/qALB7uY7mqA7tXpsAjoWaRxsVd9eYygfqhkAeycEclTepkB6vi0ACKiAC7kXvp97m4u7vZW7vavnvF1vvAC/mAq+b/V7wC0/mCH/wX57wibBzQ9LwljDhv6FmbGromLBTK8yrzm4JoGQdC6DxG+QJaP3x8hrweDhL0tQfX/TyisXpRmxC+KDybG7xldCgwzRuKZEqD9ArM98U9Wfz+YDzEv+t8EExvRKEzyj0djcTwC4JKngPeh7pBG8JBxBJIyJuQmUT0lHydzPzUt+HRi/s4c7ylwDOK/cYolIS6+j2ZN+YZn/2vCutVJ70kja0kaD30+r3rYLzK//wDB/yam7/+OqK+N0A+MnK+NOp+PQK+RNk8IWf9Q68Eds+soaPkWIX9bKrCMNr8ppv+UXPktAL+umb+SFL+n1YVWL0+gcgTZdeD5jvFfwBIbuSZOgtnptvDwcw96cffKNN7SePZ7bfH5PLJUHhZVQoAc7//NAf/dI//c4P5qzfKcCfjVw7QJGR+rbPLT1BXeKIAdRf/ub//Nav9pa3W1pzfzx+QSDs/QgK/qvem7HT+9jfFO6yAPsPCAcJAQEJAAuEBgEAjIwBBweLAwWMCQsAEYQBl42dnp+goaIAi6Omp6ipqqusra6vsLGys7S1s6W2ubqnuLu+v8DBwsPExbG9xsmqyMrNis7P0NHSrczTz9XW2drb3N3L3s7Y4OPk5ebA4ue56ert7u/wpPG+7PP29/jN9fmp+/z/AAO+0kSwoMGDCBMqXMiwIUOBECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXSoxEAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure presents a commonly cited comparison derived from 6 randomized trials. By plotting the aggregate LDL-C values and outcome rates of 12 observations (5 placebo groups and 7 statin treated groups), it appears that there is a strong linear association between LDL levels and outcomes across trials, independent of statin therapy, however this may be misleading.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rodney A Hayward, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1326=[""].join("\n");
var outline_f1_18_1326=null;
var title_f1_18_1327="Empiric IV rx pneumonia in children";
var content_f1_18_1327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral empiric antibiotics for inpatient treatment of pediatric pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age group and suspected pathogens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested empiric regimens*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        1 to 6 months",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacterial (not",
"        <em>",
"         Chlamydia trachomatis",
"        </em>",
"        or",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        <p>",
"         Ceftriaxone 50 to 100",
"         <sup>",
"          &Delta;",
"         </sup>",
"         mg/kg per day in 1 or 2 divided doses (2 doses should be used for severe infection or substantial local penicillin resistance),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Cefotaxime 150 mg/kg per day in 3 or 4 divided doses (4 doses should be used for severe infection or substantial local penicillin resistance)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Chlamydia trachomatis",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        &gt;6 months",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uncomplicated bacterial (not",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"        ,",
"        <em>",
"         Chlamydophila pneumoniae",
"        </em>",
"        , or",
"        <em>",
"         S. aureus",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        <p>",
"         Ampicillin",
"         <sup>",
"          &loz;",
"         </sup>",
"         150 to 200 mg/kg per day in 4 divided doses (MAX 12 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Penicillin G",
"         <sup>",
"          &loz;",
"         </sup>",
"         200,000 to 250,000 units/kg per day in 4 or 6 divided doses,",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Cefotaxime",
"         <sup>",
"          &sect;",
"         </sup>",
"         150 mg/kg per day in 3 divided doses (MAX 8 g/day or 10 g/day divided in 4 doses for severe infection or substantial local penicillin resistance),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone",
"         <sup>",
"          &sect;",
"         </sup>",
"         50 to 100",
"         <sup>",
"          &Delta;",
"         </sup>",
"         mg/kg per day in 1 or 2 divided doses (MAX 2 g/day or 4 g/day divided in 2 doses for severe infection or substantial local penicillin resistance)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         M. pneumoniae",
"        </em>",
"        or",
"        <em>",
"         C. pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        <p>",
"         Azithromycin 10 mg/kg once per day for two days (MAX 500 mg/day); transition to oral therapy at 5 mg/kg per day as soon as clinically appropriate,",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Erythromycin",
"         <sup>",
"          &yen;",
"         </sup>",
"         20 mg/kg per day in 4 divided doses (MAX 4 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Levofloxacin 16 to 20 mg/kg per day in 2 divided doses for children 6 months to 5 years; 8 to 10 mg/kg per day for children 5 to 16 years (MAX 750 mg)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested empiric regimens",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Severe pneumonia",
"        <sup>",
"         ������",
"        </sup>",
"        (see text for clinical features)",
"       </td>",
"       <td>",
"        <p>",
"         Ceftriaxone 100 mg/kg per day in 2 divided doses (MAX 4 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Cefotaxime 150 mg/kg per day in 4 divided doses (MAX 10 g/day)",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        <p>",
"         Azithromycin 10 mg/kg once per day for two days (MAX 500 mg/day); transition to oral therapy at 5 mg/kg per day as soon as clinically appropriate,",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Erythromycin",
"         <sup>",
"          &yen;",
"         </sup>",
"         20 mg/kg per day in 4 divided doses (MAX 4 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Doxycycline** 4 mg/kg per day in 2 divided doses (MAX 200 mg/day); transition to oral therapy as soon as clinically appropriate",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Severe pneumonia requiring ICU admission",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"        (see text for details)",
"       </td>",
"       <td>",
"        <p>",
"         Vancomycin 60 mg/kg per day in 4 divided doses (MAX 4 g/day)",
"         <strong>",
"          PLUS either",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 100 mg/kg per day in 2 divided doses (MAX 4 g/day)",
"         <strong>",
"          or",
"         </strong>",
"         Cefotaxime 150 mg/kg per day in 4 divided doses (MAX 10 g/day)",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        <p>",
"         Azithromycin 10 mg/kg once per day for two days (MAX 500 mg/day); transition to oral therapy at 5 mg/kg per day as soon as clinically appropriate",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS (if necessary)",
"         </strong>",
"        </p>",
"        <p>",
"         Nafcillin",
"         <sup>",
"          &Delta;&Delta;",
"         </sup>",
"         150 mg/kg per day in 4 or 6 divided doses (MAX 12 g/day)",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS (if indicated)",
"         </strong>",
"        </p>",
"        <p>",
"         Antiviral treatment for influenza",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Complicated pneumonia/abscess",
"        <sup>",
"         &loz;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Ceftriaxone 100 mg/kg per day in 2 divided doses (MAX 4 g/day)",
"         <strong>",
"          or",
"         </strong>",
"         Cefotaxime 150 mg/kg per day in 4 divided doses (MAX 10 g/day)",
"        </p>",
"        <p>",
"         <strong>",
"          PLUS (if necessary)",
"         </strong>",
"         <sup>",
"          &sect;&sect;",
"         </sup>",
"        </p>",
"        <p>",
"         Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 3.6 g/day)",
"         <strong>",
"          or, for patients allergic to clindamycin,",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin 40 to 60 mg/kg per day in 3 or 4 divided doses (MAX 4 g/day)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Nosocomial (hospital-acquired) pneumonia",
"        <sup>",
"         &yen;&yen;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          ������������",
"         </sup>",
"         7.5 mg/kg per day divided in 3 doses for children &lt;5 years; 6 to 7.5 mg/kg per day divided in 3 doses for children &ge;5 years",
"         <strong>",
"          or",
"         </strong>",
"         Amikacin 15 to 22.5 mg/kg per day divided in 3 doses,",
"         <strong>",
"          PLUS",
"         </strong>",
"        </p>",
"        <p>",
"         Piperacillin-tazobactam 300 mg/kg per day in 4 divided doses (MAX 16 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Ticarcillin-clavulanate 300 mg/kg per day in 4 or 6 divided doses (MAX 24 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Meropenem 60 mg/kg per day in 3 divided doses (MAX 3 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftazidime 125 to 150 mg/kg per day in 3 divided doses (MAX 6 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Cefepime 150 mg/kg per day in 3 divided doses (MAX 4 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 3.6 g/day)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Community-acquired aspiration pneumonia",
"        <sup>",
"         ������������",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Ampicillin-sulbactam 150 to 200 mg/kg per day in 4 divided doses (MAX 8 g/day of ampicillin component)",
"        </p>",
"        <p>",
"         <strong>",
"          OR, if MRSA is a consideration,",
"         </strong>",
"        </p>",
"        <p>",
"         Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 3.6 g/day)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospital-acquired aspiration pneumonia in patients colonized with unusual gram-negative pathogens",
"        <sup>",
"         ������������,",
"        </sup>",
"        ***",
"       </td>",
"       <td>",
"        <p>",
"         Piperacillin-tazobactam 300 mg/kg per day in 4 divided doses (MAX 16 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Ticarcillin-clavulanate 300 mg/kg per day in 4 or 6 divided doses (MAX 24 g/day),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Meropenem 60 mg/kg per day in 3 divided doses (MAX 3 g/day)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MAX: maximum dose; ICU: intensive care unit; MRSA: methicillin-resistant",
"     <em>",
"      Staphylococcus aureus",
"     </em>",
"     .",
"     <br/>",
"     * Consultation with a specialist in infectious diseases for children is suggested for children with severe hypersensitivity to beta-lactam antibiotics (eg, penicillins and cephalosporins).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Add vancomycin 40 to 60 mg/kg per day in 3 or 4 divided doses or clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses for suspected community-associated methicillin resistant",
"     <em>",
"      S. aureus",
"     </em>",
"     pneumonia.",
"     <br/>",
"     &Delta; The 100 mg/kg per day dose of ceftriaxone should be used only if local rates of penicillin resistance to",
"     <em>",
"      Streptococcus pneumoniae",
"     </em>",
"     are substantial.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Fully immunized with conjugate vaccines for",
"     <em>",
"      Haemophilus influenzae",
"     </em>",
"     type b (Hib) and",
"     <em>",
"      S. pneumoniae",
"     </em>",
"     in communities where penicillin resistance in invasive strains of pneumococcus is insignificant.",
"     <br/>",
"     &sect; Not fully immunized with conjugate vaccines for Hib and",
"     <em>",
"      S. pneumoniae",
"     </em>",
"     or in communities where penicillin resistance in invasive strains of pneumococcus is significant.",
"     <br/>",
"     &yen; Parenteral erythromycin is associated with phlebitis, prokinetic and, rarely, cardiotoxic effects.",
"     <br/>",
"     &Dagger; Dosages recommended are for patients with normal renal function.",
"     <br/>",
"     &dagger; Children of any age with severe infection may benefit from broad-spectrum therapy that addresses both atypical and typical pathogens.",
"     <br/>",
"     ** Should be used with caution under the age of 8 years.",
"     <br/>",
"     <span class=\"double_bullet\">",
"      &bull;&bull;",
"     </span>",
"     These recommendations are for children of any age.",
"     <br/>",
"     &Delta;&Delta; If",
"     <em>",
"      S. aureus",
"     </em>",
"     is likely, since methicillin-sensitive",
"     <em>",
"      S. aureus",
"     </em>",
"     is more rapidly killed by nafcillin than by vancomycin.",
"     <br/>",
"     <span class=\"double_lozenge\">",
"      &loz;&loz;",
"     </span>",
"     Pneumonia complicated by significant parapneumonic effusion or necrotizing process (",
"     <em>",
"      S. pneumoniae",
"     </em>",
"     ,",
"     <em>",
"      S. aureus",
"     </em>",
"     , and",
"     <em>",
"      Streptococcus pyogenes",
"     </em>",
"     are possible pathogens).",
"     <br/>",
"     &sect;&sect; If MRSA is a consideration.",
"     <br/>",
"     &yen;&yen; The aminoglycoside/meropenem combination should be used if extended-spectrum or Amp C beta-lactamase-producing gram-negative rods are possible etiologies. The aminoglycoside/cephalosporin combination should",
"     <strong>",
"      not",
"     </strong>",
"     be used if aspiration pneumonia is a possibility. Vancomycin should be",
"     <strong>",
"      added",
"     </strong>",
"     to the empiric regimen if MRSA is a consideration.",
"     <br/>",
"     &Dagger;&Dagger; Gentamicin dosage is adjusted for peak concentration of 7 to 9 mcg/mL and trough of &lt;2 mcg/mL.",
"     <br/>",
"     &dagger;&dagger; Patients with severe hypersensitivity reaction to beta-lactam antibiotics can be treated with a combination of clindamycin plus an aminoglycoside.",
"     <br/>",
"     *** Vancomycin should be added to the empiric regimen if MRSA is a consideration.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.",
"      </li>",
"      <li>",
"       Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.",
"      </li>",
"      <li>",
"       American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK. (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.799.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_18_1327=[""].join("\n");
var outline_f1_18_1327=null;
